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Summary 
Successful treatment of prostate cancer (PCa) depends on early diagnosis and 
screening, which currently relies on the measurement of serum prostate specific 
antigen (PSA) levels. The overarching aim of the project was to generate 
molecularly imprinted polymers for PCa biomarkers, with subsequent integration 
with a sensing platform to allow for rapid, point of care detection and monitoring.  
The initial work involved the use of simple PSA epitopes for epitope imprinting 
using conventional imprinting techniques. A four amino acid sequence from the C-
terminus of PSA was imprinted with MAA, Aam and Urea monomers to obtain bulk 
imprinted polymers. Apparent Kd of 102 µM, 154 µM, 194 µM was obtained for 
MAA, AAm, Urea based bulk mini-MIPs respectively. Epitope imprinting was 
further developed using a surface imprinting approach, via electropolymersiation of 
dopamine to detect an epitopic sequence from pro-PSA. An improvement in Kd from 
bulk-imprinted polymers, with an apparent Kd of 2.9 µM was obtained with the 
surface electrochemical MIP sensor. However, both epitope imprinting technique 
lacked sensitivity to measure clinical relevant concentrations of PSA (nM range). As 
a consequence, a more sophisticated technique called hybrid imprinting was 
developed to build an electrochemical MIP sensor. Hybrid MIP imprinting utilised 
an aptamer with established affinity towards PSA to trap the aptamer-PSA complex 
into a surface grown electropolymer (polydopamine). The resulting aptamer lined 
polymer pockets exhibited high selectivity and affinity towards PSA (apparent Kd 
0.3 nM). The apta-MIP sensor was also able to discriminate from a homologous 
protein (human Kallikrein 2) and was resilient to fouling from serum proteins. The 
apta-MIP sensor was further translated to a MOSFET device whereby successful 
detection of PSA at clinically relevant concentration was obtained in human plasma. 
Although good sensitivity and selectivity was obtained with the hybrid-MIP sensors, 
further research is required to understand the binding mechanism of the template to 
the MIP.  
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  recognition	  site	  in	  the	  polymer	  that	  
displays	  both	  chemical	  and	  steric	  selectivity	  for	  the	  template.	  _______________________________________	  20	  
Figure	  1.	  5:	  Epitope	  is	  immobilised	  on	  a	  surface	  (i).	  Monomers	  interact	  with	  epitope	  (ii).	  Polymers	  
can	  be	  grown	  around	  the	  epitope	  to	  create	  an	  imprinted	  site	  (iii,	  iv).	  After	  extraction	  of	  the	  
template	  the	  whole	  protein	  is	  introduced	  for	  rebinding	  which	  can	  be	  detected	  by	  voltammetric	  or	  
piezoelectric	  techniques	  (v).	  ____________________________________________________________________________	  29	  
Figure	  1.	  6:	  Protein	  hybrid	  imprinting	  technique	  whereby	  a	  receptor	  holds	  the	  protein	  in	  its	  
preferred	  conformation	  on	  the	  surface	  during	  polymerisation	  for	  the	  formation	  of	  chemically	  
selective	  cavity.	  Post	  removal	  of	  protein	  the	  cavity	  lined	  with	  the	  receptor	  exhibits	  superior	  
recognition	  towards	  the	  template.	  _____________________________________________________________________	  31	  
Figure	  2.	  1:	  Homogenous	  cleavage	  of	  AIBN	  to	  generate	  two	  equally	  reactive	  radicals,	  which	  
activate	  surrounding	  acrylate	  monomers.	  Nitrogen	  gas	  is	  a	  by-­‐product	  of	  the	  reaction	  ___________	  55	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Figure	  2.	  2:	  A	  schematic	  illustrating	  the	  epitope	  imprinting	  process.	  A	  small	  portion	  of	  the	  protein	  
that	  is	  exposed	  on	  the	  protein	  surface	  is	  used	  as	  the	  template.	  Functional	  monomers	  form	  a	  
complex	  with	  the	  epitope	  which	  is	  subsequently	  locked	  in	  place	  during	  the	  polymerisation	  process	  
(initiated	  by	  the	  application	  of	  UV	  radiation	  or	  heat).	  Extraction	  of	  the	  epitopic	  molecule	  leaves	  a	  
cavity	  capable	  of	  recognising	  both	  the	  template	  and	  the	  native	  protein	  that	  displays	  the	  epitope	  on	  
its	  surface.	  _______________________________________________________________________________________________	  58	  
Figure	  2.	  3:	  General	  schematic	  of	  solid-­‐phase	  peptide	  synthesis.21	  The	  strategy	  highlights	  the	  
orthogonal	  protection	  scheme	  where	  the	  amine	  protecting	  group	  (R)	  is	  deprotected	  using	  a	  base	  to	  
expose	  the	  primary	  amine	  to	  facilitate	  attachment	  of	  a	  carboxyl-­‐activated	  amino	  acid	  (coupling).	  
The	  side	  chain	  groups	  are	  protected	  by	  an	  acid	  labile	  group	  (P).	  The	  process	  is	  repeated	  until	  the	  
peptide	  sequence	  is	  complete,	  with	  cleavage	  from	  the	  resin	  being	  achieved	  using	  a	  strong	  acid.	  
Reproduced	  from	  Jose	  M.	  Palomo	  et	  al.	  (2014),21	  with	  permission	  from	  The	  Royal	  Society	  of	  
Chemistry.	  _______________________________________________________________________________________________	  62	  
Figure	  2.	  4:	  MBHA	  rink	  amide	  resins	  are	  popular	  for	  peptide	  amide	  synthesis.	  The	  amine	  is	  always	  
protected	  with	  a	  Fmoc	  group	  and	  requires	  deprotection	  before	  the	  first	  coupling.	  _________________	  63	  
Figure	  2.	  5:	  2-­‐cholorotitryl	  chloride	  resins	  are	  typically	  used	  for	  those	  peptide	  sequences	  that	  
contain	  proline	  as	  the	  first	  amino	  acid	  to	  help	  prevent	  diketopiperization	  reaction	  and	  also	  reduce	  
racemisation32.	  __________________________________________________________________________________________	  64	  
Figure	  2.	  6:	  Fmoc	  protection	  scheme	  on	  amino	  acids	  _________________________________________________	  64	  
Figure	  2.	  7:	  Fmoc	  deprotection.	  Methyl	  piperidine	  attacks	  the	  proton	  in	  the	  fluorenyl	  ring	  (i)	  
eliminating	  hydrogen	  and	  releasing	  dibenzofulvene	  and	  carbon	  dioxide	  (ii).	  Dibenzofulvene	  is	  
scavenged	  my	  methyl	  piperidine	  to	  prevent	  it	  from	  further	  reacting	  with	  the	  α-­‐amine	  of	  the	  amino	  
acid	  (iii).	  _________________________________________________________________________________________________	  66	  
Figure	  2.	  8:	  The	  Kaiser	  test	  is	  based	  on	  a	  ninhydrin	  test.	  1,2,3	  tricarbonyl	  carbon	  in	  ninhydrin	  (i)	  is	  
a	  strong	  electrophile	  and	  readily	  attacks	  the	  free	  amine	  on	  the	  amino	  acid	  to	  form	  a	  stable	  
compound	  which	  is	  a	  Schiff’s	  base	  (ii).	  The	  base	  further	  reacts	  with	  another	  ninhydrin	  molecule	  to	  
give	  a	  strong	  chromophore:	  2-­‐(1,3-­‐dioxoindan-­‐2-­‐yl)iminoindane-­‐1,3-­‐dione	  which	  forms	  an	  intense	  
blue	  colour(iii).36	  The	  Kaiser	  test	  is	  only	  positive	  for	  primary	  amines.	  _______________________________	  68	  
Figure	  2.	  9:	  Coupling	  agents	  HOBt	  and	  HBTU	  _________________________________________________________	  69	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Figure	  2.	  10:	  Mechanism	  of	  amino	  acid	  activation	  can	  be	  divided	  into	  three	  steps:	  The	  base	  
(DIPEA)	  deprotonates	  the	  amino	  acid	  first	  (i).	  Post	  deprotonation	  the	  resulting	  carboxylate	  ion	  
attacks	  the	  electron	  deficient	  carbon	  atom	  of	  HBTU	  (ii),(iii).	  The	  newly	  formed	  HBTU	  –	  amino	  acid	  
intermediate	  reacts	  with	  the	  HOBt	  anion	  to	  form	  an	  OBt	  activated	  ester	  (iv).	  ______________________	  70	  
Figure	  2.	  11:	  The	  OBt	  activated	  ester	  attacks	  the	  electron	  rich	  free	  amine	  on	  the	  resin	  to	  form	  the	  
amide	  bond.	  _____________________________________________________________________________________________	  71	  
Table	  2.	  1:	  Gradient	  run	  conditions	  for	  elution	  of	  peptide.	   ___________________________________________	  75	  
Table	  2.	  2	  Concentration	  of	  peptide	  added	  to	  each	  mini-­‐MIP	  vial	  using	  sequential	  addition	  of	  
peptide	  with	  stock	  concentration	  of	  200-­‐μg/ml	  peptide	  solutions.	  Additonal	  MeCN	  was	  added	  to	  
the	  vials	  to	  get	  the	  total	  volume	  of	  the	  solution	  to	  500	  μl.	  ____________________________________________	  86	  
Figure	  2.	  12:	  PSA	  crystal	  structure	  showing	  the	  C-­‐terminus	  portion	  of	  the	  protein	  highlighted	  in	  
red.	  The	  C	  terminus	  peptide	  formed	  an	  alpha	  helix	  structure	  44.	  _____________________________________	  88	  
Figure	  2.	  13:	  Protein	  Blast	  results	  for	  the	  C	  terminus	  sequence	  IKDTIVANP	  showing	  a	  100	  %	  match	  
to	  PSA	  (KLK3)	  ___________________________________________________________________________________________	  88	  
Figure	  2.	  14:	  HPLC	  chromatogram	  of	  the	  as-­‐synthesised	  4-­‐mer	  peptide	  (Fmoc-­‐VANP)	  showing	  one	  
major	  peak.	   _____________________________________________________________________________________________	  90	  
Figure	  2.	  15:	  Mass	  spectrometry	  of	  VANP	  4mer	  peptide	  showing	  the	  sodium	  adduct	  of	  the	  peptide	  
(+22)	  with	  a	  mass	  of	  643.3	  g/mol.	  This	  is	  common	  in	  chemical	  species,	  which	  do	  not	  contain	  a	  
positive	  site	  for	  ionisation.	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  90	  
Figure	  2.	  16:	  Diketopiperization	  reaction:	  the	  free	  amine	  group	  of	  asparagine	  attacks	  the	  ester	  
linkage	  on	  the	  resin	  to	  form	  a	  diketopierazine	  product.	  ______________________________________________	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Figure	  2.	  17:	  Chromatogram	  of	  Fmoc-­‐VANP(COOH)	  using	  gradient	  elution	  showed	  two	  peaks	  with	  
the	  peptide	  eluting	  at	  22	  minutes.	  _____________________________________________________________________	  93	  
Figure	  2.	  18:	  Mass	  spectrometry	  analysis	  of	  the	  peptide	  showed	  the	  mass	  of	  the	  peptide	  with	  two	  
sodium	  adducts	  (666.25	  g/mol).	  This	  is	  due	  to	  the	  absence	  of	  any	  site	  for	  positive	  ionisation	  in	  the	  
MS.	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Figure	  2.	  19:	  UV	  spectrum	  of	  FMOC-­‐VANP(COOH)	  peptide	  scanned	  from	  220-­‐320	  nm.	  The	  peptide	  
showed	  characteristic	  peaks	  at	  265	  nm,	  285	  nm	  and	  301	  nm.	  _______________________________________	  95	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Figure	  2.	  20:	  Peptide	  calibration	  curve	  for	  Fmoc-­‐VANP(COOH)	  peptide.	  The	  peptide	  demonstrated	  
a	  linear	  detection	  range	  up	  to	  400	  ug/ml	  at	  301	  nm,	  while	  the	  calibration	  curve	  at	  265	  nm	  was	  
only	  linear	  unto	  200	  ug/ml.	  ____________________________________________________________________________	  96	  
Figure	  2.	  21:	  	  Calibration	  curve	  for	  Fmoc-­‐VANP(COOH)	  at	  300	  nm	  wavelength	  as	  obtained	  by	  UV	  
spectroscopy	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Figure	  2.	  22:	  NIPs	  incubated	  overnight	  in	  acetonitrile	  did	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  98	  
Figure	  2.	  23:	  NIP	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  2.	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  2.	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Figure	  2.	  27:	  Binding	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  28:	  Binding	  isotherm	  fitted	  with	  Freundlich-­‐Langmuir	  adsorption	  isotherm	   __________	  111	  
Figure	  2.	  29:	  Binding	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  of	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Figure	  2.	  32:	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  2.	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  2.	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  Scatchard	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  analysis	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Figure	  2.	  36:	  Binding	  isotherm	  for	  the	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  with	  urea	  monomers	  imprinted	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  DMF	  porogen.	  (N	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  the	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  Functional	  monomers	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  that	  interact	  with	  the	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  These	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  are	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  into	  place	  by	  polymerisation	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of	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Figure	  3.	  2:	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  of	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  the	  template	  and	  the	  functional	  monomer.	  
The	  template	  is	  then	  entrapped	  into	  the	  polymer	  upon	  electropolymerisation	  locking	  the	  
interactions	  in	  place.	  The	  template	  is	  washed	  away	  to	  expose	  the	  imprinted	  cavities.	  Rebinding	  of	  
the	  template	  is	  measured	  via	  different	  electroanalytical	  techniques.	  The	  schematic	  has	  been	  
reproduced	  from	  Sharma	  et	  al.,	  2012.12	  _____________________________________________________________	  138	  
Figure	  3.	  3:	  Schematic	  of	  3-­‐electrode	  setup	  showing	  the	  working	  electrode	  (WE),	  reference	  
electrode	  (RE)	  and	  a	  counter	  electrode	  (CE)	  connected	  to	  an	  external	  potentiostat.	  _____________	  140	  
Figure	  3.	  4:	  Structure	  of	  electrochemical	  double	  layer:	  The	  inner	  Helmholtz	  plane	  (IHP)	  is	  closest	  
to	  the	  metal	  surface	  containing	  specifically	  adsorbed	  species,	  the	  outer	  Helmholtz	  plane	  (OHP)	  
consists	  of	  solvated	  ions	  non-­‐specifically	  attracted	  towards	  the	  IHP	  and	  the	  diffuse	  layer	  consists	  of	  
ions	  that	  are	  attracted	  by	  long	  distance	  forces.	  _____________________________________________________	  142	  
Figure	  3.	  5	  Cyclic	  voltammetry	  (a)	  demonstrates	  the	  variation	  of	  voltage	  versus	  time.	  In	  cyclic	  
voltammetry	  the	  voltage	  is	  switched	  from	  one	  potential	  to	  another	  over	  time	  and	  resulting	  current	  
is	  recorded	  to	  obtain	  a	  graph	  as	  show	  in	  3.5	  (b).	  This	  graph	  of	  current	  versus	  voltage	  in	  cyclic	  
voltammmetry	  is	  termed	  as	  cyclic	  voltammogram.	  In	  figure	  3.5	  (b)	  cyclic	  voltammogram	  of	  a	  
reversible	  oxidised	  species	  is	  depicted.	  The	  graph	  shows	  peak	  similarity	  in	  both	  forward	  and	  
reverse	  scan.	  An	  increase	  in	  potential	  (voltage)	  leads	  to	  oxidation	  of	  species,	  which	  causes	  an	  
increase	  in	  anodic	  current	  (faradaic	  current)	  shown	  by	  the	  sharp	  increase	  in	  the	  curve.	  When	  all	  
the	  species	  on	  the	  surface	  of	  the	  electrode	  are	  oxidised	  the	  anodic	  current	  reaches	  its	  peak	  (ipa)	  at	  
anodic	  potential	  (Epa),	  Thereafter,	  further	  increase	  in	  potential	  leads	  to	  decrease	  in	  current	  shown	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by	  the	  drop	  in	  curve.	  When	  the	  potential	  is	  reversed,	  the	  oxidised	  species	  on	  the	  surface	  is	  reduced	  
leading	  to	  an	  increase	  in	  cathodic	  current	  in	  the	  opposite	  direction.	  As	  the	  species	  can	  be	  reversibly	  
oxidised	  and	  reduced	  a	  similar	  peak	  (ipc)	  is	  obtained	  in	  the	  reverse	  scan	  at	  cathodic	  potential	  (Epc).	  
Any	  residual	  current	  not	  obtained	  from	  oxidation	  of	  species	  is	  termed	  as	  non-­‐faradaic	  current.	   146	  
Figure	  3.	  6:	  A	  sinusoidally	  varying	  potential	  is	  applied	  to	  a	  sample	  and	  the	  time	  dependent	  current	  
is	  measured	  as	  a	  function	  of	  frequency.	  It	  can	  be	  seen	  from	  the	  image	  that	  the	  current	  induced	  is	  
out	  of	  phase	  with	  the	  potential	  by	  a	  time	  lag	  θ.53	  ___________________________________________________	  148	  
Figure	  3.	  7:	  If	  one	  plots	  the	  applied	  sinusoidal	  perturbation	  signal	  Vt	  on	  the	  X-­‐axis	  and	  the	  resulting	  
sinusoidal	  current	  response	  signal	  It	  on	  the	  Y	  axis	  of	  a	  graph,	  an	  oval	  shape	  is	  obtained	  on	  the	  
graph	  which	  is	  termed	  as	  ‘Lissajous	  Figure’.	  The	  Lissajous	  figureis	  	  used	  to	  calculate	  impedance.
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Figure	  3.	  8:	  The	  figure	  represents	  the	  Nyquist	  plot	  on	  which	  the	  impedance	  can	  be	  represented	  as	  a	  
vector	  of	  length	  |Z|.	  The	  angle	  between	  the	  vector	  and	  the	  X	  axis	  is	  referred	  to	  as	  phase	  angle	  
f(=argZ).	  Impedance	  is	  represented	  as	  a	  complex	  number	  with	  the	  following	  equation:𝑍𝜔 = 𝐸𝐼 =𝑍0exp𝑗𝜙 =   𝑍0(𝑐𝑜𝑠𝜙 + 𝑗𝑠𝑖𝑛𝜙)	  where	  Z	  is	  impedance,	  ω	  is	  radians	  which	  is	  related	  to	  frequency	  by	  2πf,	  E	  potential,	  I	  current	  and	  j	  is	  an	  imaginary	  number.	  Hence,	  from	  the	  equation	  Z(ω)	  is	  composed	  of	  Z’	  (real)	  (Z0	  cosφ)	  plotted	  on	  the	  X	  axis	  and	  Z’’	  (imaginary)	  component	  (Z0	  j	  sinφ)	  on	  Nyquist	  plot.	  __________________________________________________________________________________________	  151	  
Figure	  3.	  9:	  A	  typical	  Randle’s	  equivalent	  circuit	  for	  EIS	  circuits.	  Rs	  is	  the	  solution	  resistance	  which	  
remains	  more	  or	  less	  constant.	  Rs	  is	  in	  series	  with	  charge	  transfer	  resistance	  (Rct)	  and	  double	  layer	  
capacitance	  (Cdl).	  Rct	  is	  the	  charge	  transfer	  resistance	  of	  the	  biolayer	  immobilised	  on	  the	  surface.	  
Cdl	  is	  defined	  as	  the	  capacitance	  exhibited	  by	  the	  two	  parallel	  layers	  of	  charge	  surrounding	  the	  
electrode.	  W	  is	  defined	  as	  the	  Warburg’s	  element,	  which	  models	  the	  diffusion	  process	  in	  the	  system.
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Figure	  3.	  10:	  Formation	  of	  active	  PSA	  and	  pro-­‐PSA	  forms	  distinguished	  by	  the	  amino	  acid	  sequence	  
and	  the	  site	  of	  truncation.	  PSA	  is	  a	  237	  amino	  acid	  protein	  with	  7	  amino	  acid	  activation	  sequence	  
in	  the	  pro-­‐form	  which	  is	  cleaved	  by	  hK2	  extracellulary	  to	  give	  active	  PSA.61	  ______________________	  154	  
Figure	  3.	  11:	  Structure	  of	  pro-­‐PSA	  peptide,	  APLILSR,	  showing	  alanine-­‐proline-­‐leucine-­‐isoleucine-­‐
leucine-­‐serine-­‐arginine	  in	  the	  chemical	  structure.	  __________________________________________________	  154	  
 xxiii  
Figure	  3.	  12	  Schematic	  of	  the	  Pro-­‐PSA	  peptide	  imprinting	  process.	  (a)	  A	  gold	  bare	  electrode	  was	  
first	  cleaned	  electrochemically	  and	  chemically	  (b)	  Thiolated-­‐pro-­‐PSA	  peptide	  was	  immobilised	  on	  
the	  electrode	  (c)	  Immobilised	  electrode	  was	  trapped	  into	  a	  polymer	  via	  electropolymerisation	  (d)	  
The	  peptide	  was	  removed	  to	  expose	  imprinted	  cavities	  (e)	  pro-­‐PSA	  peptide	  was	  reintroduced	  to	  
study	  binding	  characteristics	  using	  electrochemical	  techniques.	  __________________________________	  157	  
Figure	  3.	  13:	  Three-­‐electrode	  setup	  with	  working	  (green),	  counter	  (white)	  and	  reference	  (red)	  
electrodes.	  The	  set	  up	  is	  connected	  to	  a	  potentiostat	  that	  records	  electrochemical	  measurements.
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Table	  3.	  2:	  Polymerisation	  conditions	  for	  electroactive	  monomers	  for	  NIP	  screening	  study.	  _____	  164	  
Figure	  3.	  14:	  Synthesis	  process	  of	  MUA-­‐(Trt)	  whereby	  equimolar	  (2.28	  mmol)	  concentration	  of	  Trt-­‐
Cl	  and	  MUA	  dissolved	  in	  7.5	  ml	  	  dry	  DCM	  and	  stirred	  overnight	  at	  room	  temperature.	  The	  TLC	  
shows	  the	  retention	  of	  Trt-­‐Cl	  (A),	  MUA	  (B)	  and	  the	  product	  (C),	  which	  forms	  a	  bright	  yellow	  colour	  
upon	  exposing	  to	  sulphuric	  acid,	  with	  a	  different	  retention	  time	  than	  Trt-­‐Cl.	  _____________________	  169	  
Figure	  3.	  15:	  Structure	  10-­‐(triphylthio)	  decanoic	  acid	  (MUA-­‐(Trt))	  _______________________________	  170	  
Figure	  3.	  16:	  1H	  NMR	  of	  10-­‐trypheynlthiodecanoic	  acid	  showing	  respective	  shifts	  for	  hydrogen	  
molecules.	  _____________________________________________________________________________________________	  171	  
Figure	  3.	  17:	  Chromatographic	  evaluation	  of	  pro-­‐PSA	  activation	  peptide	  containing	  one	  major	  or	  
the	  dominant	  peak	  at	  5.38	  minutes.	  _________________________________________________________________	  173	  
Figure	  3.	  18:	  Mass	  spectrometry	  of	  pro-­‐PSA	  activation	  peptide	  (APLILSR)	  showing	  the	  correct	  mass	  
of	  768	  g/mol.	  __________________________________________________________________________________________	  173	  
Figure	  3.	  19:	  Chromatography	  of	  MUA	  tagged	  pro-­‐PSA	  activation	  peptide	  showing	  slightly	  longer	  
retention	  time	  than	  the	  pro-­‐PSA	  peptide.	  A	  drift	  in	  baseline	  during	  the	  analytical	  run	  was	  obtained	  
which	  could	  be	  a	  result	  of	  residual	  solvents	  in	  the	  HPLC	  gradient	  run.	  ____________________________	  174	  
Figure	  3.	  20:	  Mass	  spectrometry	  of	  MUA	  tagged	  pro-­‐PSA	  peptide	  showing	  the	  correct	  mass	  of	  968	  
g/mol.	   _________________________________________________________________________________________________	  174	  
Figure	  3.	  21	  Cyclic	  voltammogram	  of	  electropolymerisation	  of	  dopamine.	  The	  polymerisation	  of	  
dopamine	  leads	  to	  reduction	  in	  peak	  current	  at	  3.9	  V	  with	  increasing	  number	  of	  cycles	  indicating	  
deposition	  of	  a	  non-­‐conducting	  polymer.	  ____________________________________________________________	  177	  
Figure	  3.	  22:	  Polymerisation	  of	  dopamine	  is	  proposed	  to	  occur	  via	  an	  ECE	  mechanism.	  The	  first	  
step	  involves	  the	  electrochemical	  oxidation	  to	  dopamine	  orthoquinone	  (DAQ),	  which	  proceeds	  to	  
 xxiv  
form	  leucodopaminechrome	  (LDAC).	  LDAC	  further	  oxidises	  to	  dopaminechrome,	  which	  rearranges	  
itself	  to	  5,6-­‐dihydroxyindole,	  which	  further	  polymerises	  on	  the	  gold	  surface.	  _____________________	  178	  
Figure	  3.	  23	  Cyclic	  voltammogram	  of	  electropolymerisation	  of	  aminophenol,	  which	  depicts	  a	  large	  
decrease	  in	  current	  after	  1st	  cycle	  of	  polymerisation	  indicating	  maximum	  polymer	  coverage	  after	  
the	  1st	  cycle.	  A	  decrease	  in	  current	  also	  indicates	  the	  deposition	  of	  a	  non-­‐conducting	  polymer.	  _	  179	  
Figure	  3.	  24:	  Electropolymerisation	  mechanism	  of	  polyaminophenol.	  The	  O-­‐AP+.	  radical	  forms	  a	  
dimer,	  which	  is	  subsequently	  oxidised	  to	  form	  polyaminophenol.	  __________________________________	  180	  
Figure	  3.	  25	  Cyclic	  voltammogram	  of	  electropolymerisation	  of	  poly	  3-­‐aminobenzoic	  acid.	  The	  CV	  
shows	  one	  large	  oxidation	  peak	  at	  0.9	  V,	  which	  significantly	  reduces	  after	  the	  first	  cycle	  indicating	  
deposition	  of	  a	  non-­‐conducting	  polymer.	  ____________________________________________________________	  181	  
Figure	  3.	  26:	  The	  first	  step	  of	  the	  polymerization	  process	  of	  aniline	  is	  the	  formation	  of	  aniline	  
cation	  radicals	  by	  anodic	  oxidation	  on	  the	  electrode	  surface.	  Following	  the	  formation	  of	  the	  
cations,	  coupling	  of	  the	  anilinium	  radicals	  occurs,	  which	  is	  then	  followed	  by	  elimination	  of	  two	  
protons	  and	  re-­‐aromatization	  leading	  to	  formation	  of	  dimer.78	  The	  dimers	  is	  further	  oxidised	  
leading	  to	  the	  formation	  of	  polyaniline	  on	  the	  electrode	  surface.	  __________________________________	  182	  
Figure	  3.	  27:	  EIS	  response	  of	  electropolymers	  to	  1µg/mL	  PSA	  (a)	  polydopamine	  (PDA)	  (b)	  
polyaminophenol	  (PAP)	  (c)	  polyaminobenzoic	  acid	  (ABA)	  _________________________________________	  184	  
Figure	  3.	  28	  Capacitance	  responses	  of	  electropolymers	  upon	  incubation	  with	  1µg/mL	  PSA.	  
Polydopamine	  (PDA)	  showed	  the	  maximum	  change	  in	  capacitance	  when	  compared	  to	  
polyaminophenol	  (PAP)	  and	  polyaminobenzoic	  acid	  (P	  3-­‐ABA)	  (n=2).	  ____________________________	  186	  
Figure	  3.	  29:	  Compares	  the	  CV	  of	  bare	  golf	  with	  gold	  modified	  with	  1mM	  peptide-­‐MUA.	  	  CV	  of	  a	  
bare	  gold	  (black)	  showing	  well-­‐defined	  oxidation	  and	  reduction	  peaks.	  CV	  post	  pro-­‐PSA-­‐(MUA)	  
peptide	  modification	  on	  the	  electrode	  (red)	  shows	  (∼	  100	  %)	  loss	  in	  peak	  current.	  ______________	  188	  
Figure	  3.	  30:	  Polydopamine	  polymerisation	  on	  the	  MUA/Peptide	  functionalised	  electrodes	  _____	  189	  
Figure	  3.	  31:	  Cyclic	  voltammograms	  of	  the	  bare	  gold	  electrode	  (black)	  showing	  well	  defined	  peaks	  
at	  0.23V	  corresponding	  to	  oxidation	  of	  gold	  in	  K3/K4.	  A	  subsequent	  reduction	  in	  peak	  current	  was	  
observed	  with	  increasing	  concentrations	  of	  peptide	  (100	  nM	  to	  10	  µM)	  due	  to	  presence	  of	  a	  
resistive	  peptide	  layer	  on	  the	  surface.	  _______________________________________________________________	  190	  
Figure	  3.	  32:	  Pro-­‐PSA-­‐MUA	  peptide	  approximate	  surface	  coverage	  on	  the	  bare	  gold	  electrodes	  
measured	  at	  different	  concentrations	  of	  the	  peptide.	  _______________________________________________	  192	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Figure	  3.	  33:	  Polydopamine	  polymerisation	  on	  the	  electrodes	  pre-­‐incubated	  with	  500	  nM	  peptide	  
with	  5	  cycles	  of	  electropolymerisation.	  The	  CV	  shows	  distinct	  oxidation	  and	  reduction	  peaks	  
indicative	  of	  successful	  dopamine	  polymerisation.	  __________________________________________________	  193	  
Figure	  3.	  34	  Cyclic	  voltammogram	  of	  the	  peptide	  modified	  electrode	  post	  electropolymerisation.	  A	  
further	  decrease	  in	  current	  was	  observed	  following	  5	  cycles	  of	  polymerisation.	  __________________	  194	  
Figure	  3.	  35:	  Reductive	  desorption	  of	  pro-­‐PSA	  peptide	  from	  the	  bare	  gold	  electrode	  in	  50	  mM	  NaOH	  
shows	  a	  peak	  at	  -­‐1.0	  V	  which	  is	  assumed	  to	  be	  corresponding	  to	  the	  pro-­‐PSA-­‐MUA	  peptide.	   ____	  196	  
Figure	  3.	  36	  CV	  of	  pro-­‐PSA	  peptide	  immobilised	  electrodes	  pre	  and	  post	  reductive	  desorption.	  An	  
increase	  in	  current	  and	  a	  shift	  in	  voltage	  was	  observed	  post	  desorption	  of	  peptide	  by	  subjecting	  
electrodes.	  _____________________________________________________________________________________________	  197	  
Figure	  3.	  37:	  CV	  of	  the	  electrodes	  showing	  change	  in	  peak	  current.	  There	  is	  a	  decrease	  in	  peak	  
current	  post	  polymerisation	  of	  polydopmaine	  (blue)	  at	  0.22V.	  Post	  desorption	  of	  the	  peptide,	  the	  
peak	  current	  is	  observed	  to	  increase	  (red	  line)	  which	  is	  likely	  due	  to	  removal	  of	  the	  peptide	  and	  
increased	  permeability	  of	  polydopamine.	  ___________________________________________________________	  199	  
Figure	  3.	  38	  MIPs	  with	  different	  cycles	  (3,6,9)	  of	  polymerisation	  when	  challenged	  with	  100	  μM	  
peptide	  showed	  different	  imprinting	  factors.	  MIPs	  with	  3	  cycles	  showed	  a	  lower	  imprinting	  factor	  
than	  6	  cycles,	  which	  could	  be	  due	  insufficient	  coverage	  of	  the	  peptide	  during	  polymerisation.	  9	  
cycles	  of	  polymerisation	  showed	  a	  reverse	  effect	  suggesting	  certain	  entrapment	  of	  the	  peptide	  into	  
the	  polymer.	  ___________________________________________________________________________________________	  204	  
Figure	  3.	  39:	  RC	  circuit	  fro	  modelling	  the	  impedance	  curves	  obtained	  for	  the	  polydopamine	  
modified	  electrodes.	   __________________________________________________________________________________	  205	  
Figure	  3.	  40	  Impedance	  cole-­‐cole	  plots	  of	  MIP	  (a)	  and	  NIP	  (b)	  response	  to	  the	  pro-­‐PSA	  peptide.	  It	  
can	  be	  seen	  from	  the	  graphs	  that	  MIP	  response	  to	  the	  pro-­‐PSA	  peptide	  was	  significantly	  higher	  
that	  the	  NIP	  electrodes.	  _______________________________________________________________________________	  206	  
Figure	  3.	  41	  Relative	  changes	  in	  capacitance	  of	  MIP	  and	  NIP	  electrode	  to	  different	  concentration	  of	  
the	  pro-­‐PSA	  peptide	  (APLILSR).	  MIP	  electrodes	  demonstrated	  a	  higher	  response	  when	  compared	  to	  
NIP	  electrodes	  at	  the	  same	  concentration,	  which	  was	  indicative	  of	  an	  imprinting	  effect.	  (Data	  
represents	  n=6	  and	  error	  bars	  represent	  standard	  deviation.)	  _____________________________________	  208	  
Figure	  3.	  42	  The	  pro-­‐PSA	  MIP	  sensor	  responses	  to	  test	  peptide	  and	  cross-­‐reactant	  peptide	  in	  a	  non-­‐
competitive	  assay.	  The	  test	  peptide	  contained	  a	  random	  amino	  acid	  sequence	  (Threonine-­‐
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Isoleucine-­‐Valine-­‐Alanine-­‐Aspargine-­‐Proline),	  which	  would	  demonstrate	  very	  low	  shape	  and	  
chemical	  similarity	  to	  the	  pro-­‐PSA	  activation	  peptide.	  Hence,	  it	  was	  expected	  that	  the	  MIP	  sensor	  
would	  not	  recognise	  the	  test	  peptide.	  The	  sensor	  displayed	  some	  response	  towards	  the	  test	  peptide	  
however	  it	  was	  a	  non	  –specific	  binding	  response.	  The	  MIP	  electrode	  failed	  to	  distinguish	  between	  
cross-­‐reactant	  (pro-­‐hK2)	  peptide	  and	  the	  pro-­‐PSA	  activation	  sequence	  which	  had	  greater	  than	  
90%	  sequence	  similarity.	  Data	  represents	  n=4	  and	  error	  bars	  represent	  standard	  deviation.	  ___	  212	  
Figure	  3.	  43	  Response	  of	  conventionally	  prepared	  pro-­‐peptide	  MIP/NIP	  sensors.	  Data	  represents	  
n=3	  and	  error	  bars	  represent	  standard	  deviation.	  __________________________________________________	  214	  
Figure	  4.	  1	  Generation	  of	  aptamers	  using	  the	  SELEX	  process.	  The	  aptamers	  are	  chosen	  from	  a	  pool	  
of	  nucleotides	  sequence	  and	  checked	  for	  binding	  to	  the	  target	  repeatedly	  till	  a	  high-­‐affinity	  
sequence	  is	  identified	  and	  amplified.	  Figure	  adapted	  from	  (http://www.creative-­‐
biogene.com/Services/Aptamers/Technology-­‐Platforms.html)	   ___________________________________	  233	  
Figure	  4.	  2:	  PSA	  aptamer	  folds	  into	  a	  secondary	  structure	  upon	  binding	  to	  PSA	  predicted	  by	  Mfold	  
program,	  obtained	  from	  Savory	  et	  al.	  (2010),15	  with	  permission	  from	  Elsevier.	  __________________	  236	  
Table	  4.	  1:	  Summary	  of	  PSA	  aptamer	  sensors,	  detection	  technique	  and	  their	  sensitivity.	   ________	  238	  
Figure	  4.	  3:	  Schematic	  of	  apta-­‐MIP	  electrode	  preparation	  process:	  aptamer-­‐PSA	  complex	  is	  
immobilised	  via	  thiol	  chemistry	  (a)	  dopamine	  is	  electropolymerised	  to	  entrap	  the	  PSA	  (b)	  PSA	  is	  
extracted	  by	  washing	  with	  detergent	  and	  acid	  (c)	  Post	  template	  extraction	  sensor	  is	  tested	  for	  
rebinding	  of	  proteins	  (d)	  _____________________________________________________________________________	  240	  
Figure	  4.	  4:	  Three-­‐electrode	  setup	  with	  working	  (green),	  counter	  (white)	  and	  reference	  (red)	  
electrodes.	  The	  set-­‐up	  is	  connected	  to	  a	  potentiostat	  measures	  electrochemical	  changes	  in	  the	  
system.	  _________________________________________________________________________________________________	  243	  
Figure	  4.	  5:	  Cyclic	  voltammograms	  showing	  a	  reduction	  in	  current	  and	  shift	  in	  peak	  voltage	  
following	  immobilisation	  of	  complex	  performed	  in	  10	  mM	  PBS	  (pH	  7.4)	  containing	  10	  mM	  
ferro/ferricyanide	  [Fe(CN)6]3-­‐/4.	  _____________________________________________________________________	  250	  
Figure	  4.	  6:	  Reduction	  of	  peak	  current	  with	  increase	  in	  polymerisation	  times	  ____________________	  252	  
Figure	  4.	  7:	  Use	  of	  autopolymerisation	  of	  dopamine	  for	  imprinting.	  PSA	  binding	  results	  of	  apta-­‐MIP	  
and	  NIP	  ________________________________________________________________________________________________	  253	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Figure	  4.	  8:	  Cyclic	  voltammograms	  showing	  electropolymerisation	  of	  dopamine	  on	  DNA	  aptamer-­‐
PSA	  modified	  gold	  electrodes.	  A	  reduction	  in	  peak	  current	  at	  0.39V	  as	  well	  as	  at	  0.07V	  and	  -­‐0.35V	  
was	  observed	  showing	  deposition	  of	  insulating	  polymer	  on	  the	  surface.	  __________________________	  255	  
Figure	  4.	  9:	  Cyclic	  voltammograms	  showing	  steps	  of	  apta-­‐MIP	  fabrication-­‐.	  The	  blue	  curve	  shows	  
the	  reduction	  in	  peak	  current	  post	  polymerisation	  of	  dopamine.	  There	  is	  a	  significant	  reduction	  in	  
current	  compared	  to	  bare	  gold	  as	  a	  result	  of	  an	  insulating	  polymer	  being	  deposited.	  The	  inset	  
shows	  the	  magnified	  view	  of	  the	  peaks	  post	  polymerisation.	  _______________________________________	  256	  
Figure	  4.	  10:	  Cyclic	  voltammograms	  showing	  steps	  of	  apta-­‐	  MIP	  fabrication	  performed	  in	  10mM	  
PBS	  (pH	  7.4)	  containing	  10	  mM	  ferro/ferricyanide	  [Fe(CN)6]3-­‐/4-­‐.	  The	  Apta-­‐MIP	  shows	  an	  increase	  
in	  current	  indicating	  removal	  of	  protein.	  Apta-­‐NIPs	  also	  show	  an	  increase	  in	  current,	  although	  
smaller,	  which	  is	  attributed	  to	  the	  loss	  of	  some	  polymer	  during	  the	  wash	  process.	  The	  increase	  in	  
current	  0.5V	  is	  attributed	  to	  non-­‐faradaic	  current.	  _________________________________________________	  258	  
Figure	  4.	  11:	  Anson	  plot	  of	  Q	  versus	  t1/2	  for	  determination	  of	  surface	  charge.	  The	  measurements	  are	  
taken	  before	  (black)	  and	  after	  the	  addition	  (red)	  of	  ruthenium	  redox	  molecules	  and	  the	  intercept	  
can	  be	  extrapolated	  from	  the	  graphs	  which	  corresponds	  to	  Qdl+nFAΓ0	  ___________________________	  260	  
Figure	  4.	  12:	  Change	  in	  surface	  confined	  charged	  for	  electrodes	  washed	  with	  water	  (red)	  and	  
electrodes	  washed	  with	  SDS	  and	  acetic	  acid	  (black).	  Change	  in	  surface	  confined	  charges	  indirectly	  
represents	  the	  change	  in	  DNA	  molecules	  on	  the	  surface.	  The	  DNA	  molecules	  decreased	  from	  
2.99x1013	  to	  2.78x1013	  post	  washing	  with	  SDS	  and	  acetic	  acid.	  __________________________________	  261	  
Figure	  4.	  13:	  (a)	  Dose	  response	  of	  PSA	  for	  apta-­‐MIPs	  with	  25	  cycles	  of	  polymerisation.	  (b)	  Dose	  
response	  for	  apta-­‐MIPs	  with	  7	  cycles	  of	  polymerisation.	  Both	  show	  a	  loss	  in	  sensitivity	  in	  terms	  of	  
changes	  in	  capacitance	  and	  poor	  imprinting	  effects	  compared	  to	  7	  cycles	  of	  polymerisation	  as	  
described	  in	  section	  4.4.5.	  ____________________________________________________________________________	  264	  
Figure	  4.	  14:	  Change	  in	  contrast	  of	  the	  image	  from	  bare	  gold	  (a)	  to	  gold	  coated	  with	  apta-­‐MIPs	  (b)	  
is	  indicative	  of	  a	  uniform	  polymeric	  layer	  on	  the	  surface	  ___________________________________________	  265	  
Figure	  4.	  15:	  SEM	  images	  of	  the	  cross-­‐Section	  of	  polymer	  on	  gold.	  The	  bottom	  grey	  part	  is	  glass,	  
followed	  by	  chromium	  (62	  nm)	  and	  gold.	  The	  gold	  layer	  (90	  nm)	  is	  the	  brightest	  as	  it	  becomes	  
charged	  with	  electrons	  from	  the	  beam.	  The	  dark	  layer	  on	  top	  of	  the	  gold	  is	  the	  polydopamine	  layer	  
showing	  thickness	  measurements	  of	  8.42,	  8.23	  and	  10.1	  nm.	   ______________________________________	  266	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Figure	  4.	  16:	  The	  polymer	  depth	  was	  measured	  using	  AFM.	  A	  step	  edge	  on	  the	  polymer	  coated	  
electrode	  was	  created	  by	  making	  small	  scratches	  in	  each	  film	  using	  a	  sharp	  cantilever	  tip,	  <	  10	  nm,	  
on	  a	  rigid	  cantilever	  of	  spring	  constant	  42	  N/m.	  AFM	  images	  (a,b)	  and	  graphs(c,d)	  demonstrate	  
the	  height	  profile	  of	  the	  step	  edge	  created	  on	  the	  surface	  of	  apta-­‐MIPs	  before	  and	  after	  the	  
washing	  process.	  ______________________________________________________________________________________	  268	  
Figure	  4.	  17:	  FTIR	  spectrum	  of	  polydopamine	  on	  the	  gold	  surface	  (b)	  showing	  characteristic	  peaks	  
for	  NH	  and	  OH	  groups	  (3200-­‐3600	  cm-­‐1).	  A	  small	  C=O,	  C=C	  and	  C=N	  stretch	  is	  also	  observed	  from	  
1200-­‐1600	  cm-­‐1.	  The	  corresponding	  peaks	  are	  absent	  in	  the	  FTIR	  spectrum	  of	  bare	  gold	  (a).	  __	  269	  
Figure	  4.	  18:	  Nyquist	  plots	  showing	  changes	  in	  impedance	  of	  the	  apta-­‐MIP	  sensor	  for	  different	  
concentration	  of	  PSA	  (0.1	  pg/ml	  to	  100000	  pg/ml).	  The	  apta-­‐NIP	  on	  the	  other	  hand	  shows	  
negligible	  change	  on	  addition	  of	  PSA	  due	  to	  absence	  of	  polymeric	  cavities.	  _______________________	  270	  
Figure	  4.	  19:	  Capacitance	  plots	  showing	  changes	  in	  capacitance	  of	  the	  apta-­‐MIP	  and	  apta-­‐NIP	  
sensor	  for	  different	  concentration	  of	  PSA.	  The	  DNA	  aptamer	  folds	  into	  its	  conformation	  on	  binding	  
to	  PSA	  which	  leads	  to	  increase	  conductive	  pathways	  for	  the	  redox	  couple	  leading	  to	  increase	  in	  
capacitance	  the	  apta-­‐MIP	  sensor.	  ____________________________________________________________________	  273	  
Figure	  4.	  20:	  Dose	  response	  of	  apta-­‐MIPs	  (blue)	  and	  apta-­‐NIPs	  (green)	  with	  different	  
concentrations	  of	  PSA.	  The	  apta-­‐MIP	  sensor	  shows	  an	  increase	  in	  capacitance	  with	  different	  
concentration	  of	  protein	  while	  the	  apta-­‐NIP	  shows	  a	  negligible	  response	  to	  PSA.	  The	  horizontal	  
pink	  line	  represents	  the	  baseline	  signal	  obtained	  after	  stabilisation	  of	  the	  sensor.	  _______________	  276	  
Figure	  4.	  21:	  Polydopamine	  coated	  electrode	  washed	  only	  with	  water	  shows	  negligible	  change	  in	  
cyclic	  voltammetry	  curves	  before	  and	  after	  washing	  indicating	  no	  removal	  of	  polydopamine.	  __	  277	  
Figure	  4.	  22:	  The	  blue	  curve	  represents	  the	  apta-­‐MIP	  sensor	  response	  to	  PSA	  while	  the	  black	  curve	  
is	  the	  apta-­‐MIP	  PSA	  response	  without	  extraction	  of	  PSA.	  It	  can	  be	  seen	  when	  PSA	  is	  not	  extracted	  
from	  the	  apta-­‐MIP	  there	  is	  a	  significantly	  decreased	  response	  on	  addition	  of	  PSA	  suggesting	  that	  
protein-­‐protein	  interactions	  do	  not	  play	  a	  role	  in	  the	  recognition	  of	  PSA.	   ________________________	  278	  
Figure	  4.	  23:	  FL	  model	  applied	  to	  the	  dose	  response	  data.	  The	  data	  is	  shown	  on	  linear	  as	  well	  as	  
logarithmic	  scale.	  The	  dose	  response	  curve	  fits	  well	  with	  the	  model	  (R2	  value	  of	  0.99).	   __________	  279	  
Figure	  4.	  24:	  Comparison	  of	  conventional	  MIP	  (red)	  and	  apta-­‐MIP	  (blue)	  sensor	  performance	  with	  
different	  concentrations	  of	  PSA.	  The	  inset	  shows	  the	  magnified	  response	  data	  from	  conventional	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MIP	  sensors.	  The	  conventional	  MIP	  shows	  low	  signal	  change	  in	  comparison	  to	  apta-­‐MIP	  and	  high	  
error	  bars,	  possibly	  indicative	  of	  increased	  heterogeneity	  in	  the	  binding	  site	  population.	   _______	  282	  
Figure	  4.	  25:	  Selectivity	  study	  of	  apta-­‐MIP	  with	  different	  concentrations	  of	  hK2	  (red)	  and	  
respective	  PSA	  concentrations	  (blue).	  A	  lower	  response	  was	  observed	  with	  hK2	  than	  PSA	  following	  
incubation	  with	  apta-­‐MIPs	  in	  a	  non-­‐competitive	  binding	  assay.	  ___________________________________	  283	  
Figure	  4.	  26:	  hK2	  cross-­‐reactivity	  with	  the	  aptamer-­‐MIP	  was	  compared	  with	  the	  aptamer	  sensor.	  
The	  aptamer	  only	  sensor	  (b)	  showed	  a	  lower	  hK2/PSA	  ratio	  than	  apta-­‐MIP	  sensor	  (a)	  indicating	  
an	  increased	  cross-­‐reactivity	  to	  hk2	  with	  the	  apta-­‐MIP	  sensor.	  ____________________________________	  284	  
Figure	  4.	  27:	  Hk2	  reactivity	  with	  apta-­‐NIP	  sensor	  (purple)	  shows	  a	  signal	  change	  of	  1.5	  %	  showing	  
low	  cross-­‐reactivity	  to	  the	  polymer.	  The	  decrease	  in	  capacitance	  was	  similar	  to	  that	  observed	  with	  
PSA	  with	  apta-­‐NIPs	  (black)	  __________________________________________________________________________	  286	  
Figure	  4.	  28:	  Apta-­‐MIP	  response	  to	  HSA	  (blue)	  shows	  some	  non-­‐specific	  binding	  at	  higher	  
concentrations	  of	  HSA.	  A	  signal	  change	  of	  11	  %	  is	  observed	  for	  HSA	  concentration	  of	  6.7	  mg/ml	  
with	  apta-­‐MIPs.	  Apta-­‐NIPs	  showed	  a	  lower	  response	  to	  HSA	  (purple),	  which	  is	  mostly	  due	  to	  
absence	  of	  polymeric	  cavities.	  ________________________________________________________________________	  288	  
Figure	  5.	  1:	  Schematic	  of	  n-­‐MOSFET	  device	  containing	  the	  source	  and	  the	  drain	  through	  which	  
current	  flows	  when	  an	  external	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  is	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  across	  the	  gate	  terminal	  ______________________	  303	  
Figure	  5.	  2:	  Induced	  channel	  created	  as	  a	  result	  of	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  the	  gate	  terminal.	  ____________	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Figure	  5.	  3:	  Id	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  Vgs	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  of	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  modes	  of	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Figure	  5.	  4:	  (a)	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  the	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  complex	  (b)	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  was	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  to	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  the	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  site	  (c)	  The	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  modified	  with	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  were	  then	  utilized	  in	  an	  extended	  gate	  
MOSFET	  setup	  to	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  for	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  of	  PSA.	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  5.	  5:	  Gold	  evaporated	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  in	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Figure	  5.	  6:	  Gold	  evaporated	  electrodes	  immobilised	  in	  a	  flow	  cell	  for	  electropolymerisation	  of	  
dopamine.	  The	  electrodes	  were	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  in	  the	  flow	  cell	  and	  all	  binding	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  =	  4)	  __________________________	  318	  
Figure	  5.	  8:	  Apta-­‐MIP	  response	  versus	  apta-­‐NIP	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Figure	  5.	  9:	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  to	  1µg/mL	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  5.	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  to	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  5.	  11:	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  PSA.	  	  The	  sensor	  showed	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1.1. General Overview Of Project 
Prostate Cancer (PCa) is one of the most common cancers in men in the UK, with over 
40,000 new cases being diagnosed every year. One in every eight men suffers from 
prostate cancer in the UK.1 Successful treatment of PCa depends on early diagnosis and 
screening, which currently relies on the measurement of serum prostate specific antigen 
(PSA) levels.2 PSA is a 30 –32 KDa protein secreted by the prostate gland, levels of 
which are found elevated in men with PCa.3 PSA alone does not have sufficient 
diagnostic or prognostic power to enable patient stratification and inform treatment 
decisions.4 There is a need to develop a robust, sensitive and specific assay for prostate 
cancer detection. Monitoring the combination of different forms of PSA such as free 
PSA, total PSA and pro-PSA has been shown to improve assay specificity and 
sensitivity.3,5 This project was aimed to generate molecularly imprinted polymers as 
synthetic receptors for detection of prostate cancer biomarkers, with subsequent 
integration with a sensing platform to allow for rapid, point of care detection, diagnosis 
and monitoring. The project was part of a Marie Curie initial training network 
“PROSENSE”. 
1.2. Introduction To Prostate Cancer And Relevant Biomarkers 
1.2.1. Anatomy of the prostate gland  
The prostate gland is a small walnut sized gland located below the bladder and is part of 
the male reproductive system (Figure 1.1).6 It is divided into three anatomical zones 
known as the peripheral, central and transitional zones. The peripheral zone is closest to 
the rectum, the transitional zone is the middle section of the prostate and the central 
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zone is in front of the transitional zone and farthest from the rectum. The gland is made 
up of three different types of cells: gland cells (secrete enzymes), muscle cells (control 
urine flow) and fibrous cells that support structure of the gland. The physiological role 
of the prostate is to secrete enzymes for the de-coagulation of semen and to produce 
citrate, fructose and zinc to facilitate free movement of sperm.7 
1.2.2. Diseases of the prostate gland 
Various conditions affect the prostate such as prostatitis, benign prostatic hyperplasia 
(BPH) and cancer. Prostatis is the inflammation of the prostate, which is caused by 
infection and is treated with antibiotics. As men age, the transition zone of prostate 
gland starts to enlarge till it becomes the largest part of the gland. This condition is 
termed as BPH and affects virtually all men above the age of 50.8 BPH also leads to 
increase in PSA levels in the blood leading to false positives during PCa screening. 
Prostate cancer arises when a cell in the gland escapes its normal function during cell 
division and starts dividing abnormally and continuously as a result of mutations in 
certain genes.9 This causes the gland to enlarge abnormally as seen in Figure 1.1. Since 
the prostate gland is well connected to several lymph nodes, PCa metastases are 
relatively common in aggressive forms of PCa. Although the majority of metastases are 
found in the bone tissue, the disease is also capable of spreading to the hepatic and 
respiratory systems.10  
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Figure 1. 1: A normal prostate gland versus an enlarged prostate. Prostate enlargement can be 
because of cancer or benign prostatic hyperplasia (BPH). Source: National Cancer Institute 
website 
1.2.3. Epidemiology of prostate cancer 
Prostate cancer is the second most common male cancer, and the fourth most common 
cancer overall with more than 1,111,000 new cases diagnosed worldwide in 2012.11 It is 
also the second most common cancer in the UK, constituting 13 % of all new cancer 
cases diagnosed in men.1 In 2013, a total of 46,690 new cases of prostate cancer were 
reported in the UK, and in 2014 the disease was responsible for 11,287 deaths.12,13,14 
However, only 3 % of men with PCa die as a result of cancer as most men live with the 
disease and die of old age or other old age related diseases.15 As there are often no major 
symptoms of PCa, especially in the early stages of the disease, it mostly goes undetected 
in men unless it is actively screened for. Early and accurate diagnosis PCa has a 
relatively high 10-year survival rate (84 %) which currently relies on a combination of 
different factors such as age, levels of PSA, biopsy and family history.16 There has been 
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a steady increase in the incidence rate of prostate cancer in all cancer networks in UK 
from 1993 to 2010.12,13,14 This could be partly attributed to wide adoption of PSA testing 
for screening of prostate cancer in men along with an ageing population. As a result of 
PSA being a poor diagnostic marker (high false positives), it is highly likely that not all 
PCa cases were positive which could have also contributed to the increase in the 
incidence rate.  
Prostate cancer is predominant in older men with about 75 % of total cases diagnosed in 
men above the age of 65 and only 3 % cases being diagnosed in men below the age of 
30.17. As most old men live with PCa after diagnosis, in 2006, a total of 181,000 men 
were living with cancer in UK, 10 years since they were first diagnosed, and this 
number is only set to increase in the coming years (a predicted 12 % increase in the UK 
between 2014 and 2035).18 Seeing the trend of incidence rate, the disease burden is only 
set to rise and increase the pressure on the public health system. There is a significant 
need for better diagnostic tools to facilitate early and accurate diagnosis of PCa, which 
the network aims to address. There also exists a need for the development of a platform 
consisting of a panel of biomarkers that can not only detect PCa but also differentiate 
between benign and aggressive PCa forms, monitor disease progression and predict the 
effectiveness of treatment and chances of remission. 
1.2.4. Screening and diagnosis of prostate cancer 
A variety of physiological examinations are currently used to both screen for and 
diagnose prostate cancer. Each method of detection has certain shortfalls making it 
controversial to use any one procedure in isolation for the diagnosis of PCa. Several 
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clinical studies have tried to study combination of these techniques to increase 
specificity of diagnosis and reduce overtreatment. 19 These are discussed in turn below. 
1.2.4.1. Prostate Specific Antigen (PSA) testing  
PSA was first described as a semen biomarker for use in forensic sciences by Hara et al 
in 1971.20 It was discovered later, in 1981, that PSA could be detected in serum and was 
elevated in patients with prostate cancer.21 In 1994, FDA officially approved PSA for 
the screening of prostate cancer after a study from a multicentre trial concluded that 
serum PSA could be a useful biomarker for early detection of prostate cancer.22 Total 
PSA level in serum, tested by enzyme linked immunosorbent assays, was set with an 
upper cut-off value of 4 ng/ml for prostate biopsies.23 The test had very low sensitivity 
(44 %) but good specificity (92 %).24 The low sensitivity was a result of elevated PSA 
levels in serum due to BPH or prostatitis,25 which resulted in overdiagnosis leading to 
unnecessary biopsies and radical prostatectomy leaving patients at a high risk of 
developing serious secondary infections. Additionally, it was discovered that about 20–
50 % of prostate cancers developed in men with PSA levels below 4 ng/ml.26 This meant 
that 20 –50 % PCa cases were missed by standard screening process resulting high false 
negatives. Furthermore, large-scale clinical trials failed to show reduction in disease-
specific mortality or increase in survival rates with increased PSA testing making it a 
highly debated biomarker for PCa screening.27,28 Surrogate measures such as PSA 
density, PSA ratio, PSA velocity, age-specific PSA range, PSA isoforms have been used 
to increase specificity of t-PSA assay for PCa.23 In May 2012, the US Preventative 
Services Task Force (USPSTF) recommended against routine PSA blood test for 
screening of PCa in all men (without symptoms) regardless of age. USPSTF also 
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emphasised the need for better biomarkers to help patients make informed decision 
about their treatment options.29 
1.2.4.2. Digital rectal examination (DRE):  
The prostate peripheral zone, where the majority of prostate cancers originate, is located 
near the rectum, making it straightforward to identify tumour growth via digital rectal 
examination (DRE).30 In this procedure, a doctor examines for bumps or swellings in the 
prostate gland by inserting a gloved finger into the rectum. DRE is an inexpensive 
method for diagnosis and can detect cancers missed by PSA test. This DRE test is 
approximately 59 % accurate but has a higher specificity of 83 -94 %.31 It is regularly 
used for cancer diagnosis as it has the advantage of detecting cancer in men with normal 
PSA levels and does not cause much discomfort to patients.  
1.2.4.3. Biopsy: 	  
A prostate biopsy is carried out in patients based on (a) the DRE findings, (b) higher 
PSA levels (greater than 4 ng/ml) and (c) after considering additional factors such as 
family history, ethnicity, PSA isoform levels and PSA kinetics.19 In this technique, a 
small section of the tissue is removed and microscopically examined. Most protocols 
require a high number of samples to be removed from the peripheral zone of the prostate 
for PCa detection making it a painful procedure. However, the location and the number 
of biopsy cores from which the samples need to be retrieved remains controversial, 
reducing the accuracy of this technique.32 Apart from being painful, this method has a 
high risk of severe secondary infection.33 Gleason score, a grading system based on 
histologic pattern of cells in H&E-(Hematoxylin and eosin) stained sections, is an 
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established technique which is used to aid biopsy results for prognosis of PCa.34 
Transrectal ultrasonography (TRUS) is a technique in which an ultrasound probe is used 
to image the prostate gland by emitting high-energy sound waves.35 TRUS is used in 
conjunction with biopsies for guiding needles for the sampling of tissue. It is a 
beneficial tool for understanding tumour pathology and is well tolerated by patients.36	  
1.2.5. Prostate cancer biomarkers  
Biomarkers serve as an important diagnostic tool in the early detection and appropriate 
treatment of prostate cancer.37 A biomarker is defined as a biological molecule found in 
blood, urine or other body fluids, or tissues, which indicates the normal or abnormal 
condition of a body.38 Measurement of biomarkers can enable: screening of a disease in 
general population, predicting the outcome of a disease, diagnosis of a disease, 
predicting the outcome of treatment in patients and for post treatment surveillance of 
disease. PCa biomarkers that are currently in clinical use, as well as certain upcoming 
biomarkers, have discussed in the following Sections. 
1.2.5.1 Prostate specific antigen (PSA) 
PSA is a 30 -32 kDa protein secreted by the glandular epithelial cells in the prostate 
gland. Androgen hormones regulate the prostatic epithelial cells for expression of PSA 
at the transcriptional level.39 Prostatic glandular epithelial cells are surrounded by basal 
cells and the basement membrane. During the initial stages of PCa there is partial 
breakdown of the basement membrane, which allows PSA to enter the circulatory 
system elevating its concentration in blood (Figure 1.3). 
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PSA is a member of the tissue kallikrein family of proteins, which is a subgroup of 
serine proteases.37 There are 15 human kallikrein (hK) proteins synthesised by the 
kallikrein gene locus (discovered to date), although only three have specific biological 
function; pancreatic renal kallikrein (hK1), human glandular kallikrein (hK2) and 
prostate specific antigen (hK3).40   HK1 is located in the kidney and breaks down a 
kinnogen substrate brought from blood, hK2 cleaves the precursor form of PSA to yield 
active PSA41 and hK3 de-coagulates semen by breaking down proteins (semenogelin I 
and II) that are responsible for gelation of semen.42 The discovery of new kallikrein 
proteins has resulted in studies that indicate their possible role in prostate cancer. 
Human kallikrein proteins like hK4, hK6, hK10 and hK11 have shown promising results 
as serum biomarkers for PCa.43,44  
PSA is 237 amino acid protein which is synthesised in its inactive form, a 244 amino 
acid protein call pro-PSA.39 The final protein (active PSA) is a 30 KDa protein with five 
disulphide bridges and one asparagine-linked oligosaccharide. About 30 % of seminal 
PSA is enzymatically active while 5 % exists as a complex with protein C.45 The 
remaining free PSA in semen is rendered inactive by internal cleavage (enzyme cleaves 
at the active site) by human kallikrein proteases. In men with prostate cancer, the 
concentration of these internally cleaved inactive forms may be reduced as a 
consequence of down-regulation of other kallikrein proteases.46 Some amount (ng/ml) of 
active PSA produced by the prostate gland diffuses into circulatory system (serum PSA) 
where it is inactivated by the protease inhibitor α anti-chymotrypsin to form complexed 
PSA (Figure 1.3). 
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Figure 1. 2: Human prostate specific antigen (PSA/KLK3) with bound substrate from complex 
with antibody (PDB id: 2ZCK) Obtained from Wikipedia/E A S. A detailed description of crystal 
structure of PSA and ternary complex formation with anti-chymotrypsin can be found in Ménez, 
R. (2008).47 
The majority of serum PSA is found in complexed form with α anti-chymotrypsin.  
However, other inhibitors such as α 2-macroglobulin and α 1-antitrypsin also form 
complexes with PSA.48 Internally cleaved forms of PSA and pro-PSA, with no 
enzymatic activity, also enter the blood stream but remain uncomplexed and are termed 
‘free PSA’ (fPSA).49 Most antibody assays recognise free PSA as well as complexed 
PSA in serum and hence measure total-PSA (t-PSA).50  
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Figure 1. 3: PSA is secreted as pro-PSA by the epithelial cells in the peripheral zone of the 
prostate gland. Some amount of active PSA escapes into the circulatory system through 
basement membrane, which is inactivated by α-antichymotrypsin. During the early stages of 
prostate cancer there is break down of the basement membrane causing more PSA to enter 
blood elevating the concentration of serum PSA.  
1.2.5.2  Free PSA 
Free serum PSA (fPSA) is an enzymatically inactive (internally cleaved by various 
proteases), and non-complexed form of PSA.39 Free PSA is expressed a percentage of 
total PSA (% fPSA).51 Free PSA can be detected in serum using antibodies specifically 
raised for fPSA. Using the serum fPSA value, a ratio of fPSA to total PSA (complexed 
and free) can be calculated to give % fPSA. The % fPSA test with a cut of 25 % has a 
sensitivity of 95 %, and specificity of 13 %.52 Several studies have reported that % fPSA 
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test in combination with t-PSA is a better measure of predicting biopsy outcome than t-
PSA alone.53,54  Hence, it was proposed that fPSA could be a better diagnostic marker to 
increase specificity of the t-PSA test and preventing unnecessary biopsies specifically in 
men with PSA levels in the diagnostic grey zone of 4 - 10 ng/ml.  
1.2.5.3  Pro - PSA  
Pro-PSA is an enzymatically inactive precursor form of PSA containing an additional 7 
amino acid sequence at its N-terminus.49 The additional seven amino acid sequence 
(APLILSR) is cleaved by hK2 enzyme extracellularly to form the enzymatically active 
form of PSA (active-PSA). Another form of pro-PSA that results from cleavage between 
the second (serine) and the third (leucine) amino acids is called [- 2] pro-PSA. [-2] pro-
PSA is also enzymatically inactive and cannot be cleaved by trypsin or hK2.49 Various 
studies have found increased staining of [- 2] pro-PSA in prostate cancer tissue.55,56 
Other forms of truncated pro-PSA [-5], [-7] were also identified and shown to be 
elevated in prostate cancer.57 [-2] Pro-PSA was tested in a large multicentre trial to 
determine its relationship with aggressive form of prostate cancer. The study concluded 
that [-2] pro-PSA could be a useful biomarker for both the early detection of PCa and 
determining the aggressiveness of the disease.58  
1.2.5.4  T-PSA test refinement   
T-PSA assay was refined in an attempt to increase the specificity by using surrogate 
measures such as PSA density, PSA velocity, PSA doubling time and age-specific PSA 
levels in men. 
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• PSA density 
PSA density (PSAD) is defined as the ratio of PSA concentration to prostate 
volume and was first described in a study by Benson et al. The study reported 
that a PSAD value of 0.15 or more indicated towards the development of PCa.59 
Although initial studies using PSAD were able to differentiate between men with 
PCa and benign hyperplasia, later studies failed to demonstrate an improvement 
in the specificity of the t-PSA assay. This was likely due to variations in 
techniques used for determining prostate volume by different physicians, making 
the technique less accurate.60 PSAD, however, may be beneficial in 
understanding tumour pathology and also in the monitoring of disease 
progression in older men who live with the disease. 
• PSA Kinetics 
PSA velocity (PSAV) is termed as the rate of change of serum PSA 
concentration per year (ng /ml /year). A study by Carter et al. demonstrated  
(using longitudinal ageing data) that men with PSA levels between 4 –10 ng/ml 
and a PSAV value greater than 0.75 ng/ml/year was indicative of PCa.61 A 
PSAV value of 0.75 ng/ml/year or greater had a 90 -100 % specificity in 
differentiating between BPH and prostate cancer.62 Another kinetic parameter 
monitored was the time taken for the serum PSA concentration to double, so-
called as the ‘PSA doubling time’. PSA doubling time has reportedly been used 
to predict remission post treatment of PCa and metastasis-free survival.63,64  
Chapter 1                                                                                                                         General Introduction                                                                                                                       
 14 
There has been some scepticism regarding the measurement of PSA kinetics 
with one study concluding that PSAV values fail to predict biopsy results. This 
could be a result of variation in laboratory protocols, giving rise to differences in 
sampling and data collection.65 Standardisation of these protocols could provide 
better insight into the relationship between PSA kinetics and cancer.  
• Age-specific PSA  
Loeb et al. studied PSA values for specific age groups to understand their 
correlation with PCa.66 Normal geometric mean PSA values were defined as 0.7 
ng/ml for men < 60 years and 1.4 ng/ml for men > 60 years.66 The study also 
reported that men with PSA concentration greater than the median PSA level for 
their age group had a higher risk of developing PCa.66 
• Phi Testing 
A prostate health index called the ‘phi index’ was introduced by Beckman and 
Coulter in 2012.67 The phi index is calculated using a mathematical equation 
correlating free PSA, total PSA and [-2] pro-PSA. The phi index is calculated 
using the following equation: 
𝑃ℎ𝑖   𝜙 = !! !"#!!"#!"##  !"# × 𝑡 − 𝑃𝑆𝐴  	  	  	   	   (1.1)	  
The phi index has a reported diagnostic accuracy of 70 %67, which is higher than 
t-PSA and f-PSA standalone accuracy.68 In 2012, Beckman Coulter received US 
FDA clearance for the use of phi test to detect PCa in men with a PSA range of 4 
-10 ng/ml.  
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1.2.5.5  Emerging biomarkers of PCa 
Total PSA and refined PSA tests still remain important diagnostic markers for early PCa 
detection despite several controversies. The introduction of the Phi index, which 
measures combination of isoforms of PSA, has helped in increasing the specificity of t-
PSA assay. However, there is still a clinical need to develop a panel of biomarkers, in 
addition to PSA, that can not only detect PCa early but also distinguish between 
aggressive and benign forms of the disease. Apart from PSA there are various other 
emerging biomarkers, which are being studied for this purpose and are discussed in the 
following section. 
• Prostate cancer antigen 3 (PCA3) or DD3(PCA3) is a non-coding m-RNA which 
is overexpressed in the prostate tissue in prostate cancer.69 It is produced by the 
prostate cells and has high specificity (expressed in 95 % prostate cancers) in 
detecting cancer when combined with PSA in a clinical setting.70  
• Prostate stem cell antigen (PSCA) is cell surface glycoprotein, and its expression 
is upregulated in about 80 % prostate cancer. PSCA is highly expressed in 
aggressive forms of the disease.71 A correlation between overexpression of 
PSCA and advanced tumour stage has been reported in literature.75  
• Transmembrane protease, serine 2 (TMPRSS2) - ETS related gene (ERG) gene 
fusion is a transcription factor gene fusion secreted by prostate epithelial cells 
and upregulated in malignant prostate cancer cells.73 TMPRSS2-ERG is a 
common gene fusion found in almost half of PCa patients.  The biomarker has 
37 % sensitivity and 93 % specificity and can be detected in the urine.74 
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• Alpha-methylacyl - CoA racemase (AMACR) is a racemase enzyme expressed 
in prostate tissue, which can be detected in both blood and urine.75 AMACR is 
highly expressed in untreated metastases and castration resistant PCa (88 % 
cases) making it a highly specific biomarker for PCa. AMACR was shown to 
have 92.3 % sensitivity and 89.2 % specificity when tested in prostate needle 
biopsy specimen.76 
• KLK2 or hK2 is serine protease in prostate gland that converts pro - PSA into 
active PSA. It has shown to be highly expressed in men with prostate cancer and 
aids tumourigenesis in an advanced stage of cancer.37 It has the potential to be a 
biomarker in combination with t-PSA for differentiating between PCa and 
BPH.77 
• Human Prostatic acid phosphatase (hPAP) was the first biomarker discovered for 
prostate cancer before the use of PSA. Gutmean et al. reported higher serum 
PAP levels in men with PCa and bone metastases.78 After the discovery of PSA 
in 1981, PAP was no longer used as a biomarker due to low specificity, however, 
there has been renewed interest in this marker due to its good prognostic 
quality.79  
• Various other biomarkers that are also being evaluated for PCa include 
circulating tumour cells80, mi-RNAs81, PCa 7 gene panel: CTAM, CXCR3, 
FCRL3, KIAA1143, KLF12, TMEM204, SAMSN182 and prostate specific 
membrane antigen (PSMA). 83 
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1.3. Molecular Imprinting 
Molecular recognition is defined as the process of interaction between various 
biomolecules such as proteins, nucleic acid, carbohydrates and lipids in biological 
systems.84 Almost all diagnostic platforms currently rely on this molecular recognition 
process (with biological elements such as antibodies, enzymes and complimentary 
DNA/RNA sequences) for detection of disease-associated biomarkers.85 Biomolecules 
interact with each other via non-covalent interactions such as hydrogen bonding, 
hydrophobic and ionic interactions in aqueous systems.86 Some of these interactions are 
very strong, for example, the biotin and avidin interaction has a Kd of 10-15 M.87 In spite 
of such strong interactions, biomolecules like antibodies or DNA are not naturally well-
suited to biosensing applications because of their higher costs, poor stability over time 
and difficulty in engineering them onto various sensing platforms. Taking inspiration 
from naturally occurring molecular recognition processes, molecular imprinting 
engineers polymeric molecular recognition units, which are more robust, economical 
and possess comparable affinity and selectivity towards the template comparable to their 
biological counterparts.88 Molecular imprinting is a technique used to engineer synthetic 
receptors by polymerisation of functional monomers and crosslinkers around a template 
species. Following removal of the template from the polymer matrix, cavities remain 
which display both chemical and steric selectivity for the imprinted molecule (Figure 
1.4).89,90 These polymers are termed molecularly imprinted polymers or MIPs.  
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Molecular imprinting can be classified according to the type of interactions between 
monomers and template during synthesis, that is, covalent and non-covalent. Wulff and 
co-workers first reported covalent imprinting where the template molecule was 
chemically bonded to the monomers during polymerisation and post polymerisation the 
bond was cleaved for template extraction.91 Covalent imprinting gives rise to relatively 
more homogenous binding sites and reduces non-specific binding, giving rise MIPs with 
better binding characteristics (than non-covalent imprinting). 92 However, the covalent 
interactions are more stable and therefore require harsh conditions for the removal of the 
template, which can cause deformation of polymers and loss of binding site affinity. An 
alternative, non-covalent imprinting approach, was pioneered by Klaus Mosbach and co-
workers.93,94 Non-covalent imprinting relies on the formation of many weaker 
interactions like hydrogen bonding, hydrophobic and ionic interactions between the 
template and the monomers to provide overall affinity to the imprinted polymer. These 
bonds can be easily broken by mild conditions resulting in easier extraction of the 
template without loss in selectivity. Non-covalent imprinting is more popular due to 
simplicity of preparation and variety in choice of available monomers. However, the 
resulting MIPs generally have lower binding affinity than covalent MIPs.95 
Regardless of the imprinting approach, all MIPs share the same central components 
(Figure 1.4): 
• Template molecule: The template is a molecule, or analogue of a molecule, for 
which the imprinted polymer is generated. Template species vary from small 
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molecule, drug-like targets to biomacromolecules such as proteins or even whole 
cells. 
• Functional and/or crosslinking monomers: Functional and crosslinking 
monomers interact with template molecules to form a pre-polymerisation 
complex that is subsequently locked in place during polymerisation. Most 
commonly used functional monomers are methacrylic acid (acidic), vinyl 
pyridine (basic), acrylamide (hydrogen bonding),89 while the most common 
crosslinkers are ethyleneglycol dimethlyacrylate (EGDMA), bisacrylamide and 
divinylbenzene.88  
• Porogen: This is the solvent used to dissolve the template molecules and 
monomers. The choice of solvent should encourage the formation of a pre-
polymerisation, solution phase and template – monomer complex. The use of a 
solvent during the polymerisation process also helps to impart porosity to the 
final polymer. Certain common solvent for conventional imprinting are 
acetonitrile, chloroform and toluene.89 
• Non-imprinted polymers (NIPs) are synthesised in the same manner as MIPs but 
in the absence of a template species. NIPs allow for the non-specific interactions 
between the template and polymer to be evaluated.96   
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Figure 1. 4: Schematic of the molecular imprinting process: Functional and/or crosslinking 
monomers interact with a template molecule via non-covalent or covalent interactions. These 
interactions are locked into place during the polymerisation process, which is initiated by UV or 
heat. After polymerisation the template is extracted leaving a recognition site in the polymer 
that displays both chemical and steric selectivity for the template. 
Molecular imprinting and its principles mentioned in the section have been extensively 
reviewed in the literature.89,97,98 Molecular imprinting has evolved from using small 
molecules such as amino acids and drug molecules as templates to imprinting large 
proteins with intelligently designed monomers that demonstrate high affinity towards 
their template. The ultimate challenge of molecular imprinting has been to synthesise 
plastic antibodies for complex biomolecules (proteins) with similar affinities to their 
biological counterparts. The evolution of protein imprinting has been discussed in the 
following sections to understand the challenges involved. 
1.4. Protein Imprinting 
1.4.1 Aqueous protein imprinting 
Molecular imprinting has been demonstrated to be highly efficient when using small 
molecule templates, for example, pharmaceutical drugs99, amino acids94, peptides100, 
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nucleotide bases101 and sugars.102 The defined structures of such molecules and good 
solubility in organic solvents mean that high-affinity binding pockets, capable of 
selective recognition of the template, can be readily produced during the imprinting 
process.89 Macromolecular (e.g. protein) imprinting is however much more challenging; 
the relatively large size and dynamic structure of such molecules, coupled with their 
general incompatibility with conventional imprinting solvents, makes the development 
of well-defined imprinted sites much less likely.103 The non-polar solvents typically 
used for small molecule imprinting can cause denaturation/unfolding of proteins 
meaning that the resultant binding sites are a poor match for the native species. 
Moreover, as a consequence of their large size, it is often difficult to extract proteins 
from the imprinted site, with diffusional and mass transfer barriers further impeding re-
binding kinetics.104 Aqueous solvents are generally preferred for protein imprinting to 
maintain protein conformation and easy solubilisation of the protein. However, in an 
aqueous imprinting technique, hydrophilic protein has low complementarity to 
hydrophobic monomers leading to less favourable binding conditions.105 In the pre-
polymerisation mixture, water molecules and functional monomers compete for the 
same hydrogen bonds, effectively solvating the protein and monomer species, resulting 
in low chemical selectivity of the final polymer. As a result, to bring about complex 
formation between monomers and proteins, certain specific non-covalent interactions 
such as ionic, hydrophobic and/or π-π stacking may be required to build a chemically 
selective cavity.  
In recent years, various research groups have demonstrated efficient imprinting of 
proteins in aqueous systems with MIPs showing high affinity for template 
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molecules.106,107,108,109 Ken Shea’s group demonstrated molecular imprinting in an 
aqueous system using water-soluble monomers by synthesising MIP nanoparticles that 
were comparable in size to antibodies.110 Using a rational design of monomers and low 
crosslinking ratios, the NIP nanoparticles displayed high affinity for its template 
molecule mellitin (25 amino acid protein). Although, the study demonstrated the 
potential of MIPs in detection of proteins at clinically relevant concentration, fabrication 
of MIP-nanoparticles onto sensing platforms can be quite challenging. Piletsky’s group 
have developed a MIP nanoparticle reactor, which can synthesise uniform MIP particles 
for a surface immobilised template (vancomycin) in aqueous solutions.111 This 
technology has the potential for scale-up and large-scale adoption of MIPs with 
industrial applications. Furthermore, recent progress has demonstrated the integration of 
specialised functional monomers into these MIP-nanoparticles, which, can be further 
used for surface immobilisation and sensor fabrication.111 These studies demonstrate the 
potential of molecular imprinting in fabricating diagnostic sensors for clinically relevant 
biomarkers with comparable performance to their biological counterparts. 
1.4.2 Bulk imprinting of proteins 
Bulk imprinting approach involves entrapping the whole protein to form imprinted 
cavities into a polymer system similar to small molecule based bulk imprinting. This 
approach is relatively simpler as the functional monomers, crosslinkers and protein can 
be solubilised in suitable porogen to form a complex and subsequently subjected to 
UV/heat for polymerisation. The protein is extracted using multiple washes cycles or 
enzymatic digestion.112 Majority of the bulk imprinting work has been carried out using 
acrylamide gels and its derivatives with proteins templates such as BSA, lysosyme and 
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hemoglobin.113,114,115 Hydrogels, which are hydrophilic materials that swell in presence 
of water, have also shown good recognition properties upon being used in molecular 
imprinting with acrylamide as monomers. 116,A major disadvantage of bulk imprinting is 
inefficient template extraction. The large size of the protein restricts easy extraction of 
the protein. Complete extraction of template is seldom achieved causing inefficient re-
binding and template leaching.117 Acrylamide imprinted gels are not dense, have poor 
selectivity, deform under harsh conditions such as strong pH or temperature and lose 
their recognition properties over time making them ineffective for protein imprinting 
and sensing.103 
1.4.3 Surface imprinting 
An alternative approach to bulk protein imprinting is immobilising the protein on a 
surface for partial or complete imprinting. Immobilisation of the protein allows for 
easier template extraction (than bulk imprinting), better access to the imprinted cavity 
allowing for faster binding kinetics and greater binding site homogeneity. Surface 
immobilised template imprinting has been applied to surface of beads (silica beads118, 
glass beads119), quantum dots117, nanoparticles (magnetic NPs)121, nanomaterial  (carbon 
nanotube)108 and flat surfaces (gold)122 for imprinting of variety of proteins. A review by 
Yilmaz et al summarising the use of immobilised template for imprinting gives further 
insight into this field.123 There are various techniques to immobilise a protein on a 
surface: passive adsorption, covalent bonding, affinity interactions and metal 
coordination, which have been discussed in turn below. 
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1.4.3.1. Protein adsorption on surfaces 
In this strategy, the proteins are simply adsorbed onto a surface and subsequently 
imprinted using radical/electro-polymerisation. One of the first examples of this 
technique was described Shi et.al.124 Radiolabelled proteins (bovine serum albumin, 
immunoglobulin G, fibrinogen) were immobilised on a hydrophilic mica surface and 
coated with disaccharides to prevent denaturation. A thin fluoropolymer film was 
deposited onto the protein-sugar complex. Post removal of mica and the template 
protein, small cavities lined with disaccharides were exposed on the polymer, which 
displayed specific recognition towards the template protein. Some recent examples have 
used protein stamping and nanopatterning to create imprints in polymers, which has 
shown varying degrees of success.125 One major challenge this technique is conserving 
the natural conformation of the protein, which can change upon adsorption to a surface 
making the imprinting process less efficient. A refined technique to overcome this 
problem was demonstrated by Matsunaga et al wherein a crystallised protein (lysozyme) 
was used as the template for surface imprinting.126 The resulting imprinted polymer 
exhibited high selectivity towards the template protein.126 One major drawback of this 
technique is that it can be only applied to abundantly available proteins that are 
relatively inexpensive to obtain.   
1.4.3.2. Covalent bonding of protein to surface 
Covalent bonding of proteins to the surface is another elegant technique to control 
surface modification pre-polymerisation. Shiomi et al. first demonstrated such a 
technique whereby haemoglobin was covalently immobilised on aldehyde functionalised 
silica particles via imine bonds.118 The resulting imprinted cavities were found to be 
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highly selective for haemoglobin when compared to other proteins such trypsin, β-
amylase and BSA. Over the years, covalent immobilisation for surface imprinting has 
been applied to various surfaces such as gold, silica, magnetic nanoparticles, carbon 
nanotubes utilizing chemistries such as reversible aldehyde chemistry, cleavable 
crosslinkers and EDC/NHS for protein confinement.127,128,123 One disadvantage of 
surface imprinting is partial exposure of the protein for imprinting, which may result in 
poor selectivity or cross reactivity during the re-binding step. 
1.4.3.3. Specific/affinity interaction between protein and polymer 
Protein recognition in molecularly imprinted cavities relies heavily on multipoint non-
covalent interactions such electrostatic/hydrophobic and hydrogen bonding. Although, 
good affinity has been reported with polymers based on such interactions, an 
improvement may be required when measuring clinically relevant biomarkers that are 
present in very low concentrations (ng/ml or pg/ml). One such approach to overcome the 
problem is incorporation of affinity-based molecules to the resulting polymer, which, 
could lend higher specificity, and affinity to the resulting MIP. Some early approaches 
relied on metal-based affinity for surface imprinting of proteins.129,130 Mosbach’s group 
first demonstrated metal-affinity based surface imprinting for RNAase protein by 
exploiting the Cu2+ and histidine interaction.131 Surface imprinting was carried out by 
methacrylate derivativised silica particles using metal-ligand (Cu2+ - histidine) 
complexes. The chelating monomer N-(4-vinylbenzyl)iminoacetic acid was co-ordinated 
to histidines on RNAsae by Cu2+ ions which incorporated the protein into the surface 
imprinted polymer. The resulting polymer was reported to selectively recognise RNase 
over other proteins such BSA (bovine serum albumin), lysozyme, chymotrypsin and 
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HRP (horseradish peroxidase). Based on a similar concept of metal-ligand interaction a 
relatively new concept that has emerged in the recent years is that of hybrid imprinting. 
Hybrid imprinting utilizes bio-receptors (as protein recognition unit) also termed as 
‘supermonomers’ for high affinity based MIP recognition.132,133 Bowen et al. 
demonstrated this concept for imprinting of LPS template using polymyxin peptide as 
an affinity receptor for creation of hybrid MIP receptors on the surface of Merrifield 
resin.134 This technique has a unique advantage of confining the protein in its preferred 
conformation during polymerisation permitting homogeneous binding site formation 
while lending affinity to the polymer. Hybrid imprinting has been discussed in detail in 
Chapter 4. 
1.4.4 Epitope imprinting 
Epitope imprinting approach is a subset of protein imprinting, which uses small regions 
peptide sequences that are exposed on the surface of proteins for creating MIPs.135 The 
imprinted cavities not only recognise the small epitope sequence but also the larger 
macromolecule containing the epitope (Figure 1.6). Epitope imprinting has been 
discussed in further detail in Chapter 2. 
1.4.5 Protein molecular imprinting and sensing 
Molecular imprinting has great potential in diagnostics application for detection of 
relevant biomolecules and hence their application in biological and chemical sensing has 
been extensively studied in the literature.97,130,137 A biochemical sensor consists of few 
important components such as the analyte (proteins/peptide/DNA/RNA), recognition 
element (antibody/ DNA/ small molecules), transducer (piezoelectric/ voltammetric/ 
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amperometric/ optical) and the signal processor (potentiostat/ UV spectroscope).138 In 
MIP sensors, the imprinted polymer containing complementary cavities is 
deposited/grown on a sensor surface such as gold, carbon, silica and the binding of 
protein/biomolecules is observed using an appropriate transducer. Molecular imprinting 
and sensing have been discussed in further detail in Chapter 3. 
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1.5 Scope Of Thesis  
The overarching aim of this project was to develop an electrochemical platform for 
detection of prostate cancer biomarkers using synthetic receptors better termed as 
molecularly imprinted polymers. As part of the Marie Curie ITN, the project aimed to 
develop synthetic receptors that could be easily adapted to various sensing platforms 
that were concurrently being developed by project partners in the network. The main 
objectives of the project could be broadly divided into (a) selection of biomarker, (b) 
molecular imprinting of the selected biomarker to create MIPs and (c) electrochemical 
sensing of the biomarker using MIP. As described in Section 1.1 there isn’t a single 
perfect biomarker, which can be treated as a gold standard, for detection of prostate 
cancer. Although controversial, t-PSA is still one of the most widely used clinical 
biomarker for initial diagnosis of PCa. From a research perspective, PSA is 
commercially available, and a MIP sensor developed for PSA could be easily compared 
to commercially available kits, making it a suitable template for molecular imprinting 
and sensing. Moreover, since measuring different isoforms of PSA could improve the 
sensitivity of the test, different isoforms of PSA such as pro-PSA and free-PSA were 
also explored as templates for the development of molecularly imprinted polymers in the 
current project. Lastly, the proof of concept study of MIP sensor development for PSA 
was designed in such a way that it could be easily extended to better biomarkers of PCa 
in the future. 
With regards to molecular imprinting, conventional bulk imprinting is not suitable for 
imprinting and sensing of a large protein like PSA (due to mass transfer and diffusional 
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barriers). An alternative/simple technique was to explore epitope imprinting of PSA 
epitopes using bulk imprinting techniques (Chapter 2). It was hypothesised that the 
bulk-imprinted polymers could not only recognise small epitopes from PSA but also 
larger epitopes and subsequently the whole protein, which could be applied for PSA 
sensing. Epitope imprinting could then be taken a step further to combine with sensing 
platforms for easy detection of whole PSA protein as seen in Figure 1.5. It was proposed 
that the epitopes could be modified to get oriented immobilisation on the surface for 
producing surfaces imprinted polymers with greater homogeneity (Chapter 2). The 
resulting imprinted polymers could recognise the epitope as well as the whole protein, 
which could then be detected using electrochemical sensing.  
 
Figure 1. 5: Epitope is immobilised on a surface (i). Monomers interact with epitope (ii). 
Polymers can be grown around the epitope to create an imprinted site (iii, iv). After extraction 
of the template the whole protein is introduced for rebinding which can be detected by 
voltammetric or piezoelectric techniques (v). 
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Although epitope-imprinting is a simple approach it may lack the sensitivity to detect 
proteins like PSA, which are found in very low quantities in clinical samples (4 -10 
ng/ml). Other bulk imprinting techniques where the polymer’s recognition ability relies 
only on several weak non-covalent interactions acting cumulatively to recognise the 
whole protein may also not be sensitive enough to detect such low concentration of 
PSA. Hence a bio-affinity hybrid approach for detection of fPSA (Figure 1.6) was 
developed as described in Chapter 4 and Chapter 5. A receptor with a well-established 
affinity towards PSA was used to entrap the protein in its preferred conformation into 
the polymer. it was hypothesised that post extraction of the protein, the polymeric cavity 
lined with the bio-receptor would demonstrate greater affinity that the bio-receptor or 
the polymer alone. It was proposed that the bio-receptor would act synergistically with 
the polymer to form a superior receptor, which would result in greater affinity for the 
template. Hybrid imprinting technique could provide the added level of sensitivity 
required to detect clinically relevant templates like PSA, which are found in extremely 
low concentration in biological fluids. 
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Figure 1. 6: Protein hybrid imprinting technique whereby a receptor holds the protein in its 
preferred conformation on the surface during polymerisation for the formation of chemically 
selective cavity. Post removal of protein the cavity lined with the receptor exhibits superior 
recognition towards the template. 
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1.6 Objectives  
• Chapter 2 studied the epitope imprinting strategy for serum t-PSA (PSA complex 
with antichymotrypsin and fPSA), by creating bulk molecularly imprinted polymers 
for small epitopic sequences. The main objectives of Chapter 2 are: 
1. Selection, synthesis and purification of epitopic sequences using standard solid 
phase peptide synthesis in this case  
2. Characterisation of epitopes/peptides using HPLC - mass spectrometry. 
3. Screening of monomers to select the best functional monomer and further 
using it to imprint the epitope template. 
4. Rebinding evaluation of epitope imprinted MIPs. 
• Chapter 3 investigated the use of pro-PSA peptide (epitope) biomarker as an 
alternative to t-PSA epitope imprinting. Pro-PSA is a precursor form of PSA 
containing an additional seven amino acid sequence at the N terminus of the protein 
and known to be elevated in aggressive forms of cancer. Surface imprinting of 
epitopes was explored for easy sensing of templates. The main objectives of Chapter 
3 are: 
1. Synthesise peptide APLILSR using Fmoc solid phase peptide synthesis. 
2. Modify the peptide with a thiol-linker to enable one-step template 
immobilisation. 
3. To investigate the electropolymerisation of different electroactive monomers  
4. Optimisation of imprinting methodology for APLILSR peptide using a 
selected electroactive monomer. 
5. Evaluate MIP sensor performance by undertaking dose response assays with 
the imprinted peptide and investigating cross-reactivity with control peptides. 
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• Chapter 4 focussed on the development of the hybrid imprinting strategy for serum 
fPSA using DNA aptamers. FPSA is an enzymatically inactive form of PSA found 
in the serum. Free PSA is expressed a percentage of total PSA (% fPSA) and 
increases sensitivity of t-PSA test for detection of PCa. Main objectives of Chapter 4 
are: 
1. To study surface immobilisation strategies of PSA-aptamer complex on 
electrode surface. 
2. To understand polymerisation strategies for molecular imprinting of aptamer-
PSA. 
3. Characterisation of surface post molecular imprinting of aptamer-PSA 
complex. 
4. Evaluation of apta-MIP sensor performance by performing dose response 
studies with PSA and performing cross-reactivity studies with homologous 
proteins as well as serum proteins. 
• Chapter 5 extends apta-MIP hybrid sensing on field effect transistor devices (FET). 
Main objectives of Chapter 5 are: 
1. Evaluation of MOSFET for apta-MIP PSA sensing. 
2. Comparison with aptamer alone MOSFET sensor. 
3. Detection of PSA in human plasma to understand fouling by serum proteins. 	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2. Chapter: Conventional Bulk 
Imprinting of PSA Epitopes 
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2.1. Introduction 
2.1.1. General overview 
Conventional bulk imprinting has been successfully implemented for recognition of 
small, biomolecules such as amino acids1, dipeptides2, nucleosides3 and phosphorylated 
peptides.4,5 However, the imprinting of larger biomolecules still remains a challenge 
(Chapter 1, Section 1.4). Epitope imprinting, which utilises small sequences of amino 
acids exposed on the surface of macro-biomolecules as templates for molecular 
imprinting, helps circumvent some of the issues associated with macromolecular 
imprinting.6 The resulting imprinted polymer not only recognises the smaller epitopes 
but also, the protein presenting the epitopes. This chapter explores the use of bulk 
epitope imprinting using conventional imprinting monomers for the recognition of PSA 
epitopes. To date, epitope imprinting of PSA has not been reported in the literature. It is 
hypothesised that the imprinted materials will not only recognise the (epitopic) 
templates but also longer peptide sequences containing the epitope sequence or indeed 
the native protein. This chapter describes the systematic identification and synthesis of 
PSA epitopes alongside the screening of monomers for efficient bioimprinting, which 
could be translated to surface imprinting. 
2.1.2. Conventional bulk imprinting 
Conventional molecular imprinting has majorly relied on the use of free radical 
polymerisation to make bulk/plastic polymers.7,8 Free radical polymerisation consists of 
three steps initiation, elongation and termination. Initiation consists of the generation of 
free radical (R*), formed by decomposition of initiator species, which starts the 
polymerisation of a relatively unreactive acrylate monomer. Elongation leads to the 
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successive addition of monomers to grow a chain to form a high molecular weight 
polymer. This occurs by the attack of free radical species (R*) on the double bond of a 
monomer, which forms an initiated monomer radical. The initiated monomer radical 
then further attacks acryl groups monomer leading to chain elongation. Termination step 
consists of deactivation of reactive species ending the chain elongation process resulting 
in a stable polymer. There are two types of terminations: recombination (two growing 
chain form a covalent bond) and disproportionation (transfer of hydrogen from one 
radical to other to form stable molecules). The most common type initiators are azo-type 
free radical initiators (Azobisisobutyronitrile (AIBN) is widely used in imprinting) to 
bring about polymerisation9. These initiators upon exposure to heat or UV radiation 
generate two identical, short-lived cyanopropyl radicals and nitrogen gas (Figure 2.2). 
AIBN is a popular initiator for molecular imprinting as it can be easily decomposed by 
heating (600 C) or by exposure to UV (366 nm)10.  
 
 
Figure 2. 1: Homogenous cleavage of AIBN to generate two equally reactive radicals, which 
activate surrounding acrylate monomers. Nitrogen gas is a by-product of the reaction 
2.1.3. Epitope imprinting  
The large size, dynamic surface and complex conformational structure of proteins, 
which depends on pH, ionic strength and temperature, makes it challenging to imprint 
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them with conventional molecular imprinting techniques. Conventional imprinting relies 
on the use of non-polar solvents to form multiple non-covalent interactions. However, 
proteins may change their conformation or denature in such conventional solvents 
preventing the formation of stable non-covalent interactions.11  
Epitope imprinting, serves as an efficient alternative to the imprinting of the whole 
protein, enabling the generation of highly specific cavities by exploiting the 
functionality of the epitopic template (Figure 2.1). It offers the following advantages 
over whole protein imprinting: the length and design of the epitope can be varied to 
achieve selectivity for the native protein; non-polar solvents can be used for imprinting 
due to the small size and non-complex nature of the template; easy and complete 
extraction of template is possible leading to improved binding characteristics; and 
finally it allows for modification of epitopes with specific functional groups that can be 
used for immobilisation onto sensing platforms for surface imprinting.12 Surface epitope 
imprinting has been discussed further in Chapter 3. However, one major drawback of 
this technique is that epitope imprinting can only be adopted for proteins with known 
protein structure and amino acid sequence. This is in order select a suitable template for 
epitope imprinting.  
Rachkov and Minoura first reported the epitope imprinting approach in 2000, using a 
four amino acid sequence (YPLG) from the C-terminus of oxytocin as the template they 
created binding sites capable of recognising the 9-mer neuropeptide (oxytocin).6,13 
Methacrylic acid (MAA) and EGDMA were used as the functional and crosslinker 
monomers respectively, with binding performance characterised chromatographically. It 
was demonstrated that the imprinted polymers were capable of retaining not only the 
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epitope template but also oxytocin when compared to non-imprinted controls. However, 
to date, most bulk epitope imprinting studies have majorly employed smaller proteins 
which are < 2000 Da in size. It is anticipated that an epitope from a small protein would 
lead to a smaller conformation change of the epitope when separated from the native 
protein due to the absence of tertiary and quaternary structures. On the other hand, 
epitopes separated from a larger protein like PSA may not maintain the same 
conformation as the native protein. An epitope may lose its native conformation or adopt 
different conformations in different imprinting solvents upon being isolated from the 
whole protein. Using conventional imprinting approaches to epitope imprint larger 
proteins (greater than 10 kDa) could cause conformational restriction to rebinding of 
epitopes on native protein. This can lead to the formation of epitope-imprinted sites, 
which rebinds to the native protein less efficiently than the epitope itself.  Hence 
selecting appropriate solvents for bulk epitope imprinting could be key in maintaining 
the native conformation of the epitopes (from larger proteins) during polymerisation for 
efficient rebinding to the native protein. 
Ken Shea’s group presented an alternative approach, whereby peptide epitope sequences 
from proteins (> 30 kDa) were confined to the surface and subsequently imprinted using 
surface imprinting technique.14 The surface imprinted films were able to recognise the 
epitopes as well the native protein. Bossi et al. developed an alternative approach to 
epitope imprinting where unique peptide sequences (epitopes) were identified using 
bioinformatics tools to generate bulk MIPs, which could detect the epitopes from 
partially digested proteins.15 This approach was unique because it did not rely on surface 
presented epitopes but identified unique epitopes, which may be buried inside the 
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protein. Although the technique requires an additional protein digestion step, this 
approach could be useful for large proteins that don’t have their epitopes mapped and 
where maintaining native conformation of the epitope is a challenge. These studies 
suggested that epitope imprinting could be successfully employed for protein imprinting 
and sensing. 
 
Figure 2. 2: A schematic illustrating the epitope imprinting process. A small portion of the 
protein that is exposed on the protein surface is used as the template. Functional monomers 
form a complex with the epitope which is subsequently locked in place during the polymerisation 
process (initiated by the application of UV radiation or heat). Extraction of the epitopic 
molecule leaves a cavity capable of recognising both the template and the native protein that 
displays the epitope on its surface. 
2.1.4. Epitope selection  
Epitopes are short sequences of amino acids presented on the surface of the protein, 
which can be easily recognised by antibodies.16 There are two types of epitopes that 
participate in antibody recognition: linear and conformational. Linear epitopes are made 
of consecutive amino acids in the protein while conformational epitopes are amino acids 
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sequences that brought together due to the folding of the protein.17 From an imprinting 
perspective, it is logical to choose a linear epitope due to ease of synthesis and 
conservation of natural conformation. However, taking into consideration the 
mechanism of antibody binding (the two arms binding to different parts of the protein), 
the majority of epitopes are conformational making the process of choosing epitopes 
quite challenging. The length of the epitope sequence is also critical to maintain 
selectivity towards the native protein. Epitopes with less than nine amino acids could 
lead to cross-reactivity between proteins from the same family due to sequence 
homology. An epitope length of 9 -12 amino acids is often specific for a particular 
protein.16 This uniqueness and can be checked using sequence alignment bioinformatics 
software such as BLAST (Basic local alignment search tool) which is freely available on 
Uniprot website (http://www.uniprot.org/).18,19 A protein can possess more than one 
surface epitope and choosing the best target sequence can be a challenge. An alternative 
way of identifying an appropriate epitopic sequence is to map protein-surface antibody 
binding epitopes. A study by Lu et al. utilised epitope mapping of HIV protein to chose 
the epitopic template for imprinting and sensing.20 However, since not all proteins have 
their epitopes mapped, this technique would be limited to certain proteins only.  
2.1.5. Peptide synthesis 
As epitopes are small peptide sequences, they can be synthesised chemically using 
standard peptide synthesis reactions. Peptide synthesis in simple terms involves a 
repetitive amidation reaction between an α amino group of one amino acid and an α 
carboxyl group of another amino acid to form an amide or peptide bond.21 Various 
synthetic strategies have been described, which could be broadly categorised as either 
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solution phase or solid phase synthesis approaches.22 Bruce Merrifield pioneered the 
field of solid phase peptide synthesis (SPSS), developing an insoluble resin that 
facilitates the controlled synthesis of peptides from its surface with a single cleavage 
step required to release the peptide.23 Development of SPSS led to the much-needed 
simplification of the peptide synthesis process, reducing the tedious purification steps 
involved in solution phase synthesis. Synthesising peptides on a solid support has 
further advantages; firstly the entire process can be carried out in one vessel with excess 
reagents driving reaction equilibrium thus increasing efficiency, secondly it permits 
draining off any excess unreacted reagents while preserving the peptide on the solid 
support and thirdly it bypasses the multiple purification steps required by solution phase 
synthesis.24 Moreover, the SPPS strategy facilitated automation of the process, enabling 
integration of robotic instrumentation which permits rapid and large-scale synthesis of 
multiple peptide sequences.25 
Solid phase synthesis usually employs an amine-functionalised polystyrene bead, to 
which an amino acid (α NH2 protected) is attached via its carboxyl functionality to form 
the C-terminus of the peptide. The NH2-protecting group of the immobilised amino acid 
is then removed (usually base labile) to expose the free amine group to which the 
following amino acid can be coupled. This deprotection/coupling process is repeated 
until all the amino acids are sequentially attached to yield the desired peptide (Figure 
2.3).  
The side chain functional groups are shielded using protecting groups, which are stable 
under the coupling reaction conditions but can be removed during the final cleavage 
process. In general two protecting strategies are employed: Nα-tert-butyloxycarbonyl 
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(Boc)/(Benzyl)Bzl26 and 9-fluoromethoxycarbonyl (Fmoc)/Boc.27 The Boc/Bzl strategy 
relies on the difference in the acid lability of the two groups; the Boc group (NH2 
protecting) is deprotected with neat TFA while Bzl, the side chain protecting groups, are 
only deprotected post-cleavage by treating with hydrofluoric (HF) acid.26 The use of 
strong acids, particularly HF that is highly toxic, prevented the widespread adoption of 
this strategy, meaning that it is often reserved for the synthesis of long (>25 amino 
acids) peptides and proteins.28 Fmoc/Boc uses an orthogonal protecting group strategy 
where base labile Fmoc protects the amino group, while the side chain protecting groups 
(Boc) are acid labile.27 This approach permits selective deprotection of Fmoc groups for 
peptide elongation while masking the side chain functional group until the final 
cleavage. It also allows for the use of milder acid for peptide cleavage from the resin 
making it more practical than the Boc/Bzl strategy. 
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Figure 2. 3: General schematic of solid-phase peptide synthesis.21 The strategy highlights the 
orthogonal protection scheme where the amine protecting group (R) is deprotected using a base 
to expose the primary amine to facilitate attachment of a carboxyl-activated amino acid 
(coupling). The side chain groups are protected by an acid labile group (P). The process is 
repeated until the peptide sequence is complete, with cleavage from the resin being achieved 
using a strong acid. Reproduced from Jose M. Palomo et al. (2014),21 with permission from The 
Royal Society of Chemistry. 
2.1.6. General scheme of peptide synthesis 
Although, the overall SPPS strategy is relatively straightforward, various issues such as 
resin swelling, loading, nature of linker groups, protecting groups as well as the solvents 
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used in the synthesis need to be carefully considered and selected for synthesis of any 
peptide.26 A general scheme of peptide synthesis has been discussed here, however 
slight changes were made depending on the sequence to be synthesised, which have 
been discussed in the respective sections. 
2.1.6.1. Peptide Synthesis resin 
Polystyrene is the most common core resin used in SPSS containing 1-2 % 
diacrylatebenzene as a crosslinking agent to ensure the stability of the resins in common 
synthesis solvents.29 Rink amide resins are popular with Fmoc protection strategy to 
generate peptide amides (Figure 2.4).30 For generation of peptide acids (COOH 
terminated) containing proline and asparagine (as with the current template), 2-
cholorotitryl resin (Figure 2.5) was found to be the preferred choice to prevent 
isomerisation and avoid diketopiperization reaction.31 
 
Figure 2. 4: MBHA rink amide resins are popular for peptide amide synthesis. The amine is 
always protected with a Fmoc group and requires deprotection before the first coupling. 
Chapter 2                                                                               Conventional Bulk Imprinting of PSA Epitopes 
 64  
 
 
Figure 2. 5: 2-cholorotitryl chloride resins are typically used for those peptide sequences that 
contain proline as the first amino acid to help prevent diketopiperization reaction and also 
reduce racemisation32. 
2.1.6.2. Fmoc protection and deprotection  
The Fmoc (9-fluoromethoxycarbonyl) group is used as a protecting group for primary 
α-amines on amino acids to prevent self-polymerisation of the amino acids (Figure 2.6).  
 
 
 
 
 
Figure 2. 6: Fmoc protection scheme on amino acids 
During the deprotection step, piperidine attacks the relatively acidic proton in the 
fluorenyl ring of Fmoc, which leads to hydrogen elimination and formation of 
dibenzofulvene, which is further scavenged by piperidine, producing CO2 as a by-
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product.27 Most peptide synthesis protocols in the literature use piperidine for Fmoc 
deprotection33, however, as a consequence of piperidine being used in drug 
manufacturing, methyl piperidine was used as an alternative deprotecting solution, 
which has been shown to be equally effective as piperidine (Figure 2.7).32 Scheme of 
Fmoc deprotection has been elaborated in Figure 2.7. 
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Figure 2. 7: Fmoc deprotection. Methyl piperidine attacks the proton in the fluorenyl ring (i) 
eliminating hydrogen and releasing dibenzofulvene and carbon dioxide (ii). Dibenzofulvene is 
scavenged my methyl piperidine to prevent it from further reacting with the α-amine of the 
amino acid (iii). 
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2.1.6.3. Monitoring of peptide synthesis 
Kaiser test is a sensitive test for detecting primary amines by the formation of an intense 
blue colour, which is helpful in monitoring the coupling and deprotection of amino acids 
during synthesis.35 The presence of an intense blue colour post deprotection indicates 
the presence of free amines, while a yellow solution with clear beads indicates 
completion of coupling or absence of free amines. The mechanism of the Kaiser test is 
provided in Figure 2.8.  
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Figure 2. 8: The Kaiser test is based on a ninhydrin test. 1,2,3 tricarbonyl carbon in ninhydrin 
(i) is a strong electrophile and readily attacks the free amine on the amino acid to form a stable 
compound which is a Schiff’s base (ii). The base further reacts with another ninhydrin molecule 
to give a strong chromophore: 2-(1,3-dioxoindan-2-yl)iminoindane-1,3-dione which forms an 
intense blue colour(iii).36 The Kaiser test is only positive for primary amines. 
2.1.6.4. Coupling reaction of amino acids 
Coupling agents are required to activate the α-carboxyl group on the amino acid for the 
formation of amide bond and an extensive list can be found in the review by Alvericio et 
al.37 One of the most popular activating agents in peptide synthesis is HBTU (O-
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(Benzotriazol-1-yl)-N, N, N’, N’- tetramethyluronium hexafluorophosphate) due to its 
high coupling efficiency (< 6 mins) and minimum racemisation.38 HBTU is also added 
in lower amounts than the amino acid (0.9:1) as excess uronium salt can directly react 
with the amine of the peptide causing chain termination.38 The structure of HBTU and 
HOBt is shown in Figure 2.9. The mechanism of amino acid activation has been 
depicted in Figure 2.10, and the formation of amide bond has been depicted in Figure 
2.10.  
 
Figure 2. 9: Coupling agents HOBt and HBTU 
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Figure 2. 10: Mechanism of amino acid activation can be divided into three steps: The base 
(DIPEA) deprotonates the amino acid first (i). Post deprotonation the resulting carboxylate ion 
attacks the electron deficient carbon atom of HBTU (ii),(iii). The newly formed HBTU – amino 
acid intermediate reacts with the HOBt anion to form an OBt activated ester (iv). 
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Figure 2. 11: The OBt activated ester attacks the electron rich free amine on the resin to form 
the amide bond. 
2.1.6.5. Cleavage of peptide 
Post addition of all amino acids, the penultimate Fmoc group is deprotected, and the 
peptide is cleaved from the resin. Cleavage cocktail is made of strong acid called 
trifluoroacetic acid (TFA), which is efficient in cleaving most Fmoc based resins.39 The 
side chain protecting groups are also acid labile and get cleaved during the cleavage 
step. Scavengers like TIPS/ thioanisole/ phenol are added to scavenge the secondary 
protecting groups, which may attack certain amino acids such as tryptophan, histidine 
and cysteine.29 
2.1.7. PSA epitope synthesis and conventional imprinting  
In the current study, PSA epitopes were identified and synthesised by standard Fmoc 
solid phase synthesis using available literature methods outlined in Section 2.1.6. Post-
purification and characterisation of the epitopes, conventional monomers  (MAA, AAm, 
2-VP) were utilised for bulk imprinting of the epitopic templates. The aim was to 
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identify monomers that are suitable to imprint the PSA epitopes (peptides) to synthesise 
MIPs with maximum binding efficiency. It was hypothesised that using the conventional 
bulk imprinting methods, monomers/crosslinker/template ratios could be identified to 
efficiently imprint the PSA epitopes. This could then be easily translated to a surface 
imprinting strategy for incorporating into sensing platforms. 
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2.2. Aims And Objective 
The overarching aim of this chapter is to rationally design an epitope imprinting strategy 
for the recognition of PSA.  
Objectives: 
1. Selection, synthesis and purification of epitopic sequences using standard solid 
phase peptide synthesis in this case  
2. Characterisation of epitopes/peptides using HPLC - mass spectrometry. 
3. Screening of monomers to select the best functional monomer and further using 
it to imprint the epitope template. 
4. Rebinding evaluation of epitope imprinted MIPs. 
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2.3. Material And Methods 
2.3.1. Reagents 
All Fmoc amino acids and rink amide 4-methylbenzhydrylamine (MBHA) resin were 
purchased from Sigma Aldrich, UK and stored at -20oC. 2-Chlorotrityl chloride resin 
was obtained from Novabiochem, UK. All reagents for peptide synthesis were of 
synthesis grade and were also purchased from Sigma Aldrich, UK. DMF and DCM used 
for synthesis were analytical grade and purchased from Fisher Scientific, UK. 
Methacrylic acid (MAA), Vinyl pyridine (VP), acrylamide (AAm) and 
ethyleneglycoldimethycrylate (EGDMA) were purchased from Sigma Aldrich UK. 
HPLC grade acetonitrile and methanol were purchased from Fisher Scientific, UK. 
2.3.2. Apparatus 
A peptide synthesis vessel with medium sized frit was acquired from Sigma Aldrich, 
UK. UV absorbance experiments were carried out on Cary 60 UV-Vis, Agilent, UK. 
Reverse phase HPLC analysis was performed using a Thermo Scientific HPLC 
automated system (SpectraSystem), UK. The peptides were analysed by reverse-phase 
HPLC using a C18 RP Kromasil C18, 5 µm, 250 mm × 4.6 mm using a gradient mobile 
phase (Table 2.1) where solvent A was (99 % water, 1 % acetonitrile (MeCN), 0.1 % 
TFA) and solvent B (1 % water, 99 % acetonitrile, 0.1 % TFA), UV detection at 260 
nm, 20 µl injection volume and a flow rate of 1 ml/min. Peak areas were analysed using 
Chromquest software. 
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Time (minute) Solvent A (v/v) Solvent B (v/v) Flow rate 
0 99 % 1 % 1 ml/min 
30 1 % 99 % 1 ml/min 
40 99 % 1 % 1 ml/min 
Table 2. 1: Gradient run conditions for elution of peptide. 
The peptides were freeze dried using an Alpha 1-2 LD plus freeze drier (Martin Christ, 
Germany). Mass spectrometry analysis (LC-MS) was conducted using a Thermo 
Finnigan Navigator system (Paisley, UK), with a Thermo Separation HPLC (Paisley, 
UK), 
2.3.3. Peptide synthesis of Fmoc-vanp 
The peptide synthesis protocol was developed based on published protocols.21,29,33 
Peptides were synthesised on a 0.25 mmol scale using a peptide synthesis glass vessel 
fitted with a medium sized frit. The peptide synthesis protocol has been described for 
Valine-Alanine-Asparagine-Proline (Val-Ala-Asn-Pro) (VANP) peptide in the following 
section. However, the same protocol was also used for the synthesis of other peptides 
throughout the project. Based on the C terminus functional group, two resins were used 
in peptide synthesis:  
2.3.3.1. Swelling 
Rink amide MBHA resin was used to synthesise amide-terminated peptide (VANP)-
CONH. 2-chlorotitryl chloride resin was used to synthesise carboxyl terminated peptide 
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VANP(COOH). 250 mg of resin with a loading factor of ∼1 mmol/g was added to 20 
mL dry dichloromethane (DCM) and allowed to swell for 30 minutes in a peptide 
synthesis vessel (Sigma Aldrich, UK) before the first deprotection step.  
2.3.3.2. Deprotection 
Rink amide resins are Fmoc protected and therefore required deprotecting before 
addition of the first amino acid. After swelling the resin, DCM was drained from the 
peptide synthesis vessel with a stream of nitrogen. Approximately, 10 ml of deprotecting 
solution containing 25 % (v/v) methyl piperidine in dimethylformamide (DMF) was 
added to the swelled resin.  After two minutes, the deprotecting solution was drained 
using nitrogen and the resin was washed once with 2 ml of DMF to remove traces of 
methyl piperidine. Thereafter, a second deprotection step was carried out for 10 minutes 
to remove any remaining Fmoc protecting molecules on the resin. Following 
deprotection the resin was washed with 2 ml DMF (2X) and 2 ml DCM (2X). The vessel 
was drained under a stream of nitrogen to remove any residual DCM before conducting 
the Kaiser test. 2-cholorotitryl resins did not require an initial Fmoc deprotection step 
prior to addition of the first amino acid (see Section 2.3.3.4). 
2.3.3.3. Monitoring deprotection and coupling 
Fmoc deprotection was monitored by observing the presence of free amine group post-
deprotection using the Kaiser test.40 The three solutions require were prepared and 
stored in dark dropper bottles: 
• Solution A: 5 g ninhydrin dissolved in 100 ml ethanol 
• Solution B: 80 g liquefied phenol dissolved in 20 ml ethanol 
• Solution C: 2 ml of 0.001 M potassium cyanide (KCN) plus 98 ml pyridine 
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To test for free amine post deprotection of Fmoc group, two drops of solution A, and 
one drop of solution B and C solution were added to few beads of resin in a glass tube 
and placed in a sand bath at 1200 C. Presence of dark blue colour on the beads indicated 
presence of free amines and completion of the Fmoc deprotection step. 
2.3.3.4. Addition of the first amino acid: 
When using Rink amide resins, the first amino acid was coupled using the method 
described in Section 2.3.3.5.  
For 2-Chlorotrityl chloride, 250 mg (0.25 mmol) of resin was swelled in dry DCM (10 
mL) for 5 minutes in the peptide synthesis vessel. Upon draining the vessel with a 
stream of N2, a coupling solution containing 126.51 mg (0.375 mmol) of Fmoc-proline-
OH and 175 µl of DIEA (N,N- Diisopropylethylamine) (1mmol) dissolved in 6 mL of 
DCM was added to the resin. The reaction was carried out for 3-4 hours at room 
temperature. The resin was then twice washed with 2 mL DCM and treated with 5 mL 
of DCM/ MeOH/ DIEA (80: 15: 5) v/v) for 10 minutes. The resin was again washed 
with DMF and the reaction completion was checked using the Kaiser test (Section 
2.3.3.3). 
2.3.3.5. Coupling reaction 
A coupling cocktail was prepared to activate Fmoc-proline-OH for attachment to the 
rink amide resin. All calculations were done on the bases of loading factor of resin 
(0.25mmol). (4X resin) Fmoc-proline amino acid (1mmol, 333 mg), 169 mg of HBTU 
(2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (0.95 
mmol) was weighed out in screw cap vial and the mixture was dissolved in 2 mL DMF. 
Thereafter, N, N - diisoproylethylamine (DIPEA) (1.5 mmol, 300 µL) was added the 
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amino acid/HBTU solution to activate the Fmoc-proline-OH. The coupling cocktail 
solution was incubated for 5 minutes until the solution turned light yellow (demonstrates 
activation of amino acid). Following a positive Kaiser test after deprotecting step, the 
activated amino acid coupling solution was added to the resin. The coupling reaction 
was then carried out in the peptide synthesis vessel for 2 - 3 hours. Thereafter, the resin 
was washed with 2 ml DMF (3X) and 2 ml DCM (2X) and dried under a stream of NO2. 
A Kaiser test was conducted to check for completion of reaction as elaborated in Section 
2.3.3.3. The presence of transparent beads indicated completion of coupling reaction. 
Post coupling, steps 2.2.3.2 - 2.2.3.4 were repeated until Asparagine-Alanine-Valine 
amino acids were attached. 
2.3.3.6. Cleavage 
After coupling all the amino acids to the resin a cleavage cocktail of 90 % trifluoroacetic 
acid (TFA), 5 % water, 5 % tri-isopropylsilane (TIPS) was prepared fresh. Cleavage 
solution (5 ml or roughly double the volume of the resin) was added to the resin and 
placed on the shaker for two hours. The cleavage cocktail solution containing the 
peptide was then collected in a round bottom flask from the peptide synthesis vessel. 
The resin was further washed twice with 5 ml DCM to remove any residual TFA. The 
solution was then rota vaporised (Buchi, UK) to reduce TFA in cleavage solution before 
the precipitation step.  
2.3.3.7. Precipitation 
The cleavage solution (roughly 5-6 ml) was then added drop wise to 50 ml of ice-cold 
ether to precipitate the peptide. The precipitated solution was poured into a 15 mL 
centrifuge tubes and spun down at 3000 RPM in (Sigma 2-16 Centrifuge, UK) for 5 
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minutes in centrifuge tubes. The precipitate, obtained after discarding the supernatant, 
was washed with 10 ml ice-cold ether twice to remove any residual scavengers and 
TFA.  
2.3.3.8. Purification 
The crude peptide was analysed and purified by reversed phase HPLC fitted with a 
Luna, 5µm, C18, 250 mm x 10 mm silica column (Phenomenex, UK). The peptide was 
purified by injecting 2 mg of crude peptide per injection (injection volume 2 ml)  and 
eluting the peptide using a gradient run mentioned Table 2.1 at a flow rate of 2 ml/min. 
Peptides were collected manually and analysed using LC-MS(company). The samples 
containing the correct peptide was pooled together and roto-vaporised to remove any 
acetonitrile or solvent. The aqeous peptide solution was then poured in a centrifuge tube 
and freeze dried in liquid nitrogen for 10 minutes. Thereafter, the frozen peptide in the 
centrifuge tube was left in a freeze drier overnight to obtain the dry peptide. 
2.3.4. Peptide characterisation by UV 
Fmoc protected peptides were analysed by UV spectroscopy (Cary 60 UV-Vis Agilent 
Technologies, UK). Aliquots (1 ml) of various peptide concentrations (25 - 400 µg/mL) 
were added to 1 cm pathlength quartz cuvettes (Sigma Aldrich, UK) and a UV scan over 
200 - 500 nm obtained.  
2.3.5.  Non-Imprinted polymers for monomer screening 
Using a 1:4:20 (template: monomer: crosslinker) ratio, a series of non-imprinted 
polymers were produced. Methacrylic acid (MAA), acrylamide (AAm) and 2-
vinylpyridine (2-VP) were employed as functional monomers with ethylene glycol 
dimethacrylate serving as the crosslinker. Monomer (400 µmol; MAA - 33.8, µl, AAm - 
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56.9 mg, 2-VP - 86 µl) and EGDMA 2000 µmol (754.4 µl) were added to 850 µl 
acetonitrile (1.5 times of the total volume of monomer and crosslinker) in 20 mL 
polymerization vials. 1,1'-azobis cyclohexanecarbonitrile (ABCN, 1 % w/w, 4.1 mg) 
was added as the initiator. The vials were crimp sealed and sonicated for 5 minutes, 
before being cooled for another 5 minutes in the refrigerator. Subsequently the solution 
was degassed with nitrogen for 10 minutes. The vials were then placed on an ice pack 
and irradiated with UV light (100 mw/cm2, 325 nm at a distance of 8 inches) for 2 
hours. The polymers were dried overnight in under vacuum at 400 C, then ground using 
a mortar and pestle before washing with methanol and acetic acid (6:1) for 4 hours. The 
polymer was subsequently washed with methanol and acetonitrile to removal residual 
acid and dried overnight under vacuum. For binding evaluation, 20 mg of polymer was 
incubated with 1ml of 200 µM Fmoc-VANP-COOH peptide in 10 ml polymerization 
vials. The vials were placed on the shaker overnight.  Following centrifugation (3200 
rpm, 5 minutes), the supernatant was passed through a 0.45 µm nylon syringe filter 
(Kinesis, UK) to remove any polymer residue. The UV absorbance of the final solutions 
were analysed at 260 nm and 301 nm.  
2.3.6. Molecular Imprinting with MAA 
Due to the scarcity of the template material a shift in MIP synthesis strategy was 
undertaken. Instead of synthesising conventional bulk polymers, MIPs were synthesised 
in HPLC vials with 30 µl pre-polymerisation mixtures. The resulting MIPs were 
obtained as solid polymer pellets which were 1-2 mm in size. This prevented the need to 
grind and sieve the polymers, helped the judicious use of the template and facilitated 
easy diffusion and mass transfer of template. The binding studies were carried out in the 
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HPLC vials containing the mini-MIPs. The method of synthesising mini-MIPs was 
developed by Sellegren et al to produce a large number of MIPs for monomer screening 
studies.41 
2.3.6.1 Synthesis of MAA-MIP with ratio of 1:4:40 (T:M:C) 
10 mg of (freeze dried) peptide (16 µmol) was solubilised in 20 µl of DMSO. The 
solution was heated in a water bath at 500 C to encourage dissolution. A nitrogen-purged 
solution of 170 µl of acetonitrile (2X of monomers) with 75 µL of EGDMA (640 µmol) 
with 4.5 µL MAA (64 µmol) was added dropwise to the peptide solution with 1 mg (1 
% w/w) AIBN initiator. The resultant polymerisation solution (under nitrogen) was 
pipetted in HPLC vials (30 µL polymerisation solution per vial) and irradiated with UV 
for two hours and then left in the water bath at 600 C overnight. Post polymerisation, 
polymers were subjected to repetitive washes of methanol and acetic acid (6:1) until the 
template was undetectable in the wash solution. The wash solutions were analysed using 
analytical HPLC to check for any residual peptide (Section 2.3.2.). Non-imprinted 
polymers (NIPs) were prepared in the same fashion but in the absence of the peptide 
template.  
2.3.6.2 Peptide kinetic binding assay 
The study was conducted to understand the saturation time for binding of the template to 
the MIPs. Polymers were incubated with 1000 µL (200 µg/mL) of peptide solution. 
Aliquots (50 µl) were removed from the incubating solution at the following time 
points: 2, 5, 10, 15, 30, 60, 120, 180 minutes. The 50 µl peptide solution (incubated with 
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the polymer) was diluted with 350 µl water and analysed by RP-HPLC (as described in 
Section 2.3.2). 
2.3.6.3 Synthesis of MAA-MIP with ratio of 1:4:80 (T:M:C) 
5 mg of (freeze dried) peptide (8 µmol) was dissolved in 10 µL of DMSO to solubilise 
the peptide. The solution was kept warm by placing in a water bath at 500 C to prevent 
peptide from precipitating on addition of acetonitrile. A nitrogen-purged solution of 
259.2 µl acetonitrile with 126.9 µL of EGDMA (640 µmol) and 2.8 µL MAA (32 µmol) 
and 1.34 mg (1 % w/w) AIBN initiator was added to the peptide solution drop-wise. The 
resultant polymerisation solution was placed in HPLC vials (30 µL polymerisation 
solution per vial) and irradiated with UV for two hours and then left in water bath at 
600C overnight to form mini-MIPs. Post polymerisation polymers were subjected to 
repetitive washes of methanol and acetic acid (6:1) until the template was undetectable 
in the wash solution.  
2.3.7.  Molecular Imprinting with AAm 
2.3.7.1 Synthesis of AAm-MIP with ratio 1:4:40 (T:M:C)  
10 mg of (freeze dried) peptide (16 µmol) was dissolved in 20 µL of DMSO to 
solubilise the peptide. The solution was heated in a water bath at 500 C and a nitrogen-
purged solution of 180 µl of acetonitrile (1.5X of monomers) containing 75 µL of 
EGDMA (640 µmol), 4.54 mg AAm (64 µmol) added to the solution with 1 mg (1 % 
w/w) AIBN initiator. The solution was placed in HPLC vials (30 µL polymerisation 
solution per vial), irradiated with UV for two hours and then left in the water bath at 600 
C overnight to form mini-MIPs. Post-polymerisation, polymers were subjected to 
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repetitive washes of methanol and acetic acid (6:1) until the template was undetectable 
in the wash solution. 
2.3.8. Molecular Imprinting with urea monomer  
Dr. Panagiotis Manesiotis at Belfast University provided the monomer: 1-(4-
acrylatephenyl)-3-(3-trifluoromethylphenyl) urea (urea monomer) for the study as a kind 
gift. 
2.3.8.1 Formation of TBA peptide 
Equimolar concentrations of Fmoc-VANP-COOH (12 µmol) and tetrabutylammonium 
hydroxide (TBA) (12 µmol) was dissolved in 1ml dry methanol and incubated for an 
hour at room temperature. TBA-peptide was obtained by rota-vaporising the sample to 
remove the methanol with further drying at 400 C for an hour under vacuum. 
2.3.8.2 Synthesis of urea-MIP with ratio 1:1:4:20 (T:M1:M2:C):  
8 mg TBA-peptide (12 µmol) was mixed with 4.80 mg urea monomer (12 µmol), 3.7 µl 
AAm (48 µmol) and 38.80 µl EGDMA (240 µmol). AIBN (1 % w/v, 4.5 mg) and 100 
µL acetonitrile was added to the monomer solution. DMSO (5 µl) was added to 
solubilise the peptide that was poorly soluble in acetonitrile. A similar polymer was 
prepared using DMF as a porogen. 
All solutions were purged with nitrogen and transferred into HPLC vials (30 µL 
polymerisation solution per vial) prior to irradiation with UV (2 hours).  Subsequently, 
the vials were transferred to a 600 C water bath for 18 hours. Post-polymerisation, 
polymers were subjected to repetitive washes of methanol and acetic acid (6:1) until the 
template was undetectable  
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2.3.8.3 Peptide kinetic binding assay:  
The study was conducted to understand the time taken to reach binding equilibrium of 
the template to the MIPs. Polymers were incubated with 1000 µL (100 µg/mL) of 
peptide solution. Aliquots (50 µl) were removed from the incubating solution at the 
following time points: 2, 5, 10, 15, 30, 60, 120, 180 minutes. The 50 µl peptide solution 
(incubated with the polymer) was diluted with 350 µl water and analysed by RP-HPLC 
as described in Section 2.3.2. 
2.3.9.  Peptide binding assay for MAA/AAm/urea monomer MIPS/NIPS: 
The batch binding assay was conducted to understand binding affinities of MIPs. 
Conventionally, 1mg of the polymer is weighed in to different vials and incubated with 
varying concentrations of target analyte. In the min-MIP format the polymer yield was 
typically < 50 mg thus insufficient for a conventional systematic equilibrium-binding 
assay.  In order to make the most efficient use of the MIPs equilibrium binding was 
performed by sequential addition.  Initially, 0.5 ml of a 1 µg/ml peptide solution (in 
MeCN) and 30 mg of MIP or NIP were measured into glass vials containing the mini-
MIP monolith.  After incubation at room temperature for one hour 250 µl of MeCN was 
removed for analysis and was replaced with an aliquot of a 200 µg/ml peptide stock 
solution and an additional volume of MeCN to return the overall volume to 0.5 ml. This 
was repeated hourly to generate a range of incubation concentration as described in 
Table 2.2 moved hourly and an additional amount of a stock peptide the same polymer 
was incubated sequentially with increasing concentrations of peptide after every hour. 
The MIPs were incubated with 500 µl peptide (10 - 200 µg/mL) added sequentially for 
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one hour according to the Table 3.1 250 µL of the concentration was removed and 
diluted with 250 µL water in a HPLC vial and analysed by RP HPLC. 
Concentration 
(µg/ml) (total 
volume 500 µl) 
Amount removed 
after 1 hour (µl) 
Volume added of 
200 µg/ml peptide 
solution 
Volume of MeCn 
added (µl) 
1 250 - 
 2 250 1.5 248.5 
5 250 3.75 246.25 
10 250 7.5 242.5 
15 250 11.25 238.75 
20 250 15 235 
40 250 30 220 
60 250 45 205 
80 250 60 190 
100 250 75 175 
120 250 90 160 
150 250 111.25 138.75 
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200 250 150 100 
Table 2. 2 Concentration of peptide added to each mini-MIP vial using sequential addition of 
peptide with stock concentration of 200-µg/ml peptide solutions. Additonal MeCN was added to 
the vials to get the total volume of the solution to 500 µl. 
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2.4. Results And Discussion 
2.4.1. Selection of epitope 
PSA is a 30 kDa serine protease containing 237 amino acid residues.42 Despite the 
controversy surrounding PSA testing, it was chosen as a biomarker for this proof of 
concept study due to its ease of availability and known crystal structure. A literature 
search was conducted to select an appropriate template for PSA epitope imprinting. 
Michel et al have previously demonstrated the involvement of a C-terminal peptide of 
total-PSA in antibody recognition with peptide phage display libraries.43 The C terminal 
peptide was shown to be surface localised (as seen in the crystal structure in Figure 
2.12), which made it a potential target for epitope imprinting. Furthermore, this 
particular sequence of amino acids is known to be non – glycosylated, making it less 
complex and a better defined template for imprinting due to the absence of sugar 
moieties on the amino acids.44 A nine amino acid sequence (IKDTIVANP) from the C-
terminus of PSA was chosen as a template for molecular imprinting as it would be 
highly selective for PSA and would help in recognition of the whole protein. The protein 
BLAST (Basic Local Alignment Search Tool) search query for the sequence 
IKDTIVANP returned a 100% hit (http://www.uniprot.org/) for PSA demonstrating the 
uniqueness of the sequence (Figure 2.13). 45  
Historically, very few literature studies have reported a rationalised approach to 
choosing an appropriate template/epitope for epitope imprinting. Nishino et al’s article 
on surface epitope imprinting for selective protein capture used a unique epitope 
sequence from each of the template proteins however, they were all C terminus 
sequences.14 This approach cannot be applied to all proteins, as the C terminus 
Chapter 2                                                                               Conventional Bulk Imprinting of PSA Epitopes 
 88  
sequences may not be the best target for epitope imprinting in each case. Epitope 
mapping by phage display libraries is a more suitable technique that allows one to 
choose surface localised epitopes that are suitable for epitope imprinting. However, one 
drawback of this technique is that availability of epitope mapping data is limited to 
certain proteins.  
 
 
 
 
 
Figure 2. 12: PSA crystal structure showing the C-terminus portion of the protein highlighted in 
red. The C terminus peptide formed an alpha helix structure 44. 
 
Figure 2. 13: Protein Blast results for the C terminus sequence IKDTIVANP showing a 100 % 
match to PSA (KLK3) 
PSA	  C	  terminus PSA	  crystal	  structure 
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The peptide sequences were designed with truncated sequences of 4 mer, 6 mer and 9 
mer to design molecularly imprinted polymers and to perform competitive binding 
assays. Initially, the synthesis, characterisation and imprinting of the 4 mer sequence 
(VANP) was the focus. 
2.4.2. Optimisation of peptide synthesis protocol   
2.4.2.1. Purification and characterisation Fmoc-VANP(CONH): 
The 4 mer (Fmoc-VANP) was initially synthesised by Fmoc solid phase synthesis on 
MBHA rink amide resin to obtain a peptide amide. The crude peptide was analysed by 
RP-HPLC with MeCN/water (66/34) mobile phase, eluting as a single peak at 5 minutes 
with ≈ 95 % purity (Figure 2.15). The peptide was not purified further and was used as 
synthesised, post lyophilisation. As there was no site for positive ionization on the 
peptide, the mass spectrometry (MS) data did not show the exact mass of the peptide 
(622 g/mol), however, the sodium adduct of the peptide (+22) was observed (643.3 
g/mol) (Figure 2.16). The exact mass of the peptide could not be determined using 
MALDI due to the low molecular weight of the peptide.  
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Figure 2. 14: HPLC chromatogram of the as-synthesised 4-mer peptide (Fmoc-VANP) showing 
one major peak. 
 
Figure 2. 15: Mass spectrometry of VANP 4mer peptide showing the sodium adduct of the 
peptide (+22) with a mass of 643.3 g/mol. This is common in chemical species, which do not 
contain a positive site for ionisation.   
The calculated theoretical yield of the peptide using Fmoc solid phase synthesis (based 
on 0.25 mmol scale) should be roughly 96 % or 150 mg. This is based on the fact that 
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there is a loss of 1 % in coupling efficiency after the addition of each amino acid.33 
However, the actual peptide yield obtained from the Fmoc-VANP(CONH) synthesis 
was only 14.5 mg. The peptide synthesis produced the desired peptide, however the 
yield was ≈ 10 % of the theoretical yield. The low yield could be attributed to an 
unfavourable side reaction called ‘diketopiperisation’ reaction (Figure 2.14). This 
reaction is observed in Fmoc synthesis when using resins with benzyl ester-peptide 
linkages (rink amide resins) with certain amino acids (proline, glycine) as the first amino 
acid. In this reaction, when piperidine deprotects the Fmoc group of the penultimate 
amino acid, the free amino group cleaves the resin ester peptide linkage forming a 
cleaved dipeptide product called piperazinedione.46 This reaction is accelerated when 
proline followed by asparagine are the first two amino acids in the sequence. This is a 
consequence of improved accessibility to the ester bond on the resin and the presence of 
the cis-amide bond on proline.32 This side reaction may lead to partial or complete loss 
of the peptide. 
To disfavour this reaction, deprotection of asparagine was carried out with a reduced 
base concentration (20 % piperidine in DMF) in the deprotection solution with longer 
deprotection reaction time (20 minutes).  However, this approach increased the yield of 
the peptide by only 5 %. Given that at least 100 - 200 mg of the template would be 
required in the preparation the molecular imprints and subsequent rebinding assays, an 
alternative and potentially higher-yielding approach was explored based on a difference 
resin (Section 2.4.3).  
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Figure 2. 16: Diketopiperization reaction: the free amine group of asparagine attacks the ester 
linkage on the resin to form a diketopierazine product. 
Another point to note during the synthesis was the change in colour of resin from yellow 
to bright orange after the addition of proline and asparagine residues, and the colour 
change made it challenging to check for free amines using the Kaiser test (following 
deprotection and coupling steps). The change in colour has not been described in the 
literature and it is suspected that the change could be the result of a side chain protecting 
group reacting with the resin.  
2.4.2.2. Purification and Characterisation of Fmoc-VANP(COOH) 
The 4 mer Fmoc-VANP(COOH was synthesised by Fmoc solid phase synthesis on 2-
chlorotrityl resin to obtain a peptide acid. The peptide was purified with RP-HPLC with 
MeCN/water as mobile phase using a gradient run (Section 2.3.2) by isolating the 
largest peak at 22 minutes (Figure 2.17). The fraction at 22 minutes was analysed by 
mass spectrometry, which showed the correct mass of the peptide with two sodium 
adducts (666.25 g/mol) (Figure 2.18). The peptide obtained from 2-cholotitryl resin 
synthesis was less pure (70%) than that obtained from Rink amide resin. Incomplete 
coupling of the first amino acid to 2-cholorotitryl resin or degradation of resin due to 
moisture could explain lower purity of the peptide. Furthermore, coupling efficiency of 
rink amide resins for first amino acid is higher than other resins leading to purer yields.33 
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Figure 2. 17: Chromatogram of Fmoc-VANP(COOH) using gradient elution showed two peaks 
with the peptide eluting at 22 minutes. 
 
Figure 2. 18: Mass spectrometry analysis of the peptide showed the mass of the peptide with two 
sodium adducts (666.25 g/mol). This is due to the absence of any site for positive ionisation in 
the MS. 
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After discovering the occurrence of an undesired side reaction with rink amide resins 
and proline in the synthesis, a literature search for alternate resins was conducted to 
obtain higher yields of the peptide. Wang resins and 2-cholorotitry resins are popular 
resin for obtaining carboxyl-terminated peptides.  Peptide synthesis of VANP peptide 
using Wang resins failed to produce a significant yield of the peptide (~ 0.1 % of 
theoretical yield), however, the use of 2-cholorotitryl resin, which has been reported to 
suppress the diketopiperisation reaction31, resulted in good yields. It is known from 
literature that the rigidity of the linker and absence of ester group in 2-chlorotitryl resin 
prevented cyclisation and early cleavage of the peptide via the diketopiperisation 
reaction.31 The resin is also reported to suppresse racemisation of the first amino acid 
which results in the higher purity of the final peptide.31 Hence, 2-cholorotitryl was used 
further for the synthesis of Fmco-VANP-COOH peptide in the study. The peptide was 
obtained at much higher yields with the 2-cholorotitryl resin when compared to the rink 
amide resin; ~ 50 mg (33 %) of theoretical yield compared to 10 %.  
2.4.3. UV characterisation of Fmoc-VANP(COOH) peptide: 
The UV scans of the Fmoc-peptide showed three characteristic absorption peaks at 265, 
288 and 300 nm, which was characteristic of, n - π* and π - π* electronic transitions 
(Figure 2.19).47 The addition of Fmoc group lead to a stronger π - π* absorption 
spectrum at 265 nm as a result of low valence p electrons (present in fluorenyl ring) and 
weaker n - π* interaction at 285 and 301 nm as shown in Figure 2.19. Electronic 
transitions for organic molecules in the visible spectrum mostly involve p, n, s electrons 
and the most common transitions for organic molecules involve π to π* or n to π* 
electronic transitions which fall in the visible range 200-700 nm.48 The π - π* absorption 
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spectrum in peptides (without aromatic amino acids) comes from the amide bonds 
(CONH) which occurs at 190 nm (strong transition) and n - π* transition which occurs 
at 220 nm (weak transition).49 The absorption wavelength of 210 - 220 nm however, is 
not ideal for analysing peptides as there are various other organic molecules that absorb 
in this region making discrimination of peptides difficult.  The chosen epitope template 
VANP did not contain an aromatic residue therefore the Fmoc protecting group on the 
valine residue was left to enable detection using UV. 
 
Figure 2. 19: UV spectrum of FMOC-VANP(COOH) peptide scanned from 220-320 nm. The 
peptide showed characteristic peaks at 265 nm, 285 nm and 301 nm. 
Recording the absorbance maxima at 265 nm and 301 nm allowed the generation of a 
calibration curve (Figure 2.20). The peptide calibration at 265 nm was used for assays 
with the lower concentration of peptide while 301 nm was used for higher concentration 
of peptide. The peptide calibration curve was linear from 25 µg/ml- 200 µg/ml at 265 
nm wavelength and linear from 25 µg/ml to 400 µg/ml at 301nm wavelength. The 
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calibration curves were used to calculate the amount of peptide bound to the polymers in 
the monomer screening assays. 
 
Figure 2. 20: Peptide calibration curve for Fmoc-VANP(COOH) peptide. The peptide 
demonstrated a linear detection range up to 400 ug/ml at 301 nm, while the calibration curve at 
265 nm was only linear unto 200 ug/ml. 
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Figure 2. 21:  Calibration curve for Fmoc-VANP(COOH) at 300 nm wavelength as obtained by 
UV spectroscopy 
2.4.4. Monomer screening study with Fmoc-VANP(COOH): 
As a control, non-imprinted polymers, synthesised with different monomers, were 
incubated with the peptide to understand and evaluate interaction of the peptide with the 
non-imprinted polymers. The polymers were initially incubated with acetonitrile to 
check for any unreacted monomer leaching. Upon incubation of polymers in acetonitrile 
(no peptide) overnight, the UV spectrum in Figure 2.22 suggested that there was no 
leaching of unreacted monomer (if any) at 300 nm (wavelength for analysing the 
peptide). The high absorbance below 300 nm was an artefact produced by polystyrene 
cuvettes. This suggested minimal (< 2 %) interference from any monomers (if present) 
in the incubating solution. 
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Figure 2. 22: NIPs incubated overnight in acetonitrile did not show a peak for peptide 
indicating any unreacted monomer did not interfere with peptide absorption peak. 
The Figure 2.23 demonstrates that the p(EGMA-co-MAA) polymer displayed the 
highest non-specific binding to the peptide, binding 13.35 nmol of peptide per mg of 
polymer while p(EGMA-co-AAm) and p(EGMA-co-VP) bound 6.37 nmol/mg and 0.7 
nmol/mg respectively.  
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Figure 2. 23: NIP screening study showing the amount of peptide non-specifically bound to 
different non-imprinted polymers: p(EGMA-co-MAA), p(EGMA-co-AAm), p(EGMA-co-VP). 
Due to the scarcity of pure peptide it was not possible to perform NMR titration 
experiments to identify suitable candidate functional monomers for the imprinting of 
Fmoc-VANP(COOH). Therefore, as an alternative, studies were undertaken to evaluate 
the non-specific interaction of the peptide with a number of non-imprinted polymer 
(NIP) systems.  Monomers for the polymer system were chosen based on their 
functionality and on previously reported applications in the area of peptide/amino acid 
imprinting.5 Three monomers were chosen for creating NIPs with different properties to 
evaluate non-specific interactions of the peptide (Fmoc-VANP(COOH)): methacrylic 
acid (MAA) as an acidic monomer, 2-vinyl pyridine (2-VP) as a basic monomer and 
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acrylamide (AAm) as a monomer that interacts via hydrogen bonding. EGDMA was 
chosen as crosslinker initially as it produces polymers with mechanical and thermal 
stability, demonstrating good wettability in most imprinting solvents and good 
recognition properties.7 Acetonitrile was chosen as the porogen due to its ability to form 
polymers with higher porosity and better ability to solubilise amino acids and dipeptides 
than non-polar solvents such as chloroform and toluene.7 In a co-polymerisation system 
containing one or various monomers, cross linker/ moles of monomer ratio and the 
volume of porogen are the two parameters that govern the physical nature of the 
polymers. Peter Cormack’s review titled 'Molecularly imprinted polymers: synthesis and 
characterisation’ presented a pseudo-phase diagram, which could be used to predict the 
physical nature of the polymer based on volume of porogen and cross-link ratio.10 Based 
on the pseudo-phase diagram, it can be observed pre-polymerisation mixtures containing 
higher cross-link ratio and/or in presence of high volume of solvent gave rise to 
macroporous polymers. These types of polymers contain permanently porous structures 
(even in dry state) and have mechanical strength which are ideal characteristics 
preferred for a MIP (allows for easy diffusion of template to binding site).10 Polymers 
containing very high solvent or very low cross linker lead to the formation of gel-like 
powder or microgel polymer both of which are not preferred characteristics for MIPs. 
As a starting point the ratio of 1:5 monomer: crosslinker (EGMA) along with 1.5X of 
solvent to total monomer content, which has been traditionally used for creating 
molecularly imprinted polymers, was used for synthesising the NIPs.10,50,51 This was a 
suitable approach in the absence of NMR titration study to understand peptide binding  
to polymers with different functional monomer content. It is proposed that the higher 
Chapter 2                                                                               Conventional Bulk Imprinting of PSA Epitopes 
 101  
non-specific binding for p(EGMA-co-MAA), p(EGMA-co-AAm) could be attributed to 
hydrogen bonding and good porosity of the resulting polymer. On the other hand, 
absence of any amine group in p(EGMA-co-VP) and lack of any π-π interaction could 
be attributed to low non-specific binding with Fmoc-VANP(COOH).52 As the p(EGMA-
co-MAA), p(EGMA-co-AAm) based NIPs displayed higher interaction with the Fmoc-
VANP(COOH) peptide, they were studied further for imprinting of the peptide. 
2.4.5. Solubility study with Fmoc-VANP(COOH) peptide 
A solubility study with the Fmoc-VANP(COOH) peptide also was undertaken 
simultaneously with the NIP screening study to select an appropriate solvent for 
imprinting. As observed in literature the peptide was found to insoluble in non-polar 
solvents like DCM, chloroform, toluene at a concentration of 1 mg/mL. The peptide was 
sparingly soluble in acetonitrile at 1 mg/mL but became soluble at lower concentrations 
of 200 µg/mL. The peptide was found to be highly soluble in DMSO and DMF (aprotic 
solvents) at a concentration of 1 mg/mL. The solubility of the peptide in the choice of 
porogen is important due to its influence on the type of interactions taking place 
between the monomers and the peptide.50 The choice of porogen is also important as it 
brings all the component of the pre-polymerisation mixture in one phase and is 
responsible for creating well defined pores and high specific surface area in the final 
polymer which aid in the rebinding capacity and efficiency MIP.10 Polar and hydrogen 
bonding interactions are more favourable in non-polar solvents, however, peptides, in 
general, have very low solubility in such solvents.53 Use of polar solvents is generally 
not preferred, as they compete with the peptide for hydrogen bonding lowering the 
overall binding efficiency of the imprinted system. Certain groups have demonstrated 
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imprinting of peptides in aprotic solvents such as DMF15 and DMSO54 using monomers 
that interact strongly with complementary functional groups to form good MIP 
recognition systems.  Acetonitrile although slightly more polar than chloroform and 
toluene, has been demonstrated to be a good choice of solvent in imprinting peptides 
and amino acids as a result of increased porosity of MIPs.55 Hence, to keep the pre-
polymerisation mixture as non-polar as possible, acetonitrile was chosen as a solvent for 
imprinting and as a compromise, DMSO was added to improve the solubility of the 
peptide. It was hypothesised that DMSO would help solubilise the peptide while 
acetonitrile would encourage hydrogen bonding in the pre-polymerisation complex. The 
amount of DMSO was kept below 10 % of total solvent encourage these interactions.  
2.4.6. Molecular imprinting with MAA as a functional monomer: 
2.4.6.1. Synthesis of MAA-MIPS 
Based on the NIP study, p(EGMA-co-MAA) and p(EGMA-co-AAm) demonstrated 
higher interaction with the template. As a consequence these polymers were studied 
further for imprinting of the VANP template. Although, it is ideal to have equal number 
of monomer molecules to functional sites on the template to maximise complexation and 
increase imprinting efficiency, conventional molecular imprinting ideally uses excess 
monomers (1:4) (T:M) for preparation of MIPs to encourage formation of template and 
functional monomer assemblies. The template Fmoc-VANP(COOH) contained various 
hydrogen bonding sites for template interaction, however initial studies with higher 
(T:M) ratios did not result in a positive imprinting effect. This could be due to various 
reasons from non-optimised crosslinker ratio to the choice and amount of porogen 
(acetonitrile). 
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Hence, the ratio of (1:4:20) (T:M:C), which has been widely used in the literature, was 
adopted for preparing the MIPs to start understanding the effect of T:M ratio on 
imprinting effect. Post the NIP screening study, the ideal experiment would have been to 
synthesise MIPs with the same monomer to cross linker ratio (M:C 1:5) with the peptide 
template (Fmoc-VANP(COOH)) (1:4:20) (T:M:C). It was hypothesised that the peptide 
although insoluble in acetonitrile, would be soluble in the pre-polymerisation mixture 
due to presence of acidic monomer and the interaction of MAA with peptide. However, 
the peptide was found to be insoluble in the given pre-polymerisation mixture of 1:4:20 
(T:M:C) ratio. However this was not case which was suggestive of weak interaction of 
the peptide with the monomer. As a result, MIPs with two different ratios were 
synthesised and tested: 1:4:40 and 1:4:80 (T:M:C). This was done in order to increase 
the volume of pre-polymerisation mixture to better solubilise the peptide. Wulff et al. 
demonstrated for covalent molecular imprinting, enantioselectivity of MIPs increased 
with maximization of crosslinker.56 In the study, the polymer was prepared with a 
template, a non-crosslinking monomer and varying concentration of EGDMA. An 
increase in enantioselectivity was observed for MIPs upon increasing the crosslinker 
from 50 % to 70 %, after which enantioselectivity increased slowly to a maximum for 
95 % crosslinker. Furthermore, Shoravi et al. demonstrated that EGDMA contributed to 
template complexation via hydrogen bonding and hence contributed in the development 
of a highly selective cavity.57 As a result, it was hypothesised that doubling the 
crosslinker from 5 times of monomer to 10 times of monomer in the current study 
should not significantly affect the polymer’s recognition ability and selectivity.  
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The resulting mini-MIPs were washed exhaustively with methanol and acetic acid to 
break the hydrogen bonds between the template and the polymer to facilitate the 
removal of the template. Acetic acid causes a change in pH while methanol alters the 
porosity of the polymer encouraging solubilisation and removal of the peptide in the 
extraction solution.58 MIPs treated with multiple rounds of wash solution were incubated 
in acetonitrile overnight. The supernatant analysed by HPLC (Section 2.3.2) on the 
following day demonstrated an absence of peptide peak at 22 minutes indicating 
successful template extraction. Due to optimisation of various steps involved, total 
peptide extracted was not calculated as the aim was to determine an imprnitng effect and 
evaluate the performace of the MIPs in the intial study. 
2.4.6.2. Kinetic binding assay  
A binding study was undertaken to study the binding kinetics of the MAA mini-MIP. 
The amount of peptide bound to the MIP was calculated by analysing free peptide by 
RP-HPLC and concentrations were calculated using the calibration curve in Figure 2.24.   
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Figure 2. 24: Peptide calibration curve for Fmoc-VANP(COOH) peptide analysed by RP-HPLC 
It can be observed from the binding isotherm (Figure 2.25) that maximum binding (60 
%) was achieved within 10 minutes of incubation while complete saturation occurred 
within 1 hour of peptide incubation. Beyond one hour, a second curve or further binding 
was observed with the template. A possible explanation for the two curves could be 
faster binding kinetics for surface imprnited cavities follwoed by slow diffusion of the 
template to the binding cavities present in the inner core polymer leading to slower 
binding kinetics.  As close to 75% binding was observed in one hour (Figure 2.25), MIP 
binding studies with Fmoc-VANP(COOH) peptide were conducted with 1 hour 
incubation periods to obtain binding isotherms. 
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Figure 2. 25: Equilibrium binding kinetics for Fmoc-VANP(COOH) peptide (100 µg/ml) 
demonstrating faster binding kinetic till 30 minutes and slower binding kinetics beyond 30 
minutes.   
2.4.6.3. Peptide binding assay with MAA MIPs (1:4:40) 
Studies were undertaken to understand the binding efficiency between MAA MIPs and 
NIPs. The binding data of the peptide for MAA (1:4:40) MIP and NIP has been depicted 
in Figure 2.27. NIPs displayed some level of non-specific binding to the peptide, which 
was expected given the non-specific binding observed in NIP screening study in Figure 
2.23.  However, the NIP response was considerably lower than MIPs suggesting an 
imprinting effect.  
It is reasonable to assume that a number of non-covalent interactions (dipole, hydrogen, 
ionic) between monomer and template lead to the formation of a selective cavity capable 
of recognising the template. However, these non-covalent interactions are majorly 
dominated by hydrogen bonding between MAA and Fmoc-VANP(COOH) peptide as 
0 20 40 60 80 100 120
0
2
4
6
8
10
Time (minutes)
nm
ol
 p
ep
tid
e 
bo
un
d 
/ m
g 
po
ly
m
er
Chapter 2                                                                               Conventional Bulk Imprinting of PSA Epitopes 
 107  
shown in Figure 2.26. MAA has multiple points of hydrogen bond interactions with the 
amide backbone of the peptide, which could lend specificity to the MIP cavity (Figure 
2.26). The R groups on the amino acid residues mainly consist of methyl groups (valine, 
alanine and asparagine) with the exception of an additional amide group on asparagine, 
which suggests that the dominant interaction was hydrogen bonding. It is known from 
various published studies that ionic interactions lead to more stable and specific 
interactions leading to higher to imprinting factors.59,60  As the Fmoc group protected the 
amine group on N-terminus of VANP, it was hypothesised that the imprinting factor and 
binding affinity could be lower than what could have theoretically been achieved if the 
peptide was not protected. However, due to the limitation of the detection technique 
(UV) used for analysing the peptide, Fmoc protection was necessary for the study. 
 
Figure 2. 26: MAA hydrogen bonding with amide bond in the peptide backbone 
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Figure 2. 27: Binding data of MAA MIPs and NIPs with Fmoc-VANP(COOH) peptide in 
acetonitrile. (N = 8 +/- SD). Langmuir adsorption isotherm fitted data for MAA imprinted 
polymers 
To further understand and characterise the binding properties of the MIP, the binding 
data was fitted to Langmuir adsorption isotherm (Figure 2.27).  
𝐵 = 𝐵𝑚𝑎𝑥  ×  [𝑋]𝑋 +𝐾𝑑    (2.1) 
A Bmax 4.622 nmol/mg polymer and Kd of 222 µM was obtained for MAA MIPs using 
Langmuir adsorption isotherm binding model. The R2 value of 0.915 was obtained for 
fitting the MIP binding data to the model. A usable Scatchard plot of the data could not 
be obtained due to an absence of experimental data points at higher concentrations of 
peptide. The reason for this was the low solubility of the peptide in acetonitrile, with 
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200 µg/ml being the upper end of its solubility. The linear regression of the data 
indicated poor fit with a Kd > 1100 µM. 
The Langmuir adsorption isotherm with the limiting slopes analysis of Scatchard plots 
has been applied to various MIP systems for evaluation of binding affinities.61,62,63 
However, an important assumption made for fitting Langmuir adsorption isotherm is the 
binding site homogeneity. Theoretically, to build a MIP system where all binding sites 
have the same affinity towards the template molecule would require every monomer-
template interactions to take place in the same manner, with the same affinity, every 
time during the polymerisation. In practice, this is extremely difficult to achieve because 
the interactions between template and monomer are not consistent but vary from batch-
batch and time-to-time. Furthermore, in a pre-polymerisation mixture, various 
complexes exist at the same time, and their capture during various stages of 
polymerisation leads to further heterogeneity within a polymer.61 Moreover, the 
monomers do not interact with all of the template interaction sites with the same binding 
affinity, which could lead to the formation of MIPs with two to infinite binding site 
models preventing accurate representation of binding model with Langmuir adsorption 
isotherm.  
The degree of variation is also dependent on the rigidity of the template and type of 
functional groups on the template in non-covalent imprinting. Rigid templates have 
historically shown the highest imprinting efficiency with non-covalent imprinting 
possibly due to the stability of the interactions in the pre-polymerisation mixtures.64 
Peptides on the other hand are not rigid molecules, they rotate around the amide 
backbone, which further disrupts the formation of stable interactions between monomer 
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and template in the pre-polymerisation mixture.65 Langmuir model can approximate 
heterogeneity to a certain extent by grouping the heterogeneous data into two binding 
groups: low and high affinity, which can be observed from a Scatchard plot (bound vs 
free) with varying slopes. However, the plot only demonstrates heterogeneity in the 
system and cannot be used for estimating binding affinities. An example of Scatchard 
plots illustrating such grouping of low and high binding affinities can be seen in Figure 
2.35. Freundlich isotherm has also been applied for modelling the MIP binding data as it 
seemed a better fit to experimental binding data obtained with heterogeneous MIPs.66 
However, Freundlich isotherm also suffers from certain drawbacks such as problems in 
modelling saturation behaviour and validity over a large set of concentrations.  
As a result, a different model was used for modelling the heterogeneous MIP binding 
data. Langmuir-Freundlich isotherm also termed as Sips equation, first described by 
Umpbley et al 67, describes the relationship between the equilibrium concentrations of 
bound analyte and free analyte with three constants Bmax, a and m, whereby Bmax is 
the total number of binding sites, a is related to median binding affinity and m represents 
the heterogeneity index.67 Heterogeneity index m, indicates the heterogeneity of the 
system and varies from 0 to 1. A system which is completely homogenous has m = 1 
which translates the equation into Langmuir adsorption isotherm. Freundlich-Langmuir 
adsorption (FHL) model was shown to be a better fit to the MAA-MIP binding affinity 
data as it accounted for binding site heterogeneity in its model. 
𝐵 = 𝐵𝑚𝑎𝑥  𝑎  𝑋!1+ 𝑎𝑋!       (2.2) 
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Figure 2. 28: Binding isotherm fitted with Freundlich-Langmuir adsorption isotherm 
FHL model demonstrated better fit to the MAA-MIP binding data with an R2 value of 
0.994 with a Bmax of 6.019 nmol/mg polymer and apparent Kd of 102.1 µM (Figure 
2.28). This further establishes that MIP binding cavities for complex molecules like 
peptides are not made of similar binding sites that promote equal interaction with the 
template. An imprinting factor of the 2.07 was obtained for MAA MIP polymers. An 
imprinting factor > 1 suggests imprinting effect in the system and preference for the 
template. However, it is important to note that imprinting factor is meaningful for 
understanding binding efficiency between MIP and NIP at saturation concentrations 
(Bmax).7 Imprinting factors calculated below the saturation concentration can result in 
skewed IF values, which may not truly reflect the binding performance of MIPs. In the 
current study, IF could not be calculated at saturation conditions due to solubility issues 
with template. Hence, understanding of the MAA MIP systems was limited due to 
absence of Bmax data. With the available data, although a reasonable imprinting factor 
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was obtained with MAA MIP, the binding capacity and affinity was lower than that 
observed with conventional MIP systems for small molecules in literature.68,69,70   
The maximum (1:4:40) MAA MIP response was 2.4 times lower that the response of 
p(MAA-co-EGDMA) in the NIP screening study in Section 2.4.4. A possible 
explanation for this could be the change in porosity and rigidity of the polymer due to 
the addition of DMSO71 and the use of higher amount of crosslinker in synthesis of the 
imprints.72 It was also hypothesised that DMSO interacted with the peptide competing 
with MAA for hydrogen bonding, preventing formation of cavity with superior 
recognition properties. Furthermore, the use of mini-MIPs, which is larger in size than 
traditionally ground and sieved MIPs, could limit easy diffusion of the peptide to the 
imprinted cavities in the polymer. It was proposed that all these factors could have an 
overall effect on the binding kinetics and mass transfer of the peptide from/to the 
binding site in the polymer lowering its binding capacity and affinity. 
2.4.6.4. Peptide binding assay with MAA MIP (1:4:80)  
To understand the effect of cross linker on MIP imprinting efficiency another MIP 
system was synthesised with a ratio of 1:4:80 (T:M:C). The system demonstrated a 
reverse effect with NIPs displaying more binding than MIPs (Figure 2.29). This could 
be explained by inefficient removal of template leading to loss in imprinting effect in the 
polymer. It is proposed that an increase in crosslinker in the polymer reduces its porosity 
making the polymer more rigid, which could further prevent easy diffusion of the 
template during extraction/binding. Furthermore, increase in crosslinker leads to dilution 
of the template, which causes less binding sites per gram of polymer further reducing 
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the binding properties of the MIP. As a consequence higher crosslinker to monomer 
ratios were not investigated further for imprinting of Fmoc-VANP(COOH) peptide. 
 
Figure 2. 29: Binding Isotherm of MAA MIP (1:4:80) demonstrating loss of imprinting effect  
between MIP/NIPs for peptide. 
2.4.7. Molecular imprinting with AAm as a functional monomer: 
A comparison study was conducted with AAm as a monomer to understand the 
influence of monomer on the MIP system. Although AAm would still be heavily 
dependent on hydrogen bonding to form interactions with Fmoc-VANP(COOH) 
peptide, it was proposed that a higher imprinting efficiency could be achieved as a result 
of low non-specific binding of peptide to the NIPs as observed in NIP screening study 
(Figure 2.22). AAm monomers are strong hydrogen donors, as seen in Figure 2.30, and 
can interact with the peptide backbone and have been used for imprinting various 
proteins and peptides in the literature.5,14,73,74  
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Figure 2. 30: Hydrogen bonding of peptide backbone ‘CONH bond’ with acrylamide monomer 
Upon conducting binding studies with Fmoc-VANP(COOH) peptide, AAm MIPs 
displayed recognition towards Fmoc-VANP(COOH) peptide when compared to NIP as 
seen Figure 2.31. The imprinting efficiency or factor (IF) of 2.04 was comparable to 
MAA MIP, which further suggested that the dominant interaction between monomers 
and template was hydrogen bonding. Surprisingly, AAm MIPs demonstrated slightly 
higher binding capacity than MAA MIPs, possibly owning to more monomer molecules 
being available for interacting with the template (lack of self-association as observed 
with MAA). Bmax 23.57 nmol/mg and an apparent Kd of 254.3 µM were obtained by 
fitting the Freundlich Langmuir adsorption isotherm model to the data (R2 - 0.995). An 
imprinting factor of 2.04 was obtained using AAm MIP polymers.  
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Figure 2. 31: Binding isotherms for AAm/MAA MIPs and NIPs fitted with Langmuir-Freundlich 
isotherm (N = 8 +/- SD). 
MAA and AAm MIPs both demonstrated reasonable recognition and affinities towards 
the Fmoc-VANP(COOH) template over NIP with an IF ≈2. However, considering the 
clinical concentration of PSA in the blood which is 4-10 ng/ml 42, much higher 
affinities, close to few pM, would be required to detect the peptides in this clinical 
range. Such high affinities have been reported by Nishino et al. for mellitin MIP 
nanoparticles where the apparent dissociation constant was reported to be in the range of 
7.3-25 pM.75 However, to obtain such high affinities with conventional bulk polymers is 
quite challenging. The lower imprinting efficiency of the mini-MIPs could be a result of 
non-specific nature of interaction that is mostly dominated by hydrogen bonding used to 
build the polymeric cavities. To better utilise the peptide functionality, the template’s 
carboxylate group (COOH) was targeted using a specialised urea monomer for 
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imprinting the peptide. It was proposed that if slightly higher affinity (than MAA/Aam 
MIPs) could be obtained with the specialised urea monomer then the polymers could be 
transferred to a surface imprinted system to achieve higher sensitivity. 
2.4.8. Molecular imprinting with urea monomer as a functional monomer: 
Various groups have reported the use of specialised monomers to form strong 
interactions with certain function groups on peptides and amino acids for obtaining 
highly selective MIP cavities. For example, Ken Shea's group utilised the strong 
interaction between Ni and histidine to form polymeric cavities that could discriminate 
between histidine containing dipeptide sequences in aqueous solution.76 Sellegren's 
group targeted the phosphorylated tyrosine (pTyr) residue by using urea based host 
monomers to form strong interactions with the pTyr dianion in pre-polymerisation 
solution leading to highly specific binding cavities.77 
Based on a similar concept, Fmoc-VANP's carboxyl functional group was targeted for 
using urea monomers to form strong interaction in pre-polymerisation mixtures. Urea 
monomers associate strongly with carboxylate ion to form ionic interactions78 (Figure 
2.32). Furthermore, to increase the specificity of the polymer towards the peptide, a 
secondary monomer was introduced to improve the binding affinity of the MIPs. AAm 
was chosen as a secondary monomer to provide hydrogen bonding for the amide 
backbone of the peptide during polymerisation. Although MAA MIPs displayed a 
slightly higher affinity for the peptide than Aam MIP, it was not used as a secondary 
monomer to prevent interaction between MAA's carboxyl group with the urea monomer. 
A strong base: tertrabutylammmonium hyrodoxide (TBA) was used for deprotonating 
the carboxyl group to allow it to freely interact with the urea monomer. Two different 
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progens DMF and acetonitrile were used for imprinting the peptide to understand the 
effect porogen on monomer template interactions. 
 
Figure 2. 32: Ionic interaction of urea monomer with carboxylate ion of the peptide. 
2.4.8.1. Peptide equilibrium binding assay 
Binding saturation of Fmoc-VANP(COOH) peptide reached within 60 minutes of 
incubation for urea imprinted MIPs (Figure 2.33) . 
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Figure 2. 33: Equilibrium binding kinetics for acetonitrile imprinted urea monomer polymers. 
2.4.8.2. Peptide binding assay with Urea Monomer MIPs 
Binding studies of the Urea MIP polymer demonstrated certain recognition over NIPs 
(Figure 2.34), however the resulting imprinting efficiency/factor (1.42) was not greater 
than AAm and MAA MIPs.  The binding capacity of the polymers (23.1 nmol/mg 
polymer) was however, slightly higher than that of AAm and MAA polymers. It is 
proposed that this could be a result of slightly stronger interaction with the template than 
MAA/AAm leading to more template incorporation into the polymer.  Bmax of 23.1 
nmol/mg and apparent Kd of 194 µM was obtained using Langmuir Freundlich 
adsorption isotherm (R2 - 0.978). An imprinting factor of 1.42 was obtained for the 
MIPs. On comparing the Scatchard plot in Figure 2.35, two distinct slopes could be 
obtained indicating heterogeneous binding sites. The heterogeneous binding sites could 
arise from two different monomer producing binding sites with varying affinities in the 
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polymer. The low imprinting effect could be explained by urea monomers non-
specifically interacting with the carboxylate group in the peptide in NIPs. 
 
Figure 2. 34: Binding isotherm for acetonitrile imprinted urea monomer polymers. MIPs 
demonstrated higher binding than NIPS (N = 8 +/- SD). 
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Figure 2. 35: Scatchard plot analysis showed more than one slope for the data indicating 
binding site heterogeneity. This could be a result of AAm and urea monomers playing a role in 
formation of binding sites with different binding affinities. 
The urea monomer MIPs were also prepared using DMF as a porogen to understand the 
effect of solvent on binding affinities (Figure 2.36). The DMF based MIPs showed 
lower imprinting efficiency than acetonitrile imprinted MIPs indicating DMF was a poor 
solvent for imprinting. Bmax value of 11.07 nmol/mg was obtained with an apparent Kd 
of 96.20 µM. The imprinting factor was 1.29 was obtained for the DMF imprinted 
system. It is proposed that the slightly lower binding capacity of DMF imprinted urea 
MIP could a result of DMF inhibiting hydrogen bonding between AAm and peptide in 
the pre-polymerisation mixture. Slightly higher non-specific binding indicated that the 
urea monomer itself was participating in non-specific binding of the peptide suggesting 
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use of special monomers may not necessarily provide greater imprinting efficiency in 
molecular imprinting of biomolecules such as peptides. 
 
Figure 2. 36: Binding isotherm for the peptide with urea monomers imprinted in DMF porogen. 
(N = 8 +/- SD). 
2.5. Challenges Associated With Mini-MIPS: 
The study adopted the use of mini-MIPs to judiciously use the Fmoc-VANP(COOH) 
templates, which is hard to synthesise and limited in quantity. Mini-MIPs allowed for 
the formation solid polymeric particles, which were about a few mm in size with low 
initial volume of the polymerisation mixture. This technique also helped skip the 
grinding and sieving step preventing loss of precious material. Although mini-MIPs 
offered certain advantages, there were several drawbacks to the method such as; they 
were difficult to handle and weigh due to their small size, they had to be re-used for 
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binding assays, and multiple rounds of washes with methanol and acetic acid were 
required to regenerate the MIPs.  
Additionally, the mini-MIP format prevented the traditional equilibrium batch binding 
assays for generating the standard bound versus free isotherms for calculating affinity 
constants for imprinted polymers. As a consequence, a different approach had to be 
adopted whereby sequential addition of peptide was carried to understand the binding 
capacity, affinity and efficiency of MIPs. This type of experiment, whereby each peptide 
concentration was sequentially added to the same polymer mass, created new 
equilibrium conditions at each concentration. The time take to reach this new 
equilibrium for each peptide concentration could be different, but changing the 
incubation time was limited by the experimental conditions where 1 hour incubation per 
peptide concentration was kept constant conduct the experiments. This could cause 
errors in the binding data. Moreover, an error introduced in one peptide concentration 
addition could propagate to the following peptide additions preventing accurate 
representation of the binding data. Although, precautions were taken by creating stock 
peptide solutions before conducting the experiments, errros while pipetting and 
evaporation of solvent could cause unintended errors in data collection.  
Ideally, mini-MIPs would be a great tool to experimentally evaluate template binding to 
MIPs with monomers that have been screened computationally for a particular template, 
however, the template should be abundantly available for such experiments.  
In summary three polymer systems were evaluated for their binding characteristics, 
which have been summarised in the Table 2.3 below: 
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MIP Crosslinker I.F Bmax (nmol/mg 
polymer) 
Apparent Kd 
(µM) 
MAA EGDMA 2.62 7.42 102.4 
AAm EGDMA 2.02 15.83 154.3 
Urea  EGDMA 1.42 23 194 
 
Table 2. 3: Summary of bulk polymers and their binding affinities and imprinting factors. 
From Table 2.3 it can be concluded that MAA polymers demonstrated the highest 
affinity however the lowest binding capacity per mg of polymer while urea monomers 
demonstrated higher binding capacity but lower affinity for the peptide.  
Conventional epitope imprinting although a great alternative for whole imprinting has 
particular challenges associated with it such as; selection of epitopic template, lack of 
functionality of amino acids in the sequence, conformational restrictions for longer 
epitopes and low binding affinities. The study indicates that molecular imprinting of 
larger biomolecules such as peptides/proteins is quite challenging in a conventional bulk 
imprinting setting and perhaps surface imprinting would be a more feasible approach to 
efficiently imprint such biomolecules to overcome the drawbacks of bulk imprinting. 
Furthermore, regardless of the length of the sequence, each epitope template requires 
careful consideration regarding monomer, cross-linker, and porogen for successful 
imprinting. The study allowed for the identification of individual monomers that could 
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be used in a surface imprinting strategy for imprinting of the PSA C-terminus template, 
which has been further examined in Chapter 3. Further work with 6 mer and 9 mer 
templates was not conducted due to lack of promising results with 4 mer template.  
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2.6. Conclusion 
In conclusion, a strategy was developed for the synthesis C-terminus (epitope) peptide 
sequences of PSA (Fmoc-VANP(COOH) peptide) with high purity and good yields. 
Three polymers with different monomer compositions were prepared and evaluated for 
binding with the Fmoc-VANP(COOH) template. In the binding study, MAA MIPs 
demonstrated the highest affinity (apparent Kd) (102.4 µM) and imprinting factor (2.62) 
for Fmoc-VANP(COOH) peptide. The study suggests that MAA/EGDMA MIP system 
is a good monomer/ crosslinker combination when moving to surface imprinting of PSA 
epitopes. Although conventional bulk imprinting may not be suitable for imprinting of 
epitopes from large macromolecules it gives us an insight into monomer template 
interactions for smaller peptide templates.   
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3.1. Introduction 
3.1.1. General overview 
Chapter 2 demonstrated that conventional bulk imprinting of peptide (epitopes) remains 
a challenge due to their low solubility in conventional imprinting solvents and poorer 
binding performance in polar aqueous solutions. Bulk polymers are not very useful for 
sensing applications, as they are difficult to integrate with sensing platforms. This is due 
to their physical nature, meaning that MIP particles cannot be easily bound to the 
transduction platform for efficient signal transduction/amplification. Furthermore, the 
characterisation of MIP performance often relies on batch rebinding studies in which 
binding parameters are evaluated by determining the concentration of analyte left free in 
solution. For MIPs to be a useful recognition system in sensing of biomolecules, this 
disconnect between binding and ‘read-out’ needs to be addressed, that is, the MIP must 
interface directly with a transduction platform. This disconnect has been partly 
addressed by surface imprinting and in particular the area of electrochemical sensing 
which has shown great promise in direct sensing of both small and macromolecular 
templates.1,2 Various research papers have successfully demonstrated the use of 
electrochemical (E)-MIPs as sensitive recognition elements3,4 and a summary has been 
provided in Table 3.1. As a result, to overcome some of the challenges of bulk 
imprinting, the current chapter extends the concept of epitope imprinting explored in 
Chapter 1 to surface imprinting and electrochemical sensing of PSA epitopes.  
3.1.2. Surface imprinting 
Surface imprinting (Figure 3.1) refers to the growth of a polymer in the presence of a 
template to create an imprinted cavity on a suitable substrate/electrode. There are two 
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approaches for template presentation in surface imprinting; complete entrapment of the 
template (without surface immobilisation) during polymer growth and surface 
immobilisation of the template. The later approach confers several significant 
advantages:  
1. The template molecule can be presented homogenously and oriented on the 
surface, ultimately leading to higher quality, more equitable binding sites in the 
polymer.5,6 
2. Once immobilised, solubility of template in the imprinting solvent is less of an 
issue (assuming template is stable / not denatured under such conditions).7 
3. By carefully controlling the growth of the polymer around the template, the 
thickness of the polymer can be modulated to get maximum imprinting effect. 
Integration of the polymerisation and the sensing process, as in the case of 
electropolymerisation and electrochemical sensing, also enables the removal of 
template to be monitored.8 
4. Surface imprinting with thin polymers means rebinding is more efficient, with 
improved mass transfer and binding kinetics and overall greater sensitivity than 
conventional MIP systems.9,10  
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Figure 3. 1: The schematic illustrates a general surface imprinting approach. An epitope from a 
protein is immobilised on the surface. Functional monomers are introduced that interact with 
the epitope. These interactions are locked into place by polymerisation of the monomers. Post 
removal of the template/epitope cavity remains, which now has recognition properties for the 
epitope and the protein displaying the epitope.  
The Allender group has previously explored surface imprinting strategies for the 
detection of bio-macromolecules, employing Merrifield resin as a solid support. The 
resin was used for the surface imprinting of LPS using a co-immobilised template 
(polymyxin) and iniferter groups.11 However, poor control over the growth of polymer 
layers on the surface of the Merrifield resin and its inherent hydrophobicity limited the 
success and further implementation of this work. Electropolymerisation of monomers 
reportedly allows fine control over polymer growth on an electrode1 while at the same 
time enabling direct detection of template molecules via electrochemical sensing.12 As a 
result, the polymerisation of a variety of electroactive monomers for use in surface 
imprinting of a PSA epitope was explored in the current chapter. Various 
electrochemical techniques, used for surface characterisation and assessment of MIP 
binding performance, were also investigated in the current study. 
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3.1.3. Surface imprinting using electropolymers: 
Conventional imprinting involves free-radical polymerisation of vinyl/acrylate 
monomers, which leads to the formation of a solid bulk polymer. These bulk polymers 
can then be ground into a fine powder and sieved and sedimented to yield polymer 
particles. These particles, due to their physical nature, cannot be easily immobilised onto 
sensor surfaces such that close and intimate contact between the polymer and transducer 
is maintained.  This leads to poor signal transduction, which in turn gives rise to sensor 
insensitivity.12 Various methods have been used to facilitate direct immobilisation of 
MIPs on transducer surfaces including drop-coating of a polymer solution13, covalent 
immobilisation of MIPs14, in-situ polymerisation and spin coating of MIPs15, preparing a 
composite membrane using a conducting material16 (carbon nanotubes, graphite or 
carbon black) and electropolymerisation of electroactive monomers.17,10,18  
Of these methods, MIP films resulting from electropolymerisation have demonstrated 
superior properties when compared to conventional MIPs in terms of stable attachment 
to the transducer surface, ease of preparation in aqueous/non-aqueous solutions and easy 
pathway to conduction of electrons through electrodes.12 Furthermore, it is possible to 
control the rate and extent of polymer growth and polymer properties by optimising 
electrochemical parameters.19 For example, control over polymer film thickness can be 
achieved by controlling the total amount of charge passed through the electrode, and 
polymer morphology can be defined by the electrolyte / solvent employed during 
polymerisation.19 Electropolymerisation of electroactive monomers can be performed 
under galvanostatic (constant current), potentiostatic (constant potential) or 
potentiodynamic (variable potential) conditions.20 In electropolymerised MIP, just as in 
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conventional MIPs, monomers are spatially positioned around the template to form a 
stable complex in the pre-polymerisation solution, which gets locked in during the 
polymerisation process. The resulting cavity has good structural rigidity and stability 
ensuring that its shape and functionality is maintained when the polymer is washed and 
the template removed. Furthermore, the electroactive monomers possess various 
functional groups that participate in π-π interaction, hydrogen bonding, ionic 
interactions and hydrophobic interaction promoting chemical selectivity of the imprinted 
cavity similar to conventional imprinting monomers.21 Various electroactive monomers 
such as pyrrole, aniline, aminophenol, thiophene, aminophenoboronic acid, phenol, 
aminothiophenol, aminobenzoic acid, phenylenediamine, dopamine have found 
application in electrochemical sensing of amino acids, small molecules, proteins and 
nucleotides with E-MIPs.21,17 (Table 3.1) 
A general protocol for the synthesis of an E-MIP system involves preparing a combined 
solution of electroactive monomer and template (surface immobilised or in solution). 
This is then subjected to a specific voltage range that causes the oxidation/reduction of 
electroactive monomer at the surface of the electrode leading to polymer growth.17 The 
template becomes entrapped during this process, which results in the formation of 
imprinted cavities. The morphology of the polymer (porosity and rigidity) is governed 
by choice of solvent, the rate at which the charge is transferred to the monomers 
(voltage scan rate of oxidation/reduction) and the amount of charge transferred during 
electropolymerisation (dependent upon the properties of the electrode surface). 19 A brief 
overview of some electroactive monomers and their application in electrochemical 
sensing of various templates has been provided in Table 3.1.   
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Electro-monomer Conductivity Templates 
Pyrrole Conducting Adenosine/	  inosine/ATP22, caffeine23, 
paracetomol24, tryptophan25 
Thiophene Conducting Histamine26, dopamine27, avidin28 
Aminophenolboronic 
acid 
Conducting Nucleotide and monosaccherides29, 
lysosome, cytochrome C30 
4-Aminobenzoic acid Conducting Melamine31 
Dopamine Non-conducting Nicotine4, HIV-epitope32, IgG5 
Aminophenol Non-conducting 2,4-dichlorophenoxyacetic acid, 
dopamine33 Myoglobin34 
Scoloptien Non-conducting Conclavin-A35, cytochrome C 
nonapeptide8 
Phenol Non-conducting Phenylalanine1, ferritin36, theophylline37, 
D-glucose38 
1,2 phenyldiamine Non-conducting Glucose39, sorbitol40, troponin41 
Table 3. 1: Summary of electroactive monomers and templates imprinted using e-MIPs 
Chapter 3                                                                       Surface Imprinting of Pro-PSA Activation Sequence 
 137 
3.1.4. Electrochemical techniques for molecular imprinting: 
A general overview of some of the electrochemical techniques used in the fabrication 
and evaluation of electrochemical (E)-MIPs in the current work has been detailed in the 
section below. 
3.1.4.1. Electrochemical MIP biosensors  
Electrochemical biosensors are devices capable of converting and measuring a 
chemical/biochemical signal, arising from a biomolecule interacting with an analyte, 
into an electrical signal.42 In the case of molecular imprinting, the biomolecular layer 
consists of an imprinted polymer with a memory for the template as seen in Figure 3.2. 
A typical biosensor consists of an electrode surface, which has been modified with a 
bio-layer with certain recognition properties, a transducer surface that converts the 
binding events into an electrical signal and a signal processing system which quantifies 
and amplifies the signal (Figure 3.2).42 The electrochemical properties of an electrode 
change upon interaction of a template with the bio-layer. These changes convert into 
quantifiable changes in either the current (amperometric), potential (potentiometric and 
field effect devices), impedance (impedometric) or conductivity (conductometric) of the 
system.43  
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Figure 3. 2: General schematic of the construction of E-MIP sensor has been depicted. A pre-
polymerisation mixture allows for interactions between the template and the functional 
monomer. The template is then entrapped into the polymer upon electropolymerisation locking 
the interactions in place. The template is washed away to expose the imprinted cavities. 
Rebinding of the template is measured via different electroanalytical techniques. The schematic 
has been reproduced from Sharma et al., 2012.12  
3.1.4.2. Electrochemical configuration in MIP electrochemical biosensors 
The simplest electrochemical set up consists of two electrodes: a working electrode 
(WE) and a counter electrode (CE) whereby current flows from the WE to the CE. The 
working electrode is the electrode where a biolayer/polymer is immobilised, with any 
changes due to binding of analyte producing a change in the electrical signal. The 
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counter electrode completes the circuit and provides a reference potential for measuring 
the change in electrical signal occurring at the working electrode.44 Although, this may 
seem a simple set-up, practically it is difficult to implement due to challenges in keeping 
the counter electrode at a constant potential during electrochemical measurements. As a 
result, a 3-electrode setup is preferred consisting of a reference electrode (RE) in 
addition to the working and counter electrodes as shown in Figure 3.3.44 The WE and 
RE form a half-cell and maintain a constant potential allowing measurement of the flow 
of current through the CE. The RE simply provides a reference potential and does not 
participate in the flow of electrons between the working and counter electrodes. The 
internationally accepted primary reference electrode is a standard hydrogen electrode 
(SHE), which has unit potential.45 Potentials are usually quoted with reference to SHE 
because it is not experimentally convenient to use SHE in the laboratories (difficult to 
set up apparatus and maintain hydrogen gas pressure at 1 bar).45 The most common 
reference electrode applied in electrochemistry measurement is a silver-silver chloride 
(Ag/AgCl) electrode dipped in a saturated potassium chloride solution, which has a 
potential of 0.197 V with reference to SHE.45 
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Figure 3. 3: Schematic of 3-electrode setup showing the working electrode (WE), reference 
electrode (RE) and a counter electrode (CE) connected to an external potentiostat. 
3.1.4.3. Faradaic and non-Faradaic processes: 
There are two type of processes that occur at the electrode surface: Faradaic processes 
and non-Faradaic processes.46 Faradaic processes occur when there is transfer of charges 
(electrons) from the electrode to the metal-electrolyte interface, which is governed by 
Faraday’s law hence termed Faradaic processes.46 There are also secondary processes 
that occur at the surface of the electrode as a result of adsorption and desorption of 
charged molecules which are termed non-Faradaic processes.46 Both, Faradaic and non-
Faradaic processes occur simultaneously during an electrochemical reaction. 
• Non-Faradaic process 
Non-Faradaic processes occur due to adsorption/desorption of charged molecules on the 
metal-electrolyte interface. A metal (electrode) surface consists of either an excess or 
deficiency of electrons that are present in close proximity to the surface (< 0.01 nm). 
The electrolyte solution in contact with the metal surface mostly contains an excess of 
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anions and cations.47 When the metal surface comes in contact with the electrolyte 
solution, the charge distribution at the electrode-electrolyte interface depends on the 
potential difference between the electrode and the electrolyte. This potential difference 
is characterised by a double layer capacitance also termed as the electrochemical double 
layer (EDL). 47  
The structure of EDL, in solution, is made up of various layers as depicted in Figure 3.4. 
The innermost layer is present at the electrode surface and comprises of specifically 
adsorbed solvent molecules and ions and is termed as the inner Helmholtz plane (IHP).48 
The IHP molecules and ions are de-solvated and are chemically bound to the electrode 
surface. The layer that sits on top of the IHP is known as the as outer Helmholtz plane 
(OHP), which comprises of solvated ions which are non-specifically adsorbed to the 
surface and are attracted to the charged electrode by long-range electrostatic forces.48 
The OHP extends from the IHP to the electrical centers of the nearest solvated ions. 
Beyond the OHP is the diffuse layer where the ions are distributed as a result of thermal 
motion. The thickness of the diffuse layer depends on the total ionic concentration of the 
electrolyte.48 The structure of the EDL can affect the rate of electrochemical reactions/ 
Faradaic processes. The effect of EDL becomes significant when electro-active species 
are present in low concentrations, and hence it must be taken into account with Faradaic 
processes when calculating change in electrochemical signal.  
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Figure 3. 4: Structure of electrochemical double layer: The inner Helmholtz plane (IHP) is 
closest to the metal surface containing specifically adsorbed species, the outer Helmholtz plane 
(OHP) consists of solvated ions non-specifically attracted towards the IHP and the diffuse layer 
consists of ions that are attracted by long distance forces. 
• Faradaic processes: 
Faradaic processes obey Faraday’s law, which states that the total chemical deposition 
occurring at the electrode surface due to the flow of current is directly proportional to 
the amount of charge (coulombs) passed through the electrode.46 In the case of 
biosensors, Faradaic currents are of most interest as they are directly proportional to the 
binding event between an analyte and receptor. There are two types of chemical 
reactions that occur in an electrochemical cell: oxidation and reduction. If the electrode 
is driven to a more negative potential by connecting it to an external power supply, the 
electrons of ions in solution gain energy and transfer into a vacancy in the valence shell 
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of the ion.46 The current flows from metal to solution (cathodic) and the ion in the 
solution which gains an electron is reduced. This reaction can be written as: 
𝑂 + 𝑛𝑒! ↔ 𝑅	  	  
Where n is the charge, O is oxidised species and R its reduced form. 
If the electron transfer occurs in the opposite direction, from solution to metal, the 
current is anodic, and the metal atom loses an electron and thus is oxidised. The 
electrochemical reactions (oxidation/reduction) occurring in an electrochemical cell are 
governed by Faraday’s law. When investigating the electrochemical behaviour of an 
electrochemical cell, certain conditions are kept constant to allow changes in variables 
such as current, potential, or concentration to be observed. According to Faraday’s law 
the reduction and oxidation current are directly proportional the concentration of the 
reduced/oxidised species 46: 
𝑖! =   −𝜂𝐹𝐴𝐾!𝑐′!	  	  𝑖! =   𝜂𝐹𝐴𝐾!𝑐′! 	  	  
Where 𝑖! is the reduction current, 𝜂 is overpotential, which is departure of the electrode 
potential from equilibrium value upon passage of current (E -Eeq), A is the area of the 
electrode, KR and Ko are the reaction constant and 𝑐′!   and 𝑐′! are the concentration of 
the oxidised and the reduced species. If an electrochemical reaction is considered, it 
consists of various steps that cause the conversion of the dissolved oxidised species to 
its reduced state R, in solution. The rate of the electrode reaction is governed by: 
1. Movement of electrons through a solid electrode (generally very fast),  
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2. Mass transfer through the bulk solution to the interface (consisting of migration, 
convection and diffusion of charges).  
3. Chemical reactions following the electron transfer process such as protonation, 
dimerization, and catalytic decomposition on the electrode surface. 
4. Surface reactions such as adsorption, desorption or crystallization. 
All the above factors are taken into account when calculating the electrochemical rate of 
reaction in a cell.44  
3.1.4.4. Cyclic voltammetry: 
In amperometric biosensors, the reduction / oxidation current between the CE and WE is 
measured by applying a set voltage to the WE with respect to the reference electrode. In 
cyclic voltammetry (CV), the set potential of an electrode is varied with respect to time 
and the resulting current is measured.46 The potential applied to the WE can be termed 
an “excitation signal”, which is swept between two set potential values also termed as 
switching potentials.46 The linear potential scan can be represented as a triangular 
waveform as shown in Figure 3.5(a). The resulting current can be termed as a “response 
signal”. Qualitative and quantitative information about an electrochemical reaction can 
be obtained from observing the oxidation/reduction peaks of cyclic voltammogram (CV) 
(graphical representation) as shown in Figure 3.5 (b).46 A detailed description on theory 
of CV can be found in  ‘Understanding Voltammetry ’ by Richard G. Compton et al.49 A 
brief overview has been provided in the following section. 
In a typical CV experiment, the potential of the working electrode (vs reference) is 
swept linearly with respect to time from an initial potential (E0) to a switching potential 
(E1), and once again after which the direction of the linear sweep is reversed until the 
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initial potential (E0) is reached (see Figure 3.5 (b)).45 The potential voltage limits are 
chosen such that the oxidation and reduction potential of the electroactive species under 
investigation lies within the potential window. The forward scan (change in potential in 
the positive direction) produces an anodic current for an analyte that is being oxidised 
within the scanned potential range. The oxidation causes the concentration of the analyte 
to decrease at the surface of electrode, which leads to an increase in current.49 As the 
potential increases, more and more analyte is oxidised until it becomes completely 
depleted from the electrode surface. At this point mass transfer reaches its maximum 
value and a peak current (ip) is observed.49 The potential at this point is termed as Epa 
(anodic potential). Further increase in potential leads to a zone of depletion (mass 
transfer slows down) and hence the current starts to decrease. When the potential is 
switched (reverse scan), reduction of the analyte occurs causing a cathodic current to 
flow through the electrode. If the electrochemical reaction is reversible, the oxidised 
species will be reduced to its original state after reaching the switching potential on the 
reverse scan.49 In reversible electrochemical reactions, the cathodic current produced by 
the reduction of the analyte has a similar shape as that of the anodic current. In 
irreversible electrochemical reactions, the cathodic current may show different peaks as 
a result of different reactions occurring at the electrode surface.50 The result of the 
experiment is plotted as a cyclic voltammogram from which information about the 
electrochemical reactions of the system can be obtained. Faradaic currents can be 
generated either through redox activity of a chemical species in the solution at the 
electrode surface (Fe[CN]6-3/-4), a redox mediator (ferrocene) that interacts with the 
analyte of interest or by oxidation/reduction of electroactive molecules in the case of 
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electropolymerisation.50 The residual current in the absence of any electroactive species 
is a direct result of non-Faradaic processes.50 
Figure 3. 5 Cyclic voltammetry (a) demonstrates the variation of voltage versus time. In cyclic 
voltammetry the voltage is switched from one potential to another over time and resulting 
current is recorded to obtain a graph as show in 3.5 (b). This graph of current versus voltage in 
cyclic voltammmetry is termed as cyclic voltammogram. In figure 3.5 (b) cyclic voltammogram 
of a reversible oxidised species is depicted. The graph shows peak similarity in both forward 
and reverse scan. An increase in potential (voltage) leads to oxidation of species, which causes 
an increase in anodic current (faradaic current) shown by the sharp increase in the curve. When 
all the species on the surface of the electrode are oxidised the anodic current reaches its peak 
(ipa) at anodic potential (Epa), Thereafter, further increase in potential leads to decrease in 
current shown by the drop in curve. When the potential is reversed, the oxidised species on the 
surface is reduced leading to an increase in cathodic current in the opposite direction. As the 
species can be reversibly oxidised and reduced a similar peak (ipc) is obtained in the reverse 
scan at cathodic potential (Epc). Any residual current not obtained from oxidation of species is 
termed as non-faradaic current. 
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3.1.4.5. Electrochemical impedance spectroscopy: 
While cyclic voltammetry is a useful technique to understand what electrochemical 
reactions are occurring at an electrode surface, it is not sufficiently sensitive to allow for 
the detection of biomolecular interaction. Alternative techniques such as electrochemical 
impedance spectroscopy (EIS) have therefore been increasingly applied as a label-free 
electrochemical technique in biosensing.51. In EIS, a small (∼5 mV) perturbing potential 
(cyclic voltage) is applied across an electrode.  The perturbing potential applied varies in 
a cyclic sinusoidal manner such that the time-averaged overpotential is zero (a steady 
state situation occurs).51 As the voltage changes in a cyclical manner, the current also 
alternates producing an alternating current (AC). When a constant voltage, V, is applied 
across an electrochemical cell with a resistance, R, it induces a constant current, I, 
according to Ohm’s law: 
𝑉 = 𝐼𝑅            (3.1)	  	  	  	  	   	   	  	  
Similarly, if a sinusoidal varying potential is applied to an electrochemical cell it 
induces an alternating current, as shown in Figure 3.6 
𝑉 = 𝐼𝑍          (3.2)	  	  	  	  	  	  	   	   	  
Where Z is the impedance (vector form of resistance) of the circuit, and 𝑉 and 𝐼 are time 
dependent voltage and current respectively. Therefore, simply speaking, impedance is a 
resistance that varies in a cyclical manner and has the unit of ohms (Ω).52 
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Figure 3. 6: A sinusoidally varying potential is applied to a sample and the time dependent 
current is measured as a function of frequency. It can be seen from the image that the current 
induced is out of phase with the potential by a time lag θ.53 
The perturbation signal or excitation signal (V) can also be expressed with the following 
equation52: 
𝑉! = 𝑉! sin 𝜔𝑡         (3.3)  
Where, Vt is the potential at time t, V0 is the total perturbation signal applied or the 
amplitude of the signal, ω is the radian frequency (radians/sec) expressed as 2πf.  
The resulting response signal or current to the excitation signal is not equal to the total 
voltage applied and is shifted in phased by φ52: 
𝐼! = 𝐼! sin(𝜔𝑡 + 𝜙)                  (3.4) 
As impedance is defined as the ratio of voltage to current, it can be now expressed by 
the following equation52: 
𝑍 = 𝑉!𝐼! = 𝑉!  sin  (𝜔𝑡)𝐼! sin(𝜔𝑡 + 𝜙) = 𝑍! sin 𝜔𝑡sin 𝜔𝑡 + 𝜙           (3.5) 
Time lag θ   
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Hence, total impedance at a specific time point is defined in terms of magnitude Z0 and 
phase shift of φ.52  
If one plots the applied sinusoidal perturbation signal Vt on the X-axis and the resulting 
sinusoidal current response signal It on the Y axis of a graph, an oval shape is obtained 
on the graph which is termed as ‘Lissajous Figure’52 (Figure 3.7) This figure was 
analysed for impedance measurement before the arrival of EIS instruments such as 
potentiostat.  
 
Figure 3. 7: If one plots the applied sinusoidal perturbation signal Vt on the X-axis and the 
resulting sinusoidal current response signal It on the Y axis of a graph, an oval shape is 
obtained on the graph which is termed as ‘Lissajous Figure’. The Lissajous figureis  used to 
calculate impedance. 
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The potentiostat measures the impedance by applying the sinusoidal voltage and 
measuring the resulting sinusoidal current and calculates the resulting impedance for 
each specified frequency which is then plotted as a Nyquist plot as shown (Figure 3.8)52: 
With Eulers relationship (a mathematical function): exp 𝑗𝜙 = 𝑐𝑜𝑠𝜙 + 𝑗𝑠𝑖𝑛𝜙    (3.6), 
where j is an imaginary number, impedance can be expressed as a complex function: 
𝑍 𝜔 = 𝑉𝐼 = 𝑍! exp 𝑗𝜙 =   𝑍! 𝑐𝑜𝑠𝜙 + 𝑗𝑠𝑖𝑛𝜙 = 𝑍! 𝑐𝑜𝑠𝜙 + 𝑍!𝑗 𝑠𝑖𝑛𝜙     (3.7) 
  
𝑍 𝜔 = 𝑍𝑟𝑒𝑎𝑙 + 𝑍𝑖𝑚𝑔 (3.8) 
Hence, complete impedance Z(ω), is comprised of two components - real (Z’) and 
imaginary impedance (Z’’) which are related by the equation52: 
𝑍 𝜔 = 𝑍! + 𝑗𝑍′′	   (3.9)	  
Where j =    −1 , is an imaginary number and hence the term complex impedance. 
The modulus of impedance can be calculated as:  
𝑍 = (𝑍! +   𝑍"  )            (3.10)	  
If the real part (Z’) is plotted on the X axis and the imaginary part (Z”) on the Y axis of 
a chart, it forms the Nyquist plot or an impedance plot as shown in Figure 3.8. 
In an EIS experiment, the frequency dependent resistance, Z*, is measured over a wide 
frequency range (0.1Hz to 106 Hz). The potentiostat or frequency analyser applies a tiny 
voltage (sinusoidally modulated) to the electrode and measures the respective time 
dependent current, calculating Z* and the time lag φ. The potentiostat then alters the 
frequency at which the voltage oscillates and repeats the measurement until Z* at all 
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frequencies are calculated. From all the values of Z(ω) and φ., the components Z’ and 
Z” are obtained which is then plotted in the form of a Nyquist plot (Figure 3.8).52  
 
 
Figure 3. 8: The figure represents the Nyquist plot on which the impedance can be represented 
as a vector of length |Z|. The angle between the vector and the X axis is referred to as phase 
angle f(=argZ). Impedance is represented as a complex number with the following 
equation:𝑍 𝜔 =!!=𝑍!exp 𝑗𝜙 =  𝑍!(𝑐𝑜𝑠𝜙 + 𝑗𝑠𝑖𝑛𝜙) where Z is impedance, ω is radians which 
is related to frequency by 2πf, E potential, I current and j is an imaginary number. Hence, from 
the equation Z(ω) is composed of Z’ (real) (Z0 cosφ) plotted on the X axis and Z’’ (imaginary) 
component (Z0 j sinφ) on Nyquist plot. 
To analyse impedance data a critical concept is that of ‘equivalent circuits’. It is 
assumed that any electrochemical cell or electrode modified with biomolecules can be 
approximately explained by an array of electrical components. Any electrical 
component has three inherent properties: resistance (R), capacitance (C) and inductance 
(L), oxidised the first two components mostly dominate in an electrical circuit.54 The 
electrochemical cell is theoretically modelled based on an array of resistors and 
capacitors such that the behaviour in Nyquist plot can be reproduced exactly. It is 
𝑍" φ 
𝑍! 
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further assumed that the components exhibit ‘pure; behaviour such that a ‘pure’ resistor 
has nothing to do with capacitance and a ‘pure’ capacitor has nothing to do with 
resistance. The impedance of a purely resistive circuit is characterised by zero time lag 
that is the current is in phase with the potential. Hence R is described by  
𝑍∗ 𝑅 = 𝑍! = 𝑅	  	  	  	  	  	  (3.11)	  
Capacitance is defined as the ability to store charge. For a pure capacitor the time lag of 
current by voltage is -900. A pure capacitor has a resistive component hence the real 
impedance or 𝑍!  is zero. The impedance of a capacitor is given by the following 
equation: 
𝑍∗ 𝐶 = 𝑍" = − !!"#               (3.12)	  
The impedance of a capacitor is a function of frequency, hence the impedance of a 
capacitor is infinite when a DC voltage is applied (ω = 0) and the impedance approaches 
zero at very high frequencies.  
In general, when considering real electrical components we can assume that real 
impedance behaves largely like a resistor and imaginary impedance behaves largely like 
a capacitor. For many electrochemical systems, the most common employed equivalent 
circuit is the Randle’s equivalent circuit.46 In the Randle’s equivalent circuit 𝑅𝑠 
describes the solution resistance, 𝑅𝑐𝑡 is the charge transfer resistance and 𝐶𝐷𝐿 the 
double layer capacitance as shown in Figure 3.9.46 Modelling the electrochemical 
system with the Randle’s equivalent circuit can help in understanding the theory behind 
the phenomena occurring in the cell when some techniques are used for investigation. 
However, in reality, electrochemical diffusion processes affect experimental Faradaic 
currents. Diffusion processes can be modelled in an equivalent circuit by using a 
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distributed element, in series with the charge transfer resistance (Rct), called a Warburg 
element (W).54 The Warburg impedance, 𝑊, depends on the concentration of the redox 
markers and, is frequency-dependent.55 Since the Warburg element takes into account 
the mass transfer processes, it is more predominant at low frequencies.  
 
Figure 3. 9: A typical Randle’s equivalent circuit for EIS circuits. Rs is the solution resistance 
which remains more or less constant. Rs is in series with charge transfer resistance (Rct) and 
double layer capacitance (Cdl). Rct is the charge transfer resistance of the biolayer immobilised 
on the surface. Cdl is defined as the capacitance exhibited by the two parallel layers of charge 
surrounding the electrode. W is defined as the Warburg’s element, which models the diffusion 
process in the system. 
All of the above techniques have been used in this work for electrode characterisation 
and evaluation binding characteristics of the MIP sensor in the current work. 
3.1.5. PSA activation peptide sequences as a biomarker 
Pro - PSA is an enzymatically inactive precursor form of PSA containing an additional 7 
amino-acid sequence at its N-terminus (Figure 3.10).56 The seven amino acid sequence, 
APLILSR (Figure 3.11), is cleaved by the hK2/hK4 enzyme extracellularly to produce 
the enzymatically active form of PSA.57  [- 2] pro - PSA is cleaved between the third 
(leucine) and the second (serine) amino acids leaving two amino acids attached to PSA, 
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which is not cleaved further. [-2] Pro-PSA has been found in elevated levels in serum 
samples of patients with prostate cancer in several preclinical studies58,59,60, with 
immunohistochemical tests also reporting an increased staining of [-2] pro-PSA in 
cancer tissue.58  
 
Figure 3. 10: Formation of active PSA and pro-PSA forms distinguished by the amino acid 
sequence and the site of truncation. PSA is a 237 amino acid protein with 7 amino acid 
activation sequence in the pro-form which is cleaved by hK2 extracellulary to give active PSA.61 
 
Figure 3. 11: Structure of pro-PSA peptide, APLILSR, showing alanine-proline-leucine-
isoleucine-leucine-serine-arginine in the chemical structure. 
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A study by Engleheart and co-workers reported increased levels of PSA activation 
peptide sequence (APLILSR) in urine samples of patients with PCa.62 Furthermore, 
higher peptide concentrations in patients correlated with a more aggressive form of 
prostate cancer, which potentially makes the peptide an important diagnostic and 
prognostic biomarker for the disease. The study reported high concentrations of the 
activation sequence in both the kidney and bladder, in line with renal clearance of the 
peptide. The activation peptide was detected using antibodies, which were raised for the 
activation sequence, via an immunoblotting technique. The level of peptide in urine 
samples was found to be greater than 10 ng/ml. The high concentration of peptide could 
be a result of elevated PSA levels in patients with the aggressive forms of PCa.63 The 
study also proposed that the antibodies which were specific to a small part of the 
peptide, could also capture truncated sequences of the peptide (APLIL), which could be 
correlated to [-2] pro-PSA, making them highly specific for measuring aggressive PCa. 
Hence, an alternative method of detecting PSA/ [-2] pro-PSA would be the detection of 
the 7 and 5 amino acid activation sequences that are cleaved from PSA before entering 
the blood stream due to their co-relation with aggressiveness of the disease. This test 
would also lend specificity to t-PSA test for PCa detection. 
3.1.6. Pro-peptide imprinting and electrochemical sensing: 
The PROSENSE network aimed at exploring alternative biomarkers that could improve 
the specificity of the t-PSA test for PCa detection. Pro-PSA activation peptide was not 
only shown to be a diagnostic marker for PCa but also a discriminatory marker for 
benign and aggressive forms of cancer. As a result, we chose to study pro-PSA peptide 
for creating a surface imprinted MIP biosensor that would lend further specificity to t-
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PSA test alone. Furthermore, pro-PSA activation sequence, due to low molecular 
weight, could be easily synthesised with modifications to enable efficient and reliable 
surface immobilisation ahead of imprinting. The use of the peptide sequences offered 
advantages in terms of the peptide stability, ease of template synthesis and flexibility to 
engineer on to different sensing platforms, which was more efficient than using whole 
pro-PSA protein which is an expensive template. 
Figure 3.12 depicts the general scheme for the imprinting of the pro-PSA activation 
sequence. The pro-PSA peptide was modified with a thiol linker to facilitate direct 
attachment of the sequence to the electrode via thiol-gold interaction. The peptide was 
trapped on the surface using electropolymerised monomer, following which the peptide 
was extracted by selectively cleaving the thiol linkage of the peptide (subjecting to a 
specific voltage) and washing exhaustively with water to expose the imprinted cavities. 
Rebinding to the MIP modified electrodes was then evaluated using EIS. The use a 
linker / spacer thiol molecule was also hypothesised to help preserve the conformation 
of the template (mostly linear but not rigid as is the case with small molecules), while 
also leading to the uniform and oriented assembly of the peptide on the surface through 
a self-assembled monolayer (SAM), such that more homogenous binding sites should 
form upon polymerisation. As the activation peptide sequence relates to the 
aggressiveness of PCa and can be found in urine, the sensor could be potentially used as 
a non-invasive diagnostic and prognostic tool for early detection and monitoring 
progression of PCa. Furthermore, it was hypothesised that the results could be translated 
to epitope sequences from t-PSA selected in Chapter 1. 
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Figure 3. 12 Schematic of the Pro-PSA peptide imprinting process. (a) A gold bare electrode 
was first cleaned electrochemically and chemically (b) Thiolated-pro-PSA peptide was 
immobilised on the electrode (c) Immobilised electrode was trapped into a polymer via 
electropolymerisation (d) The peptide was removed to expose imprinted cavities (e) pro-PSA 
peptide was reintroduced to study binding characteristics using electrochemical techniques. 
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3.2. Aims And Objectives Of Chapter 3 
The overall aim of this chapter is to construct a surface imprinted MIP sensor for the 
sensitive and selective detection of pro-PSA activation peptide sequence (APLILSR). 
Key objectives of this chapter are: 
1. Synthesise the peptide APLILSR using Fmoc solid phase peptide synthesis. 
2. Modify the peptide with a thiol-linker to enable one-step template 
immobilisation. 
3. To investigate the electropolymerisation of different electroactive monomers  
4. Optimisation of imprinting methodology for APLILSR peptide using a 
selected electroactive monomer. 
5. Evaluate MIP sensor performance by undertaking dose response assays with 
the imprinted peptide and investigating cross-reactivity with control peptides. 
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3.3. Materials And Methods 
3.3.1. Reagents 
Dopamine hydrochloride, aniline aminophenol, aminobenzoic acid, trisma base, 
concentrated sulphuric acid, potassium phosphate monobasic solution (1 M), potassium 
phosphate dibasic solution (1 M), potassium hexacyanoferrate (III), potassium 
hexacyanoferrate (II) trihydrate, hexaammineruthenium (III) chloride, Tween 20, 
potassium chloride and magnesium chloride were all purchased from Sigma–Aldrich, 
UK. Ethyl acetate, DCM, DMF, acetic acid and acetonitrile were purchased from Fisher, 
UK. All aqueous solutions were prepared using ultra-pure water 18.2 MΩ cm from a 
Milli Q system with Pyrogard filter (Millipore, UK). Gold working electrodes were 
obtained from CH Instruments, USA and mechanical electrode polishing kit from 
Buehler, UK. 
3.3.2. Electrochemical apparatus 
Electrochemical measurements were performed using a PARSTAT 2273 potentiostat 
(Princeton Applied Research, USA) with a three-electrode configuration comprising a 
Ag/AgCl reference electrode (BASi, USA), connected via a salt bridge filled with 10 
mM phosphate buffer saline (PBS) pH 7.4 containing 150 mM NaCl and 10 mM KCl, 
and a platinum (Pt) counter electrode (ALS, Japan). The electrochemical impedance 
spectra were measured in 10 mM PBS (pH 7.4) measurement buffer containing 10 mM 
ferro/ferricyanide [Fe(CN)6]3-/4- over the frequency range of 100 kHz to 100 mHz, with 
a 10 mV a.c. voltage superimposed on a bias D.C Voltage of 0.2 V vs Ag/AgCl 
reference electrode (corresponding to the formal potential of the redox couple). All 
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measurements were performed at room temperature in 10 mL glass beakers as shown in 
Figure 3.13. 
          
Figure 3. 13: Three-electrode setup with working (green), counter (white) and reference (red) 
electrodes. The set up is connected to a potentiostat that records electrochemical measurements. 
3.3.3. Synthesis of triphenylmethyl protected mercaptoundecanoic acid (MUA): 
Tritylchloride/ Chlorotriphenylmethane, (3.1 g, 2.28 mmol) and MUA (500 mg, 2.28 
mmol) were dissolved in 7.5 mL of dry DCM in a round bottom flask and left stirring 
overnight on a magnetic stirrer at room temperature. Crude product MUA and 
tritylchloride was individually run on silica gel thin layer chromatography (TLC) plates 
(Merck KGAa, Germany) with ethyl acetate (EtOAc) / petroleum ether (v/v 20:80) as 
the eluent for 30 seconds. The silica TLC plate was dipped in concentrated H2SO4 for 10 
seconds and subsequently heated using a heat-gun. The presence of the product was 
confirmed by the formation of a bright yellow color arising from the fluorescence of 
triphenyl group. The solution containing the crude product was evaporated using a 
vacuum rotary evaporator (Buchi, Rotovapour, R-200). Thereafter, the dried crude 
product was dissolved in DCM (15 mL) and water (12.5 mL) and phase separated using 
Chapter 3                                                                       Surface Imprinting of Pro-PSA Activation Sequence 
 161 
a separating funnel. The aqueous phase was removed and the organic phase containing 
the product was washed with water (2 × 15 mL) and then dried with MgSO4 (500 mg). 
The product was then filtered (Whatman filter paper, Grade 1) and vacuum dried to 
yield crude MUA-(Trt). The crude compound (dissolved in 5 ml DCM) was loaded onto 
a silica gel column (Sigma Aldrich, UK) and eluted using EtOAc/petroleum ether 
(20:80) mobile phase. Fractions (5 mL X 30) were collected and analyzed by TLC 
(eluent 50/50 EtOAc) /petroleum ether) to detect MUA-(Trt) in the fractions. The 
fractions containing the MUA-(Trt), as confirmed by TLC, were pooled together and 
vacuum rotary evaporated with further drying under vacuum overnight (at room 
temperature). Purified MUA-(trt) was dissolved in deuterated chloroform (3 mg in 1 mL 
CdCl3) and tested for purity by NMR (Bruker BioSpin GmbH, Germany). 
3.3.4. Peptide synthesis 
The APLILSR peptide was synthesised using standard Fmoc solid phase synthesis 
strategy using 250 mg (0.15mmol) MBHA rink amide resin (Novabiochem, 200-400 
mesh, 0.60 mmol/g loading) and an automated synthesiser (Activo P11, Activotec, UK) 
fitted with a reactor-heating jacket. After swelling the resin in DMF (5 mL, 10 min) the 
Fmoc protecting group was deprotected using 20 % piperidine/DMF (v/v) (10 mL, 2 
min and then 10 min). The first amino acid was coupled manually using 4 eq of amino 
acid (Fmoc-Arginine (PMC-OH)) (0.6 mmol, 397.4 mg) activated with 4 eq DIC (0.6 
mmol, 93.9 µL) and 4eq HOBt (0.6 mmol, 81 mg) for 1 hour in 2 mL DMF. This was 
followed by an acetylation step (Acetic acid/DIPEA/DMF = 1/1/8 (v/v/v), 10 mL, 1 x 10 
min). The success of the coupling was confirmed by confirming absence of residual free 
amines using the Kaiser test. The resin was then loaded on to the Activo P11 automated 
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synthesiser fitted with a reactor heating jacket for the addition of the remaining six 
amino acids. Subsequent Fmoc deprotecting steps were performed using 20 % 
piperidine/DMF (v/v) as above, with the chain elongation steps being performed at 60°C 
using 3 eq. (0.45 mmol) of Fmoc-protected amino acid (Fmoc-Alanine-OH (140 mg), 
Fmoc-Proline(Trt)-OH (151.7 mg), Fmoc-Leucine(Boc)-OH (159 mg), or Fmoc-
Isoleucine-OH (159 mg), Fmoc-Serine (tbu)-OH (172.4 mg)) 3 eq. of PyBOP (234.2 
mg), and 6 eq. of DIPEA(157 µL) in 10 mL of DMF (1 x 25 min). 
3.3.5. Addition of MUA thiol linker to pro-PSA peptide 
After completion of coupling of all amino acids, the resin was weighed out and 50 % 
(by wt) of the resin was subsequently modified with MUA. Following Fmoc 
deprotection purified MUA-(Trt) was coupled to the peptide using 6 eq of MUA-(Trt) 
(100 mg), 5.9 eq of HATU (336.44 mg) and 6 eq of DIPEA (157 µL) in DMF (2 mL) 
for 2 hrs followed by an acetylation step (Acetic acid/DIPEA/DMF = 1/1/8, 10 mL, 1 x 
10 min). The cleavage was performed with TFA: TIPS: water (v/v) (95/25/25) (3 mL) 
for 2 hours and the peptide was obtained by precipitating in diethyl ether (10 mL) and 
centrifuging (3900 rpm, 2 mins) to separate the peptide.  
3.3.6. Purification and characterisation of pro-PSA peptide 
Analytical RP-HPLC to evaluate the purity of the synthesised sequence was performed 
using a Dionex Ultimate 3000 system (Thermo Scientific, UK), with a VWD-3400 
(Thermo Scientific, UK) variable wavelength detector, and a RF-2000 fluorescence 
detector (Thermo Scientific, UK). The analysis was performed at 35 ± 0.1 °C on a 
Gemini 5 µ C18 110A column, (150 x 4.6 mm - Phenomenex, UK), equipped with a 
SecurityGuard C18 (ODS) 4 x 3.0 mm ID guard column (Phenomenex, UK), at a flow 
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rate of 1 mL/min. A gradient elution comprising mobile phase A (0.1% aq TFA) and 
mobile phase B (0.1 % TFA in MeCN) was employed. (Method: 0.0 –10.0 min 0-95 % 
B, 10.0 –15.0 min 95 % B, 15.0–15.1 min at 95-5 % B, 15.1–18.0 min 5 % B.). Semi-
preparative RP-HPLC was performed on a Dionex HPLC with a Gemini 5 µ C18 110A 
column, (250 x 10 mm - Phenomenex, UK) and equipped with a SecurityGuard C18 
(ODS) 10 x 10 mm ID guard column (Phenomenex, UK), at a flow rate of 2.5 ml/min. 
3.3.7. Fabrication of MIP sensors 
3.3.7.1. Cleaning of electrodes 
Gold disk working electrodes with a radius of 1.0 mm (CH Instruments, Austin, TX, 
USA) were mechanically polished for 5 min with 50 nm alumina slurry (Buehler, Lake 
Bluff, IL, USA) on a polishing pad (Buehler) and then sonicated for 5 min in ethanol 
and 10 min in ultra-pure water to remove any remaining alumina particles. Electrodes 
were then treated with piranha solution (three parts concentrated sulphuric acid to one 
part hydrogen peroxide) for 5 minutes. Thereafter, electrodes were rinsed thoroughly 
with ultra-pure water to remove any residual acid. Subsequently, the electrodes were 
electrochemically cleaned in 0.5 M H2SO4 by scanning the potential between the 
oxidation and reduction of gold, − 0.05 V and + 1.1 V vs Hg/Hg2SO4, for 50 cycles until 
no further change in the voltammogram was observed. Finally, the electrodes were 
washed with ultra-pure water and dried under nitrogen.  
3.3.7.2. Screening of electropolymers 
Cyclic voltammetry was used to bring about the electropolymerisation of different 
electroactive monomers. Clean gold electrodes were set in a three-electrode 
configuration with monomer solution (see Table 3.2 for details) and the potential 
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applied with reference to Ag/AgCl (3 M KCl) reference electrode with a platinum wire 
as a counter electrode. All monomer solutions were degassed with nitrogen for 10 
minutes prior to polymerisation. 
Monomer Voltage range 
(vs Ag/AgCl) 
Scan rate Buffer (10mL) 
Aminophenol (50 mM, 5.45 
mg/ml) 
-0.2 to + 0.8 V 50 mV/sec Acetate buffer pH 4.6 
Aminobenzoic acid (50 mM,  
6.857 mg/ml) 
-0.2 to + 0.9 V 50 mV/sec 500 mM Sulphuric acid 
Dopamine (5 mM, 0.948 
mg/ml) 
-0.5 to + 0.5 V 20 mV/sec PBS pH 7.4 
Table 3. 2: Polymerisation conditions for electroactive monomers for NIP screening study.  
Post polymerisation the electrodes were washed with water and incubated with 1mL of 
10 mM ferro/ferricyanide [Fe(CN)6]3-/4- solution in 10mM PBS pH 7.4 for half an hour. 
Three impedance measurements of the WE were taken to measure the stability of the 
electropolymers. Post stability measurements, the electrodes were incubated with 1 
µg/mL PSA for 20 minutes. Thereafter, the electrodes were washed with water and the 
response was recorded using EIS measurements as mentioned in section 3.4.2. 
3.3.7.3. Peptide immobilisation 
A stock of 1mM pro-PSA peptide-(MUA) was prepared by dissolving 0.968 mg peptide 
in 1ml 50/50 (v/v) EtOH: water. The stock was used to further prepare lower 
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concentrations of the peptide. The electrochemically-cleaned gold electrodes were 
washed with water, dried under nitrogen and immediately incubated in various 
concentrations (10 µM, 5µM, 1µM, 0.1 µM) of the peptide in 50/50 (v/v) EtOH: water 
for one hour. The functionalised electrodes were subjected to scanning voltage from -0.2 
V to 0.4 V vs Ag/AgCl at a scan rate of 50 mV/sec in 10 mM ferro/ferricyanide 
[Fe(CN)6]3-/4- in 10 mM PBS pH 7.4 solution to characterise the surface coverage of the 
peptide. 
3.3.7.4. Removal of the peptide 
To evaluate the peptide desorption from the gold electrodes, 1 mM pro-PSA peptide-
MUA solution (50:50 EtOH: water) was incubated with the clean gold electrodes for 1 
hour. The functionalised electrodes were subjected to negative potential sweep 0 to -1.5 
V vs Ag/AgCL in 50 mM NaOH. To evaluate desorption, the functionalised electrodes 
were subjected to scanning voltage from -0.2 V to 0.4 V (50 mV/sec) vs Ag/AgCL in 10 
mM ferro/ferricyanide [Fe(CN)6]3-/4- solution before and after the desorption process. 
Pro-PSA peptide-(MUA) was extracted from MIP electrodes by subjecting the 
electrodes to an optimised step voltage (-1.2 V) for a short period of time (30 seconds) 
in 50 mM degassed NaOH solution using the three electrode setup. The electrodes were 
immediately rinsed with excess water and left overnight in washing solution (0.1 % v/v 
sulphuric acid and 0.1 % w/v TWEEN  20 in water) with stirring to remove any 
template embedded in the polymer.  
3.3.7.5. Molecular Imprinting of the peptide with polydopamine 
Clean gold electrodes were incubated with MUA-peptide (500 nM, 100µL water: EtOH 
(50:50)) for 1 hour. Post incubation the electrodes were washed with ethanol and water 
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mixture twice followed by multiple washes with water to remove any non-specifically 
bound thiols. The molecular imprinting step was performed by electropolymerising 
dopamine on to the peptide-modified electrode. Briefly, 10ml of 10 mM PBS buffer (pH 
7.4) containing 5 mM dopamine was degassed with nitrogen (10 min) and 
electrodeposited using cyclic voltammetry (3/6/9 cycles, -0.5 V to 0.5 V vs Ag/AgCl, 
scan rate of 20 mV/s). Optimised number of polymerisation cycles based on this study 
was used for fabricating MIPs for pro-PSA peptide. A non-imprinted ‘control’ electrode 
(NIPs) was prepared in the same way but in the absence of the pro-PSA peptide. 
3.3.8. MIP sensor evaluation with the peptide  
To evaluate the peptide rebinding, the electrodes were rinsed with water before being 
allowed to stabilise in the measurement buffer (10 mM PBS (pH 7.4) containing 10 mM 
Fe(CN)63-/4- and 0.05 % v/v TWEEN  20). To evaluate sensor performance, the 
electrodes were mounted in a three-electrode configuration with the apta-MIP or apta-
NIP as the working electrode. Following baseline stabilisation, the electrodes were 
exposed to 100 µl of a range of peptide (APLILSR) solutions (1, 2, 5, 10, 20, 50, 100 
µg/ml) in 10 mM PBS buffer pH 7.4 containing 10 mM Fe(CN)63-/4- and 0.05 % v/v 
TWEEN  20 for 20 minutes. The electrodes were washed with 10 mM PBS buffer pH 
7.4 containing 10 mM Fe(CN)63-/4- and 0.05 % v/v TWEEN  20 and electrochemical 
impedance spectroscopy (EIS) was used to measure capacitive changes at the 
electrode/electrolyte interface resulting from the peptide re-binding. The binding data 
was fitted with one site total binding isotherm using Prism 7, Graphpad Software, (CA, 
USA). 
Chapter 3                                                                       Surface Imprinting of Pro-PSA Activation Sequence 
 167 
3.3.9. MIP sensor evaluation with test and cross-reactant peptides 
Binding specificity was evaluated by challenging the MIP systems with the test peptide: 
TIVANP (Threonine-Isoleucine-Valine-Alanine-Aspargine-Proline) and cross-reactive 
peptide: VPLIQSR (Valine-Proline-Leucine-Isoleucine-Glutamine-Serine-Arginine 
(Severn Biotech, UK) under the same conditions in a non-competitive assay. Briefly 1, 
10, 100 µg/ml of control peptide in 10 mM PBS buffer pH 7.4 containing 10 mM 
Fe(CN)63-/4- and 0.05 % v/v TWEEN  20 was incubated with MIP electrodes for 20 
minutes. The electrodes were washed as described in 3.3.6 and then measured using 
EIS. 
3.3.10. Preparation of conventional MIP capacitive sensors 
For the preparation of a conventional capacitive MIP sensor i.e. without prior 
immobilisation of the template at the surface of the electrode, APLILSR peptide (5 mM) 
was solubilised with 5 mM dopamine in PBS buffer pH 7.4. The solution was degassed 
for 10 minutes with N2. The solution was then subjected to electropolymerisation by 
cyclic voltammetry (15 cycles) from - 0.5 V to 0.5 V at a scan rate of 20 mV/sec vs 
Ag/AgCl as reference electrode. The electrodes were washed with 100 mM H2SO4 and 
0.1 % TWEEN 20 solution for removal of the peptide, washed with water overnight. 
Slightly higher acidic conditions were used to remove the peptide efficiently from the 
polymer due to absence of an electrochemical stimulus as seen with the surface 
(immobilised template) imprinted sensor (3.3.7.4). The rebinding of the pro-PSA 
peptide was evaluated as described in section 3.3.8. The imprinting protocol was 
adapted from molecular imprinting of nicotine in electropolymerised polydopamine by 
Liu et al., 2006.4 
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3.4. Results And Discussion 
3.4.1. Synthesis of triphenylmethyl protected mercaptoundecanoic acid (MUA): 
Mercaptoundecanoic acid was coupled to the pro-PSA activation peptide sequence 
during Fmoc-peptide synthesis to provide a mechanism (gold – thiol) for directly 
conjugating the template to the electrode surface. MUA is 11-carbon alkane thiol which 
is widely used for immobilising biomolecules on the gold surface using EDC/NHS 
chemistry.18 Various groups have studied the formation of SAM layers by MUA on 
gold, reporting compact packing of the molecule in a well-ordered manner on 
surfaces.64,65 It was therefore hypothesised that MUA-tagged peptide would also create a 
well-organised SAM on the surface allowing for homogenous binding site creation 
during the imprinting process.  
During the synthesis reaction of MUA coupling to the peptide (on the resin), it was 
important that the thiol group on MUA was protected to prevent oxidation and unwanted 
side reactions from occurring.66 The triphenylmethyl (Trt) group was used to protect the 
thiol on MUA; Triphenylmethyl (Trt) is a popular protecting group for Fmoc-cysteine 
since it is be readily deprotected with strong acid during the final cleavage step.67 The 
synthesis was performed as described in section 3.3.3. Upon running a silica TLC of the 
reactants and crude product, different retention factors were obtained: Trt-Cl (0.8), 
MUA (0.44) and product (0.52). Upon exposing the TLC silica plate to sulphuric acid, a 
strong-yellow colour was obtained from the crude product and Trt-Cl (but not MUA) 
which was strongly suggestive of formation of MUA-(Trt) (Figure 3.14). When 
deprotonated the MUA thiol functional group is a good nucleophile and attacks the 
tertiary carbon of Trt-Cl to form 10 - triphenylthiodecanoic acid, releasing hydrochloric 
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acid in the process (Figure 3.14).68 The triphenyl group on MUA is acid-labile, and the 
addition of a strong acid such as sulphuric acid cleaves the protecting group from MUA.  
 
Figure 3. 14: Synthesis process of MUA-(Trt) whereby equimolar (2.28 mmol) concentration of 
Trt-Cl and MUA dissolved in 7.5 ml  dry DCM and stirred overnight at room temperature. The 
TLC shows the retention of Trt-Cl (A), MUA (B) and the product (C), which forms a bright 
yellow colour upon exposing to sulphuric acid, with a different retention time than Trt-Cl.  
The structure of MUA (Trt) has been represented in Figure 3.15. The total yield of the 
product was 110 mg (22 % yield). The purity of the molecule was tested using NMR 
(Figure 3.16). 1H NMR (500MHz, Choloroform-d8) δ 7.10-7.35 (9H, m), δ 7.35-7.55 
(6H, m), δ 1.10-1.45 (6H, m), δ1.6 (4H, s), δ 2.1(4H, m), δ 2.33 (4H, t)]. Figure 3.16 
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shows the 1H NMR of the final product. The NMR signal from 7.15 to 7.55 ppm 
represents the aromatic protons (no. 20 - 34), while the shifts from 1 to 1.7 ppm (no. 6 -
15) represent the alkane chain protons. The NMR shifts for MUA-(Trt) were similar to 
that reported by Stathopoulos et al.69 
 
Figure 3. 15: Structure 10-(triphylthio) decanoic acid (MUA-(Trt)) 
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Figure 3. 16: 1H NMR of 10-trypheynlthiodecanoic acid showing respective shifts for hydrogen 
molecules.  
In surface macromolecular imprinting the conformation and orientation of the template 
has a great influence on overall imprinting efficiency.70 Specifically in the case of 
epitope imprinting where the ultimate goal is to rebind the ‘whole protein’, the 
orientation of the template will influence interaction with the native protein, increasing 
sensitivity and speeding-up binding kinetics.8 Various covalent and non-covalent 
strategies have been employed for immobilisation of template molecules. For the 
peptide and protein imprinting, immobilisation strategies have used EDC / NHS 
chemistry10, reversible crosslinkers71, passive adsorption of protein,72 metal-
coordination chemistry73, and modification of the biomolecule with cysteine to confer 
thiol functionality74 allowing direct immobilisation to gold surfaces. EDC/NHS and 
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cross-linker approaches are often non-specific as they can involve multiple amino acid 
residues (lysine/ arginine), moreover, they also add complexity given an additional 
synthetic step is required to prepare the E-MIP. The use of cysteine terminated peptide 
as reported by Dietrich and co-workers8 is an easy one step process, however, it can 
restrict or alter peptide conformation as a consequence of the molecule being 
immobilised in close proximity to a hydrophobic gold surface.75 Metal co-ordination 
chemistry has shown favourable results. However, the template requires presence or 
addition of histidines to form the metal co-ordination. Giving due consideration to the 
peptide template in this study was therefore modified with mercaptoundecanoic acid 
(MUA) to facilitate direct immobilisation via thiol chemistry while providing an 11 
carbon ‘spacer’ between the peptide and the electrode surface.  
3.4.2. Peptide synthesis 
Pro-PSA peptide and pro-PSA peptide-(MUA) were synthesised using standard Fmoc 
solid phase synthesis resulting in a good yield of the peptide (95%). The peptide was 
synthesised on Rink amide (MBHA) resin to obtain the amide-terminated peptide, as the 
activation sequence is part of the whole protein sequence and would therefore not 
contain a typical carboxyl terminated C terminus. There were no significant issues 
observed in the coupling of any of the amino acids, and the synthesis was completed 
with the crude peptide showing 97 % purity (peak area of the peptide/peak area of all 
peaks) as calculated from the analytical HPLC chromatogram in Figure 3.17. The 
peptide was further purified using semi-preparative HPLC with mass spectrometry 
confirming the correct mass – 768.51 g/mol (Figure 3.18). 
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Figure 3. 17: Chromatographic evaluation of pro-PSA activation peptide containing one major 
or the dominant peak at 5.38 minutes. 
 
Figure 3. 18: Mass spectrometry of pro-PSA activation peptide (APLILSR) showing the correct 
mass of 768 g/mol. 
Similarly, Figure 3.19 shows the chromatogram for pro-PSA peptide-(MUA) with mass 
spectrum again confirming the correct mass (968.1 g/mol) (Figure 3.20) The HPLC 
analysis for pro-PSA peptide-(MUA) was conducted at a higher wavelength to ensure 
residual protected MUA-(Trt) from the synthesis was not present in the crude peptide 
sample. MUA-(Trt) would ideally show a strong adsorption at 254 nm due presence of 
aromatic groups and could be easily isolated from the peptide-(MUA) peak during the 
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chromatographic run. Pro-PSA peptide tagged with MUA showed a slightly higher 
retention time (5.7 minutes) than pro-PSA peptide further indicating that the 
modification was successful. 
 
Figure 3. 19: Chromatography of MUA tagged pro-PSA activation peptide showing slightly 
longer retention time than the pro-PSA peptide. A drift in baseline during the analytical run was 
obtained which could be a result of residual solvents in the HPLC gradient run. 
 
Figure 3. 20: Mass spectrometry of MUA tagged pro-PSA peptide showing the correct mass of 
968 g/mol. 
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3.4.3. MIP electrode fabrication and optimisation: 
3.4.3.1. Electropolymer Screening study 
Three electroactive monomers –aminophenol, aminobenzoic acid and polydopamine - 
were investigated in this screening study. The screening study was conducted 
simultaneously for the apta-MIP work in Chapter 4, which used PSA as the template. It 
was hypothesised that PSA would be better template to understand non-specific binding 
(due to various epitopes presented on its surface for interaction with the polymer) than a 
small peptide.  The monomers were chosen based on the functional groups available for 
interaction with PSA. Polydopamine is predominantly a hydrogen donor and takes part 
in π-π stacking76 while polyaminophenol and polyaminobenzoic acid provide 
opportunities for ionic interactions in addition to hydrogen bonding and π-π 
stacking.77,31 Aniline, which produces a conducting polymer,78 was also evaluated as a 
monomer in screening study. However, initial experiments showed high instability over 
time meaning that interaction with PSA could not be measured. This was likely a result 
of degradation of polymer at pH 7.4 as has been previously reported in the literature.79 
Polyaminophenol, poly-3-ABA and polydopamine modified electrodes were taken 
forward into binding assays to evaluate the non-specific interaction between each 
polymer surface and PSA.  
• Polydopamine (PDA):  
The cyclic voltammogram (CV) of dopamine polymerisation showed a reduction in 
current with consecutive cycles of polymerisation (Figure 3.21). The distinct oxidation 
and reduction peaks represent oxidised and reduced species respectively of dopamine 
during the polymerisation process. The peak at 0.32 V in the oxidation cycle represents 
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dopamine orthoquinone (DAQ), while the reduction cycle shows peaks at 0.09 V, which 
represents leucodopaminechrome (LDAC), and -0.32 V represents dopaminechrome 
(DAC). In the second cycle  an oxidation peak occurs at -0.18 V which represents 5,6- 
dihydroxyindole which further undergoes polymerisation (Please refer to Figure 3.22). 
Aqueous electrochemical oxidation of dopamine is proposed to occur via an ECE 
mechanism (Figure 3.22) where E stands for electrochemical and C stands for a 
chemical reaction.80,81 The first step is the electrochemical (E) oxidation of dopamine 
into (DAQ), which proceeds to form LDAC. LDAC is an aminechrome formed by intra-
molecular cyclisation of DAQ; the chemical-step in the process (C). LDAC further 
oxidises via a two-electron transfer to give dopaminechrome (E), which spontaneously 
rearranges itself to form 5,6-dihydroxyindole, the last electrochemical step for 
polymerisation. 5,6-dihydroxyindole further undergoes polymerisation reactions to form 
melanin-like polymer layers on the gold surface as shown in Figure 3.22, which 
decreases electron transfer reactions at the surface i.e. it is an insulating, rather than 
conducting, polymer layer.82   
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Figure 3. 21 Cyclic voltammogram of electropolymerisation of dopamine. The polymerisation of 
dopamine leads to reduction in peak current at 3.9 V with increasing number of cycles 
indicating deposition of a non-conducting polymer. 
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Figure 3. 22: Polymerisation of dopamine is proposed to occur via an ECE mechanism. The 
first step involves the electrochemical oxidation to dopamine orthoquinone (DAQ), which 
proceeds to form leucodopaminechrome (LDAC). LDAC further oxidises to dopaminechrome, 
which rearranges itself to 5,6-dihydroxyindole, which further polymerises on the gold surface. 
• Polyaminophenol (PAP):  
The electrochemical oxidation of ortho-aminophenol by cyclic voltammetry is shown in 
Figure 3.23. Oxidation of o-aminophenol is recorded as a distinct, irreversible peak at 
0.52 V, which possibly corresponds to the formation of O-AP . + radical.83 The absence 
of any complementary peaks in the reverse sweeps indicates chemical certain follow-up 
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reactions. The CV showed a reduction in the current oxidation peak of O-AP (0.52 V) 
with consecutive cycles, indicating the formation of a non-conducting polymer. The 
highest current was obtained with the first cycle, with the subsequent large decrease in 
peak current observed between the 1st and 2nd cycle suggesting that almost maximum 
coverage of polymer was obtained after the first cycle.84 
 
Figure 3. 23 Cyclic voltammogram of electropolymerisation of aminophenol, which depicts a 
large decrease in current after 1st cycle of polymerisation indicating maximum polymer 
coverage after the 1st cycle. A decrease in current also indicates the deposition of a non-
conducting polymer. 
Although the structure of poly-(OAP) is quiet simple, mainly consisting of phenoxazine 
ring like units, the mechanism of O-AP electropolymerisation in acidic medium is 
complex and poorly understood.83 A general overview of OAP oxidation involves the 
formation of aromatic amine cation radicals, O-AP+., which form dimers, that  
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chemisorb on to the metal surface, followed by an anodic oxidation and polymerization 
reactions (addition of dimers) to form linear chain or ring chain polymers (Figure 
3.24).85 In this process, the polymerization sequesters the –OH groups in O-AP 
monomer through the formation of C–O–C bonds. 
 
 
 
Figure 3. 24: Electropolymerisation mechanism of polyaminophenol. The O-AP+. radical forms 
a dimer, which is subsequently oxidised to form polyaminophenol. 
• Poly- 3-aminobenzoic acid (3-ABA): 
The electropolymerisation of 3-aminobenzoic acid (3-ABA) by cyclic voltammetry is 
shown in Figure 3.25. The CV shows one large oxidation peak at 0.9 V, which 
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significantly reduces after the first cycle (Figure 3.25). The redox peaks correspond to 
the peaks associated with the electropolymerisation of 3-aminobenzoic acid.31  
 
 
Figure 3. 25 Cyclic voltammogram of electropolymerisation of poly 3-aminobenzoic acid. The 
CV shows one large oxidation peak at 0.9 V, which significantly reduces after the first cycle 
indicating deposition of a non-conducting polymer. 
Although the exact mechanism of 3-aminobenzoic acid electropolymerisation has not 
been elucidated, as it is a substituted aniline monomer it would be anticipated that it 
follows a similar mechanism to the that of the electropolymerisation of aniline.86 
Electrochemical polymerization of aniline occurs through a generally accepted 
mechanism which involves formation of anilinium radical cation by anodic oxidation on 
the electrode (rate determining step for polymerisation).78 This electrochemical reaction 
for aniline polymerisation is generally carried out in an acidic environment. The 
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anilinium radicals couple together to form polyaniline as shown in Figure 3.26. 
However, the redox peak for 3-ABA (0.9 V) differs from that of aniline (0.2 V)78, as 
observed in the literature, suggesting that the mechanism of 3-ABA polymerisation may 
be different than aniline. Furthermore, 3-aminobenzoic acid produces a non-conducting 
polymer as opposed to conducting polymers formed by other substituted anilines.87   
 
Figure 3. 26: The first step of the polymerization process of aniline is the formation of aniline 
cation radicals by anodic oxidation on the electrode surface. Following the formation of the 
cations, coupling of the anilinium radicals occurs, which is then followed by elimination of two 
protons and re-aromatization leading to formation of dimer.78 The dimers is further oxidised 
leading to the formation of polyaniline on the electrode surface.  
Electrochemical impedance spectroscopy (EIS), considered as an ideal electrochemistry 
technique to characterise interfacial phenomena,52 was used to measure the impedance 
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of the system to quantify any PSA binding with the polymeric layer. Nyquist plots 
obtained as result of EIS, provide information on the nature polymer layers attached on 
the surface. Typically, Niqust plot can be divided into two parts: the semi-circular plot, 
which represents the fast charge transfer process, and the straight line called Warburg 
diffusion element which represents the slow diffusion controlled process. Due to the 
non-conducting nature of the polymers, very high impedances (∼105 – 106 ohms) were 
observed in the Nyquist plots. The Nyquist curves with high impedance indicate that the 
behaviour of the PAP and PDA films was dominantly diffusion controlled as opposed to 
charge transfer controlled, with the absence of any well-defined semi-circular plots 
(Figure 3.27).33  
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Figure 3. 27: EIS response of electropolymers to 1µg/mL PSA (a) polydopamine (PDA) (b) 
polyaminophenol (PAP) (c) polyaminobenzoic acid (ABA) 
As a consequence of the non-conducting nature of films, the polymer behaves more like 
a capacitor than a resistor, and therefore it is more meaningful to look at the capacitive 
behaviour of such films.88 This is due to the fact that small electrochemical changes as a 
result of protein binding can better observed through capacitance than impedance. 
Capacitance has an inverse relationship to impedance and can be calculated using 
equation 3.6 : 
𝑍" 𝐶 = 𝐶" = − !!!"(!!"#)    	  	  	  	  	  	  	  (3.7)	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Where, C is the capacitance, f is the AC frequency (Hz), and Zimg is the imaginary part 
of impedance. In Bode plots the impedance is plotted with log frequency on the x-axis 
and both the absolute value of the impedance (|Z| =Z0 ) and phase-shift on the y-axis.52 
Functionalized/modified electrodes have been shown to behave like an ideal capacitor 
when the phase is close to 900.88 Capacitance was calculated at 100 Hz as the phase was 
close to 900 between 10 - 100 Hz (as observed from Bode plots).  
As is evident from Figure 3.28, polydopamine (PDA) showed a slightly higher change 
in capacitance (0.36 µF), which is indicative of greater binding to PSA, than 
polyaminophenol (PAP) and polyaminobenzoic acid (PABA), which displayed a change 
of 0.095 µF and 0.171 µF respectively. The higher response observed with 
polydopamine could be a result of its relative hydrophilicity with hydroxyl groups on 
the surface interacting with PSA.89 The hydrophilic nature of polydopamine films has 
been used to enable direct immobilisation of proteins through non-specific adsorption 
which explains the enhanced interaction between the polymer and PSA.90 
Polyaminophenol on the other hand forms a semi-permeable membrane, which excludes 
certain molecules such as uric acid.85 Given the size of PSA it is highly likely that the 
molecule is unable to diffuse into the polymer layer. Furthermore, when aminophenol is 
polymerised it is possible that the surface availability of free amino groups on the 
resulting polymer layer may be low,85 effectively lowering the number of points 
available for interaction with PSA (Figure 3.24). On the other hand, polyaminobenzoic 
acid demonstrated higher interaction with PSA that PDA. This could be due to an 
increased number of free carboxylic acid and amino groups available for interaction 
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with PSA. Polyaminobenzoic acid has been utilised to immobilise antibodies on 
surfaces by activating the carboxylic group which is supportive of the hypothesis that 
functional groups remain available to interact with PSA following polymerisation.32  
 
Figure 3. 28 Capacitance responses of electropolymers upon incubation with 1µg/mL PSA. 
Polydopamine (PDA) showed the maximum change in capacitance when compared to 
polyaminophenol (PAP) and polyaminobenzoic acid (P 3-ABA) (n=2). 
The higher interaction (0.36 µF) observed between PDA and PSA  (as seen in Figure 
3.28) meant that it was selected as the monomer to take forward into the imprinting 
studies for pro-PSA peptide and hybrid PSA imprinting (Chapter 4) for initial research. 
Other than higher interaction with PSA, dopamine also possesses low 
oxidation/reduction potential that would also allow for polymerisation to be performed 
in the presence of the surface immobilised peptide without fear of oxidising the thiol 
linkage that holds it to the surface. Moreover, due to the presence of hydroxyl and amide 
functional groups in dopamine, it was anticipated that these functional groups would 
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form multiple non-covalent interactions with the peptide, as has been demonstrated in 
the literature with various templates4,5, thus contributing to the formation of a 
chemically and sterically selective imprinted site. As a result, dopamine was studied for 
further polymerisation studies for imprinting of pro-PSA (MUA) peptide. 
3.4.3.2. Peptide Immobilisation study 
The second step of the electrode fabrication process was focused on the optimisation of 
the template immobilisation on to the electrode surface. To characterise the fabrication 
of different layers of the sensor, cyclic voltammetry was used in the presence of a redox 
couple, 5 mM Fe(CN)63−/4− solution in PBS (pH 7.4). The redox couple allowed for 
sensitive measurement of current and resistance on the electrode surface. Initial 
experiments used a high concentration peptide-(MUA) (1mM) to ensure maximum 
coverage of the electrode surface with the template. The CV of the peptide 
functionalised electrodes showed close to 100 % reduction in peak current as seen in 
Figure 3.29 suggesting very high resistance to the flow current through the electrode. 
Modification of the gold electrodes by a resistive layer such as alkanethiols, or in this 
case peptide molecules, results in passivation of the surface, which leads to lower 
oxidation/reduction currents when compared to a bare gold electrode.91 MUA is known 
to form well-packed SAMs that behave like a capacitive layer91, which would explain 
the low peak current observed with pro-PSA peptide-MUA immobilised electrodes. 
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Figure 3. 29: Compares the CV of bare golf with gold modified with 1mM peptide-MUA.  CV of 
a bare gold (black) showing well-defined oxidation and reduction peaks. CV post pro-PSA-
(MUA) peptide modification on the electrode (red) shows (∼ 100 %) loss in peak current. 
Polydopamine was subsequently polymerised on the pro-PSA peptide functionalised 
electrodes, however, as observed from Figure 3.30 the electropolymerisation CV did not 
show the major oxidation and reduction peaks typically associated with dopamine 
polymerisation. Furthermore, the peak at 0.39 V had shifted to 0.5 V, with very little 
reduction in current observed with consecutive polymerisation cycles. Upon measuring 
the impedance of the peptide functionalised electrodes surface pre- and post- 
modification with polymer, negligible change impedance or Rct (∼10-20 %) was 
observed. This suggested that there was little growth of polydopamine on the surface; as 
a very large change in impedance / current would be expected following the formation 
of a non-conducting polymer layer.92 It is likely that the well-packed peptide-MUA 
SAM, which may have minimum pinhole defects, inhibited the diffusion of dopamine 
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monomers to the electrode surface thus preventing polymerisation. A similar behaviour 
has also been reported by Spegel et al. where the SAM modified electrodes were used to 
improve the resistance of the electrode surface to dopamine polymerisation.93 The study 
concluded that charged SAM layers (such as MUA) more effectively prevented 
dopamine polymerisation than uncharged SAMs.  
 
Figure 3. 30: Polydopamine polymerisation on the MUA/Peptide functionalised electrodes 
In order to explore the influence of the template (pro-PSA peptide-(MUA)) layer on the 
subsequent electropolymerisation of dopamine, the electrodes were incubated with 
varying concentrations of the template in an effort to prepare a less densely pack surface 
layers. It was proposed that a lower concentration of the peptide immobilised on the 
surface would provide more opportunity for dopamine molecules to diffuse to the 
surface and polymerise on the electrode surface. Figure 3.31 shows that as the template 
concentration was increased a proportional decrease in oxidation and reduction peak 
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current was observed.  The bare gold electrode showing well-defined peak potential at 
0.23 V, which is a higher peak current than was observed for any of the bio-
functionalised electrodes.94  
 
Figure 3. 31: Cyclic voltammograms of the bare gold electrode (black) showing well defined 
peaks at 0.23V corresponding to oxidation of gold in K3/K4. A subsequent reduction in peak 
current was observed with increasing concentrations of peptide (100 nM to 10 µM) due to 
presence of a resistive peptide layer on the surface.  
The observed decrease in peak current allows for estimation of fractional monolayer 
surface coverage, termed θiCV. The peak current is directly proportion to SAM surface 
coverage according to equation 3.7. 95  
𝐼! = !!  !!      !!" Γ𝐴𝜐                                  (3.8) 
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where Ia is peak current,  Γ is surface coverage, A is the surface area,  𝜐 is the sweep rate, 
T is the temperature, R is the universal gas constant, F is the Faraday’s constant, n is 
total number of moles/electrons transferred.  Fractional coverage of monolayer, 
assuming diffusion in uncovered parts is linear and is given by equation 3.8. 91  
𝜃!"! = 1− !!!"#!!!"#                         (  3.9) 
Where, IaAuE is the peak current of bare electrode and IaSAM is the peak current of the 
modified electrode. The electrode coverage was calculated for each of the incubation 
concentrations (10 nM, 100 nM, 1 µM, 10 µM pro-PSA peptide). The predictive surface 
of the electrode that was exposed to 10 µM peptide was close to 100 %, while 10 nM 
peptide showed 40 % coverage following a one-hour incubation with the peptide 
solution.  From Figure 3.32 it can be observed that the surface coverage reaches it’s 
maximum at a peptide concentration of 100 nM. Concentrations > 100 µM, were also 
investigated to explore the limits of this approach as a predictive tool for surface 
coverage and although surface coverage of > 80 % were observed it seemed likely that 
this was the result of secondary events such as peptide stacking and secondary SAM 
layer formation influencing the result. 
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Figure 3. 32: Pro-PSA-MUA peptide approximate surface coverage on the bare gold electrodes 
measured at different concentrations of the peptide.   
It was feared that concentrations lower than 100 nM would provide very low initial 
concentration of the template on the surface with less than 40 % coverage. Dietrich et al. 
for a similar surface imprinted study using cysteine-modified peptide used 60 % surface 
coverage of the peptide on the electrode surface for electropolymerisation. As a result, 
initial experiments were carried out with 500 nM peptide concentrations. 
Electropolymerisation of dopamine with 500 nM peptide demonstrated 
electropolymerisation of dopamine with similar oxidation and reduction peaks to 
polydopamine electropolymerisation on the bare electrode. 
Since the peptide concentration of 500 nM was calculated to have a slightly higher 
approximate surface coverage of the peptide (60 %) than 100 nM or 10 nM on the 
electrode surface, it was taken forward into initial polymerisation studies. Cyclic 
voltammogram of dopamine polymerisation on the pro-PSA MUA functionalised 
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electrode is plotted in Figure 3.33 showing reduction in current with consecutive cycles. 
The distinct oxidation and reduction peaks represent oxidised species of dopamine 
during the polymerisation process.  The peak at 0.36 V in the oxidation cycle represents 
DAQ, while the reduction cycle shows peaks at 1.2 V which represents LDAC and - 
0.28 V represents DAC. In the second cycle  an oxidation peak occurs at -0.18 V which 
represents 5,6- dihydroxyindole which further undergoes polymerisation. No new peaks 
were observed during polymerisation demonstrating that no conducting analogues were 
being produced during electropolymerisation. The polymer growth is self-limiting as the 
insulating polymer being deposited prevents electron transfer reactions for further 
oxidation of dopamine. 
 
Figure 3. 33: Polydopamine polymerisation on the electrodes pre-incubated with 500 nM 
peptide with 5 cycles of electropolymerisation. The CV shows distinct oxidation and reduction 
peaks indicative of successful dopamine polymerisation. 
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In Figure 3.34 the CV peak currents for the bare gold electrode decreased from 52.4 µA 
to 9.2 µA with an associated shift in peak voltage from 0.25 V to 0.45 V, following 
polymerisation with dopamine.  These results also provide further evidence of polymer 
growth on the peptide functionalised electrodes.  
 
Figure 3. 34 Cyclic voltammogram of the peptide modified electrode post electropolymerisation. 
A further decrease in current was observed following 5 cycles of polymerisation.   
From these experiments, a concentration of 500 nM peptide was chosen for the 
functionalization of electrodes pre-electropolymerisation of dopamine. 
3.4.3.3. Removal of the peptide: 
Further studies were undertaken to optimise the peptide removal from the polymer to 
expose the imprinted a great number of imprinted cavities. As the peptide was 
covalently bound to the gold surface, changes in potential were applied to break the thiol 
bond between the template and the surface in order to maximise the peptide removal. It 
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is accepted that the properties of SAM immobilised on the gold electrodes undergo 
significant change upon application of various potentials.96,97 A study by Imabayashi et 
al. exploited this effect, selectively removing specific alkanethiols from an immobilised 
mixed SAM on the gold electrodes by applying slightly different desorption (stripping) 
voltages.98 The study demonstrated that the length of the carbon chain of the alkanethiol 
influences the voltage required to effectively strip the SAM molecules from the 
electrode surface. As a result, it was hypothesised that polydopamine (being a polymer) 
would posses slightly different stripping potential than the pro-PSA-MUA. Hence, 
selective desorption of the peptide from the polydopamine (MIP) layer could be 
achieved.  
The reductive desorption voltage of MUA has been reported to be -1.0 V in the 
literature.96 To understand the stripping voltage of the pro-PSA-(MUA), the peptide 
functionalised electrodes were subjected to a negative potential sweep (via CV) as 
mentioned in Section 3.3.5.4. The reductive desorption CV of pro-PSA-MUA 
functionalised electrode did not demonstrate any sharp peaks at -1.0 V as has been 
observed with the MUA functionalised electrodes in the literature.96 However, a broad 
peak was observed from  -1.0 to -1.1 V which could be attributed to pro-PSA-MUA 
desorption peak (Figure 3.35). It is anticipated that this peak would be absent in the 
reductive desorption CV of bare gold electrode or pre-immobilisation of SAM. This is 
because the gold electrodes were electrochemically and chemically cleaned and hence 
are not expected to have any molecules covalently bound to the surface. Furthermore in 
the second scan (post desorption of SAM), it is anticipated that the peak observed in 
Figure 3.35 would reduce in area due to desorption/removal of some SAM molecules. It 
Chapter 3                                                                       Surface Imprinting of Pro-PSA Activation Sequence 
 196 
is not expected that the peak would completely disappear as the scanning voltage ranges 
from 0 to -1.5 V and the resulting electrochemical signal would not be strong enough to 
remove all SAM molecules.98,99 Hence, some SAM molecules will remain bound to the 
electrode after the first scan, which will result in a smaller peak in the second scan. 
However, it is hypothesised that with subsequent scans, the peak would eventually 
disappear leaving only an activated gold electrode surface.  
 
Figure 3. 35: Reductive desorption of pro-PSA peptide from the bare gold electrode in 50 mM 
NaOH shows a peak at -1.0 V which is assumed to be corresponding to the pro-PSA-MUA 
peptide. 
The CV of the peptide functionalised electrodes was measured pre and post desorption 
in presence of Fe(CN)63-/4-  to understand the change in electrochemical properties of the 
electrodes. This is because the redox couple are more sensitive to electrochemical 
changes on the electrode surface. Following the reductive desorption CV scan, a 20 % 
increase in current (0.55 µA) was observed, suggesting the successful removal of at least 
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some of the pro-PSA-MUA peptide (Figure 3.36). However, the MIPs subjected to this 
protocol for the peptide removal, did not subsequently show efficient rebinding of the 
peptide template (data not shown). Hence, further optimisation studies were undertaken 
to successfully remove pro-PSA template from the imprinted cavity.  
 
Figure 3. 36 CV of pro-PSA peptide immobilised electrodes pre and post reductive desorption. 
An increase in current and a shift in voltage was observed post desorption of peptide by 
subjecting electrodes. 
A study by Balasubramanian et al. used step voltage for reductive desorption of proteins 
covalently attached to MUA from the gold electrodes.99 In the step voltage process, the 
functionalised electrodes are subjected to a constant voltage for a specific amount of 
time. In the Balasubramanian et al. study complete removal of protein from the surface 
was observed by SPR after subjecting the electrodes to a step voltage of -1.2 V for 30 
seconds. It was proposed that since the pro-PSA-MUA was embedded into the polymer 
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a slightly higher step potential (- 1.2 V than -1.0 V) would help facilitate its removal 
from the polymer. An alternative (non-electrochemical) way of understanding successful 
removal of peptide/protein from the polydopamine coated electrode would be to 
fluorescently tag the pro-PSA peptide and monitor the changes in the fluorescent signal 
to understand removal of peptide using reductive desorption protocol. Loss of 
fluorescent signal could be directly correlated to the percentage of peptide removed 
from the MIP sensor.   
As a result, the MIPs were subjected to a step potential of -1.2 V for 30 seconds for 
removal of the template. Following this desorption step an increase of 26.31 µA from 
2.6 µA was observed suggesting increased permeability of the polydopamine to the 
redox couple potentially resulting from the template desorption (Figure 3.37) (The CV 
scan of the electrode was conducted from -0.2 to 0.8 V. As Fe(CN)63-/4- oxidised 
between -0.2 V and 0.4 V only the relevant voltage has been depicted in the Figure 3.37) 
Dechtrirat et al. also used a similar protocol to desorb surface immobilised the peptide 
from an imprinted polymer whereby the peptide entrapped within the polymer was 
subjected to oxidative desorption at 1.5 V for 30 seconds (the removal of the 
fluorescently labelled template peptide was monitored by measuring changes in 
fluorescence)8 In the absence of a fluorescent tag in our study, pro-PSA template 
removal could only be predicted by changes in the electrode current post desorption. 
Post reductive desorption, the MIP modified electrodes were further washed with water 
and wash solution, to encourage removal of any trapped pro-PSA peptide. 
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Figure 3. 37: CV of the electrodes showing change in peak current. There is a decrease in peak 
current post polymerisation of polydopmaine (blue) at 0.22V. Post desorption of the peptide, the 
peak current is observed to increase (red line) which is likely due to removal of the peptide and 
increased permeability of polydopamine. 
Surprisingly, on the following day (after overnight washing of the electrodes) a further 
decrease in peak current (27.1 µA) was observed upon measuring the CV of the 
electrodes. The high impedance/low current obtained from MIP modified electrode 
following treatment was suggestive of a non-conducting polymer present on the 
electrode surface. It was expected that the peak current would change relatively little 
following desorption, however, the decrease in peak current post overnight incubation 
suggest further passivation (non-conductive) of the surface. A bare electrode incubated 
in TWEEN 20 solution did not show any change in current suggesting that TWEEN was 
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not responsible for this passivation. Another, theory could be reattachment of the 
polymer trapped pro-peptide to the electrode surface, however, in that case very little 
peptide binding should be observed in the re-binding step (Section 3.3.4) which was not 
the case. One possible explanation could be the oxidation/reduction of dopamine 
monomers on the surface leading to secondary reactions post-desorption process causing 
decreased permeability of the polymer. Over-oxidation of dopamine monomer post 
polymerisation has been reported by Łuczak, 2008.80 Łuczak et al. reported that post 
oxidation of polydopamine film in NaOH led to considerable change in morphology of 
the polymer, which was also observed in the SEM images, whereby the uniform 
structure of the film was destroyed replacing it with granular-like structures. The study 
also reported that films adhered to gold more strongly suggesting passivation of the 
surface due to changes in the polymer characteristics, which is likely due to 
oxidation/reduction of certain monomeric species.  
3.4.3.4. Molecular Imprinting and optimisation of polymerisation cycles 
The assumption underlying this work is that electropolymerisation of dopamine on a 
peptide functionalised electrode, following the template removal, will result in a 
polymer layer containing cavities that are complimentary in shape and functionality to 
the template. To achieve this, the dopamine polymer must be able to interact with all the 
available interaction sites on the template and that these interactions must be maintained 
during electropolymerisation process. The most likely interaction between dopamine 
and pro-PSA peptide is proposed to be via hydrogen bonding which lends chemical 
selectivity to the cavity (Figure 3.30). In addition to these interactions, template removal 
should be possible post-polymerisation without damaging the imprinted cavities and fast 
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binding kinetics and mass transfer should occur during the template rebinding process.  
A key variable influencing these processes is the polymer layer thickness. If the polymer 
layer is insufficiently thick (too thin) and does not entrap the peptide then minimal 
imprinting effect is anticipated leading to inefficient rebinding.9 On the other hand, if 
the polymer layer is considerably thicker than the total length of the immobilised 
peptide then there is the possibility of imprinted sites being ‘buried’ deep within the 
polymer layer leading to inefficient template removal and rebinding. Additionally, with 
a thicker polymer layer, complete removal of the template would be difficult to achieve 
with possible permanent entrapment of the template. 9 Hence, it was important to study 
the optimum polymer thickness for obtaining maximum imprinting efficiency for the 
MIP sensor. To understand the effect of polymer thickness on the pro-PSA activation 
peptide imprinting efficiency different numbers of cycles of electropolymerisation were 
evaluated. Different cycles of polymerisation correlate to different thickness of polymer 
layer. The imprinting efficiency was calculated by comparing the sensor response of 
MIP and NIP coated electrodes when re-challenged with the peptide. Polydopamine 
thickness can be controlled by adjusting the total amount of charge passed through the 
electrode, i.e. by changing the number of polymerisation cycles.4  
Stöckle et al. studied the precise control of polydopamine thickness via 
electropolymerisation and found that the polymer thickness was linearly proportional 
electropolymerisation cycles up to 15 cycles, after which the growth becomes non-linear 
(due to the non-conducting nature of the polymer).92 Stöckle et al. also reported that 5 
cycles of polymerisation on the bare gold electrodes resulted in a polymer that was 
approximately 9 nm (estimated by XPS) - 19 nm (estimated AFM) thick. Based on the 
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Stöckle et al. study a fair assumption could be made that electropolymerisation of 
polydopamine on the pro-PSA functionalised electrodes (up to 5 cycles) would lead to 
deposition of a very thin polymer layer which is likely between 10 - 20 nm. During the 
apta-MIP construction (in chapter four) it was observed that 13 cycles of polymerisation 
on the bio-functionalised electrodes produced polymers of ~ 9 – 10 nm thick.100 The 
length of MUA modified peptide sequence was calculated to be ≈ 4 nm (MUA - 1.2 nm 
and peptide - 3 nm) and therefore using 13 cycles would likely result in significant 
overgrowth of the peptide. Consequently three different polymerisation cycles (3, 6 and 
9) were investigated. It was anticipated that 6/7 cycles of polymerisation would result in 
a polymer layer thickness not dissimilar to the length of the MUA-peptide template. 
MIP and NIP surfaces were produced for each of the polymerisation cycle studies to 
allow imprinting factors (IF) to be calculated. 
Figure 3.38 illustrates how sensor signals for both MIPs and NIPs varied for the three 
different polymerisation regimes. Assuming sensor signal was proportional to the 
amount of the peptide rebinding to the electrode then for the NIPs binding varied in the 
order 9 > 3 > 6 and for the MIPs 6 > 3 > 9.  Interestingly the variation in binding across 
the 3 systems was greater for the NIPs than it was for the MIPs. This suggests that 
polymer thickness influences the peptide rebinding significantly. The imprinting factors 
for each of the polymerisation regimes (3, 6, 9) were 2.2, 14.1 and 0.6 respectively for 
100 µM of the peptide template.  
Three cycles of polymerisation demonstrated an imprinting effect but there was a 
relatively small difference between the rebinding to the MIP and NIP (IF of 2.2) 
suggesting that the polymer was only interacting with part of the peptide molecule 
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(Figure 3.38). Nine cycles of polymerisation led to more peptide binding to the NIP 
compared to the MIP, which suggests a high degree of non-specific binding and possible 
entrapment of the template within the polymer structure prevents further peptide binding 
to the MIP electrode. The most efficient imprinting demonstration was achieved with 6 
cycles of polymerisation, giving rise to an imprinting factor of 14. Further increasing the 
number of cycles to 7 resulted in the imprinting factor reducing to 10 suggesting that 6 
cycles of polymerisation were optimal for the imprinting of the pro-PSA activation 
peptide sequence. It was hypothesised that 6 cycles of polymerisation resulted in 
thickness closest to the peptide length allowing for efficient imprinting and rebinding. A 
similar observation was made in a study investigating the imprinting of IgG using 
electropolymerised dopamine.5 The study reported that the MIP with a thickness closest 
to the length of IgG displayed maximum binding efficiency when compared to NIPs, as 
a result of improved binding kinetics and easy accessibility of the template to the 
binding cavity. The study also reported that NIP/MIP thickness varies for the same 
cycles of electropolymerisation due to lesser surface area available in the functionalised 
electrodes (used for fabricating MIPs) which could also give rise to slightly different 
binding characteristics in resulting MIPs and NIPs. 
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Figure 3. 38 MIPs with different cycles (3,6,9) of polymerisation when challenged with 100 µM 
peptide showed different imprinting factors. MIPs with 3 cycles showed a lower imprinting 
factor than 6 cycles, which could be due insufficient coverage of the peptide during 
polymerisation. 9 cycles of polymerisation showed a reverse effect suggesting certain 
entrapment of the peptide into the polymer. 
3.4.4. MIP sensor evaluation with the peptide  
Electrochemical impedance spectroscopy (EIS) was used in this study to measure 
capacitive changes at the electrode/electrolyte interface resulting from pro-PSA peptide 
re-binding as cyclic voltammetry is not sensitive enough to measure small changes in 
template binding. It was anticipated that upon binding of the peptide to the polymer 
layer, the surface properties of the electrode would change which could be monitored 
using changes in impedance using EIS.  
The imprinted sensor was mounted in a three-electrode configuration as the working 
electrode and stabilized in measurement buffer (10 mM PBS (pH 7.4) containing 10 mM 
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Fe(CN)63-/4- and 0.05 % v/v TWEEN  20 for 1 hour before measuring the impedance. 
The Niquist data was modelled using ZSimWin software (Solarton Analytical, USA). 
The Niquist data could be best fitted with a variation of Randle’s equivalent circuit: Rs 
(Q1//R1(Q2//R2))) (Figure 3.39, data plotted in Figure 3.40) which comprised two 
R1//C1and R2//C2 (resistance in parallel with capacitance ) circuits. One circuit was in 
series with Rs also termed as solution resistance, while the other was in series with R1, 
which represents the resistance of the polymer layer. R2 resistance element could 
originate from the residual peptide molecules embedded in the polymer layer. Q1 and 
Q2 are constant phase elements (CPE) with impedance ZCPE≡1/QCPE(jω)n, which 
accounts for a suitable fitting of the data.  The two curves in the Niquist plot are likely 
to be associated with the electrochemical double layer and the polymer itself. For the 
blank measurement of the sample shown in Fig. 3.34 (a) with a 1.0 mm radius, the fitted 
values are R1 125.3 Ω, R2 13.08 KΩ, Q1 44.1 µF, Q2 7.754 µF, R3 0.159 KΩ. 
Measurement errors in impedance data = < 2.67 pct. The high value of charge transfer 
resistance (R2 13.08 KΩ), indicate the presence of an insulating layer (polydopamine) 
on the surface of the electrode. 
 
Figure 3. 39: RC circuit fro modelling the impedance curves obtained for the polydopamine 
modified electrodes. 
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However, polydopamine being a non-conducting polymer behaves more like a capacitor 
than resistor, and hence, it is more meaningful to look at capacitance than impedance. 
Given the high impedance values of the polydopamine-coated electrode, which has 
certain pinhole defects, the impedance data evaluated with traditional circuit elements 
yields large errors.101 As a result a better evaluation of the capacitance was obtained by 
defining a complex capacitance in equation 3.10.102,101  
𝐶∗ = 𝐶! + 𝑗𝐶" ≡    1𝑗𝜔𝑍 = − 𝑍"𝜔 𝑍 ! − 𝑗 𝑍!𝜔 𝑍 !             (3.10)              	  
The capacitance was calculated as C = -1/jωZ’’ for the plotting dose response with the 
MIP and NIP sensors based on the frequency which showed maximum changes. A 
frequency of 1 Hz was chosen for calculating capacitance as maximum changes were 
observed at this frequency. The EIS Niquist plots for pro-PSA polydopamine imprinted 
sensor were similar to the apta-MIP sensor response, as seen in Chapter 4.100  
 
Figure 3. 40 Impedance cole-cole plots of MIP (a) and NIP (b) response to the pro-PSA peptide. 
It can be seen from the graphs that MIP response to the pro-PSA peptide was significantly 
higher that the NIP electrodes. 
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It can be observed from Figure 3.40 that the MIP sensor showed a decrease in 
capacitance with increasing concentration of peptide. A decrease in capacitance is 
related to an increase in impedance, which could be explained by the blocking effect of 
the peptide to easy diffusion of the redox couple Fe(CN)63-/4-  to the sensor surface. 
Increased impedance in MIP based sensors has been reported in the literature whereby 
non-electroactive templates upon binding to the polymeric cavity change it's properties 
making them more resistive to the easy flow of charge.39 A change of 4.01 % was 
observed at 1 µM peptide concentration while a change 16.11 % was seen at 100 µM. 
Non-imprinted polymers on the other hand showed negligible change (< 5 %) in 
impedance even at 100 µM peptide concentration. The slight initial increase in 
capacitance with the NIP electrodes (decrease in impedance) could be a result of the 
sensor establishing equilibrium with the redox couple, which takes time to diffuse 
through the polymer to the surface of the electrode. However, as the concentration of the 
peptide was increased a decrease in capacitance was observed which suggested non-
specific interaction of the polymer with the peptide. Modelling the pro-PSA binding 
data with a Langmuir adsorption isotherm (total binding fit) gave an apparent Kd of 2.90 
µM, Bmax of 9.019 µM with an R2 value 0.87 (Prism 7, Graphpad Software). The limit of 
detection (calculated based on discrimination from baseline signal of NIPs) was found to 
be 1 µM peptide (Figure 3.41).  
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Figure 3. 41 Relative changes in capacitance of MIP and NIP electrode to different 
concentration of the pro-PSA peptide (APLILSR). MIP electrodes demonstrated a higher 
response when compared to NIP electrodes at the same concentration, which was indicative of 
an imprinting effect. (Data represents n=6 and error bars represent standard deviation.) 
Although a good imprinting factor was observed with the MIP electrode, variation in 
response between electrodes led to large errors in aggregate data. The macro electrodes 
used for fabricating the MIPs are not uniform and the surface roughness varies 
depending on the level of polishing and cleaning.103 It is hypothesised that the variations 
observed in the data could be a result of variations in the number of peptide molecules 
binding to the uneven gold surface, ultimately causing a change in the amount of 
polymer deposited as well as contributing to changes in the overall density of imprinted 
sites. It is anticipated that moving the fabrication process to a less-rough gold surface, 
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such as gold evaporated on to mica, would reduce variability between electrodes. Work 
was initiated with thin film electrodes from MicruX technologies (Spain), however, due 
to low stability of the electrodes post-polymerisation, further progress could not be 
reported. It should be noted that the NIP sensor was fabricated with only polydopmaine 
and subjected to similar template extraction conditions as MIP sensor. However, it is 
understood that the thickness of the polymer can vary depending on the SAM present on 
the surface of the electrode as discussed in section 2.4.3.2. As a result, the polymer 
thickness between MIP and NIP in this study could vary leading to an imperfect control. 
A closer control NIP sensor that could provide better understanding of MIP/NIP binding 
would be a NIP sensor made with MUA SAM layer only. However, achieving similar 
peptide-MUA versus MUA surface coverage could prove to be a challenge.  
When compared to the bulk-imprinted mini-MIPs described in Chapter 2 for Fmoc-
VANP epitope, an improvement in Kd and LOD was observed for surface imprinted the 
pro-PSA peptide MIPs (although the template are slightly different the backbone of the 
template remains the same). This suggests that surface imprinting is slightly more 
efficient that bulk imprinting technique for peptide imprinting. Although, an 
improvement in Kd and LOD was achieved, the LOD of the sensor meant that it would 
not be possible to use the system to detect the presence of the pro-PSA sequences in 
clinical samples where typical concentrations range from 1 to 10 ng/mL (1.42 - 14.2 
nM).56 The binding characteristics of the current system are similar to the peptide 
imprinted sensor produced by Dietrich et al. where the LOD and Kd were ~ 1 µM , 8.5 
µM respectively.8 Dietrich’s sensor also showed early saturation at 12 µM, similar to the 
pro-PSA peptide MIP sensor.8 This suggests that there could be an inherent limitation to 
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achieving higher affinities with peptide-imprinted sensors created with 
electropolymerised monomers. It is proposed that this could be due to the relatively 
limited functionality of electroactive monomers meaning that interactions between the 
template and monomer are heavily dependent on hydrogen bonding. Furthermore, it is 
hypothesised that the peptide molecules cannot form as strong π-π interactions with 
electroactive monomers as small aromatic molecules, suggesting that better designed 
electroactive monomers may be required to specifically target certain peptide 
functionality to achieve higher affinities.23,29 Moving forward it would be better to use 
multifunctional electroactive monomers or employ a copolymerisation strategy to 
increase binding interactions to encourage the formation of high affinity imprinted sites.  
3.4.5. Sensor response with test peptide and cross-reactant peptide: 
To understand the selectivity of the sensor, a test-peptide was introduced in the system 
in a non-competitive assay.  The test-peptide was made with a random amino acid 
sequence (TIVANP) containing 3 amino acids (I,A,P) matching the pro-PSA activation 
peptide sequence (APLILSR). Upon performing the binding study, the test peptide 
(TIVANP) showed an opposite behaviour to the pro-PSA peptide with the MIP 
electrode, that is a decrease in impedance upon binding was observed. The sensor 
displayed a 2 % change in capacitance when challenged with 1 µM test-peptide, while a 
maximum signal of 5 % was reported at 100 µM test-peptide. However, the response 
was lower and discriminatory than the signal change for 100 µM pro-PSA peptide (15 
%) (Seen in Figure 3.42). The test peptide has an overall positive charge, which could 
potentially increase the ionic interaction between the polymer surface and the negatively 
charged redox couple (Fe(CN)63−/4−) hence, decreasing the impedance of the sensor. It 
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was hypothesised that the decrease in impedance (increase in capacitance) could be due 
to a combination of the charge effect of the peptide as it non-specifically interacts with 
the surface of the polymer rather than the imprinted site and equilibration of the redox 
couple with the MIP surface.  
To further challenge the selectivity of the sensor a potential cross-reactant peptide   
(VPLIQSR) was used in the selectivity study (non-competitive assay). The VPLIQSR 
peptide is the activation sequence from pro-hK2 (similar clearing mechanism as the pro-
PSA activation sequence), which has only two amino acid mismatches with the pro-PSA 
peptide.57 The peptide would be a potential cross-reactant in the clinical setting when 
measuring the pro-PSA peptide. The sensor showed a response of 6.32 % and 19 % 
when challenged with 1 µM and 100 µM pro-hK2 peptide respectively (Figure 3.42), 
which was slightly higher than the response observed with the template pro-PSA peptide 
sequence. This is not surprising given the close homology of the two sequences; the 
difference between valine and alanine is only one methyl group, making the sequence 
almost identical.  It is hypothesised that the actual binding of pro-Hk2 peptide and the 
pro-PSA peptide to the imprinted sensor is fairly similar and the difference could be 
attributed to the low n value for the experiments.   
Additional control study for understand the selectivity of the MIP sensor could be to 
fabricate a control MIP sensor with a test/cross-reactive peptide and challenging it with 
the template peptide to understand robustness of the fabricating technique and 
establishing selectivity of the sensor. However, this study was not conducted during the 
work.  
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Figure 3. 42 The pro-PSA MIP sensor responses to test peptide and cross-reactant peptide in a 
non-competitive assay. The test peptide contained a random amino acid sequence (Threonine-
Isoleucine-Valine-Alanine-Aspargine-Proline), which would demonstrate very low shape and 
chemical similarity to the pro-PSA activation peptide. Hence, it was expected that the MIP 
sensor would not recognise the test peptide. The sensor displayed some response towards the 
test peptide however it was a non –specific binding response. The MIP electrode failed to 
distinguish between cross-reactant (pro-hK2) peptide and the pro-PSA activation sequence 
which had greater than 90% sequence similarity. Data represents n=4 and error bars represent 
standard deviation.  
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3.4.6. Conventional MIP performance (non-surface immobilised template)  
The purpose of this study was to understand whether confining the peptide to the surface 
using MUA tag offered any significant advantage over conventional imprinting 
protocols where the template is simply entrapped and randomly incorporated within the 
polymer (no surface confinement). The majority of surface imprinted technique in 
literature have not utilised immobilised or orientated template for fabrication of 
imprinted sensors. Hence, it was important to understand the difference in the two 
techniques. The protocol for the conventional imprinting of the pro-PSA peptide was 
adopted from literature studies for direct comparison. An equimolar concentration of the 
template and monomer was used in an attempt to maximise the amount of the template 
ultimately entrapped within the polymer during polymerisation. The number cycles were 
restricted to 15 so as to encourage the template entrapment while producing a relatively 
thin layer of polymer to maximise signal transduction. As is evident from Figure 3.43, 
the limit of detection for the conventionally imprinted system was 10 µM pro-PSA 
peptide compared to 1µM for the surface immobilised imprinted MIP. It is likely that 
despite the higher template concentrations being used during the imprinting process and 
a greater number of polymerisation a cycle, fewer peptide molecules become entrapped 
into the polymer. Furthermore, it is proposed that the peptide molecules are entrapped 
randomly throughout polymer layers meaning that binding sites are distributed 
throughout, thus providing an additional diffusional barrier in the rebinding process.  
This suggests that surface immobilisation of the template provides the advantage of 
carefully controlling the polymer thickness while hopefully encouraging localisation of 
binding sites at the surface, thus providing improved access for the template on 
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rebinding. Additionally, the resistance of conventional NIP to the peptide indicates the 
low non-specific binding (2 % for 100 µM peptide) of polydopamine to the peptide. 
 
Figure 3. 43 Response of conventionally prepared pro-peptide MIP/NIP sensors. Data 
represents n=3 and error bars represent standard deviation. 
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3.5. Conclusion: 
In conclusion, a pro-PSA activation sequence imprinted sensor was fabricated with an 
LOD of 1 µM and Kd of 9.2 µM. The sensor showed a good imprinting factor (IF = 14) 
when compared to its non-imprinted counterpart and could also discriminate a random 
peptide sequence possessing 50 % sequence homology. When comparing with a 
conventional MIP sensor the oriented template MIP sensor had 10 times higher 
sensitivity. This suggests that using an oriented, the surface-confined template during 
the imprinting process helps to improve the overall sensitivity of the sensor. Despite not 
being sensitive enough to detect clinically relevant concentrations of the peptide, this 
technique could be extended to other peptides/ small molecule biomarkers, which are 
typically present at higher concentrations (µg/ml - mg/ml) in clinical samples. 
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4.1. Introduction 
4.1.1. General overview 
Protein imprinting is a challenging area of molecular imprinting due to their large size 
and complex nature and has been one of the stumbling blocks in realising the full 
potential of MIPs as a feasible alternative to antibodies.1 Challenges associated with 
protein imprinting have been highlighted in Chapter 1. Chapter 2 and 3 explored epitope 
imprinting of PSA protein as an alternative to whole protein imprinting, however, some 
of the biggest challenges with epitope imprinting were maintaining the conformation of 
the epitope with respect to whole protein, solubility in conventional solvents and 
sensitivity of the imprinted system to detect clinically relevant concentrations. An 
alternative approach proposed by our lab was to build a more sophisticated type of bio-
receptor with an improved affinity using a technique termed hybrid imprinting.2 Hence, 
the chapter explores surface imprinting of PSA using aptamers as ‘super monomers’ in 
the hybrid imprinting strategy. An electrochemical sensor was built with the hybrid 
receptor (apta-MIP) as the recognition unit and evaluated for detection of PSA. This 
project was carried out in collaboration with colleagues at the University of Bath, Dr. P. 
Estrela and Dr. P. Jolly and results of this study have been published in “Aptamer–MIP 
hybrid receptor for highly sensitive electrochemical detection of prostate specific 
antigen”, Biosensors and Bioelectronics, Volume 75, 15 January 2016, Pages 188-195. 
4.1.2. Hybrid molecular imprinting:  
Hybrid imprinting utilises a bio-receptor, with an established affinity towards the 
template, to confine the template in its preferred conformation during the imprinting 
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process. Post extraction of the template, the polymeric cavity lined with the bio-receptor 
displays a higher affinity than the bio-receptor or MIP alone.3 The hybrid imprinting 
technique allows for localisation of the template in its preferred conformation allowing 
for the formation of uniform binding sites which improves the binding characteristics of 
the hybrid-MIP.4 Furthermore, it is proposed that the bio-receptor receptor acts 
synergistically with the polymer to lend higher affinity to the resulting imprinted 
polymer. Bowen et al. used Merrifield resin to co-immobilise iniferters and peptide (as 
the receptor) for application in hybrid imprinting.2 The short peptide (polymyxin) was 
used to trap LPS (lipopolysaccharide) on the resin while the iniferter enabled control 
growth of a surface ‘imprinting’ polymer layer. It was proposed that the covalently 
immobilised peptide conferred greater selectivity to the resulting polymer. An 
imprinting effect was observed with hybrid polymyxin MIPs demonstrating an 
improved binding affinity compared to polymyxin alone. Over the years, various other 
groups have successfully demonstrated hybrid imprinting using aptamers5,6, lectins7 and 
small molecules4 for proteins with varying degrees of success.  
4.1.3. Aptamers  
Aptamers are short oligonucleotide sequences resulting from SELEX (systematic 
evolution of ligands by exponential enrichment) process displaying high affinity for 
their target molecules.8 The word aptamer is derived from the Latin word ‘aptus’ which 
means to fit which is appropriate as the aptamer fit into their target much like the lock-
and-key analogy from enzymes.9 SELEX technology identifies particular nucleotide 
sequences, from an extensive library of oligonucleotide sequences, which bind to a 
target, through an iterative process of in vitro selection and amplification (Figure 4.1).10 
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Using this technology aptamers can be raised for a variety of targets in a short period of 
time. The expiry of patents on SELEX technology has triggered much-needed research 
in this field. 
 
Figure 4. 1 Generation of aptamers using the SELEX process. The aptamers are chosen from a 
pool of nucleotides sequence and checked for binding to the target repeatedly till a high-affinity 
sequence is identified and amplified. Figure adapted from (http://www.creative-
biogene.com/Services/Aptamers/Technology-Platforms.html) 
Aptamers target the molecules at an atomic level by changing conformation upon 
binding to form a pocket for the ligand to fit in, allowing them to discriminate closely 
related molecules.11 Certain functional groups on the aptamer come into close proximity 
upon the conformational change, which favours binding to the target. This is a simple 
explanation for the binding mechanism for small molecule aptamers. However, the 
structural basis for specific discrimination in cases of complex molecules such as 
proteins could be based on the combination of different effects such as pi-pi stacking, 
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hydrogen bonding, electrostatic interactions and shape similarity.11,12 While there is a 
complete change in conformation of the aptamer to form a pocket surrounding the target 
in case of small molecules13, the protein aptamer interactions are confined to a smaller 
region with unique interactions between the nucleotides and amino acids.14 This 
difference in binding can be well exploited in hybrid protein imprinting to create 
polymer cavities with steric and chemical selectivity towards the protein. 
4.1.4. Aptamers for hybrid imprinting 
Use of a peptide as the bioreceptors for hybrid imprinting was observed to be 
challenging due to rigid conformation adopted by peptides and the difficulty in finding 
peptide receptors with high template affinity. Aptamers have various advantages over 
antibodies/peptides as the choice of bioreceptors for diagnostic and sensing applications. 
They are produced by chemical synthesis with high accuracy and reproducibility and 
can be chemically modified for different sensing platforms.10 They are chemically stable 
at room temperature and have a longer shelf life than antibodies.8 They can be 
regenerated for use by denaturing them at high temperatures and they are more flexible 
in their structure as compared to peptides. The chemical stability of the aptamers also 
makes them a good choice for the receptor as they can withstand harsh washing 
conditions required for template removal in MIP fabrication. Aptamers also face certain 
drawbacks such as they are easily denatured by nuclease enzymes and they demonstrate 
optimum binding only in buffers used for raising them, making their application for 
sensing somewhat limited. It is proposed that by combining aptamers with MIPs 
drawbacks of both technologies could be overcome to generate sensitive and efficient 
synthetic receptors. Wei et al. first used the aptamers in a double imprinting method to 
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detect Apple Stem Pitting Virus (ASPV).5 Polymerisable aptamers were first used to 
isolate the virus and subsequently build an imprinted hydrogel. The resulting hydrogel 
was engineered into a diffraction-gating sensor using imprinting lithography. The sensor 
showed comparable sensitivity to ELISA with LOD of 10 ng/ml. Similarly, Poma et al. 
used polymerisable aptamers for surface imprinting of cocaine which, was detected by 
QCM sensor.3 The apta-MIP nanoparticles were produced by polymerising acrylated 
aptamers on surface immobilised template and eluting them post polymerisation. The 
apta-MIPs nanoparticles showed a higher affinity (apparent Kd of 26.4 mM) than 
aptamer only / MIP only nanoparticles suggesting an improved effect due to the aptamer 
integration into the polymer. The study also demonstrated that the aptamers were 
protected from enzymatic degradation inside the polymer, as incubation with 
endonucleases did not alter the binding capability of MIP nano-particles. Both studies 
demonstrated the scope for hybrid aptamer imprinting for protein imprinting application. 
4.1.5. PSA aptamer 
Savory et al. first developed the fPSA aptamer that was used in the current study.15 The 
group studied the use of a genetic algorithm to increase the selectivity and sensitivity of 
aptamers selected by the SELEX process.15 Five aptamers were found, out of which one 
showed 48 times higher binding than the parent sequence. The PSA aptamer is a 34-
nucleotide sequence, which forms a stable loop secondary structure (Figure 4.2) on 
binding to fPSA as predicted by Mfold program (prediction based on lowering of Gibbs 
free energy). The binding affinity, Kd of 40 nM, was determined using ELISA and LOD 
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of 10 nM was reported. However, the exact mechanism of PSA binding to the aptamer 
has yet to be elucidated. 
 
Figure 4. 2: PSA aptamer folds into a secondary structure upon binding to PSA predicted by 
Mfold program, obtained from Savory et al. (2010),15 with permission from Elsevier. 
Various groups have investigated this particular aptamer for fPSA detection using 
different sensing platforms such as optical, piezoelectric and electrochemical. A 
summary of published literature demonstrating the use of aptamer for electrochemical 
detection of PSA has been listed in Table 4.1. It can be observed that the PSA aptamer is 
highly sensitive for PSA detection on various electrochemical platforms. 
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Sensing Platform: 
Electrochemical 
Detection 
technique 
Sensing strategy LOD  
Glassy carbon 
electrodes 
 
DPV, CV Gold NPs immobilised on 
mesoporous carbon 
deposited on GCE 
followed by 
immobilisation 
streptavidin and 
biotinylated aptamer.16 
7.6 pM 
Gold electrodes EIS Co-immobilisation 
sulfobetaine SAM with 
thiolated aptamers.17 
30 pM 
Gold electrodes Squarewave 
voltammetry 
Deposition of polymer to 
covalently attach amine 
terminated aptamers.18 
 
 
33 pM 
Gold electrodes EIS Use of DNA hybridisation 
for immobilisation of 
DNA aptamers.19 
0.1 pM 
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GCE Electrochemical: 
DPV/EIS 
Graphene chitosan 
composite deposited on 
GCE to form antibody-
PSA-aptamer (biotin) 
sandwich assay.20 
 
DPV: 
300aM  
EIS: 
150fM  
 
Gold surface on 
silicon 
dioxide/lithium 
tantalite wafer 
 
 
Electrochemical: 
Love- wave 
sensor 
 
 
LiTaO3 substrate with 
SiO2 film as wave guide 
layer, two set of inter-
digital transducers (IDT), 
a gold film for 
immobilisation of the 
aptamer and a 
polydimethylsiloxane 
(PDMS) microfluidic 
channels. 21 
 
 
330 pM 
 
Table 4. 1: Summary of PSA aptamer sensors, detection technique and their sensitivity. 
 
Chapter 4                                       Development of Hybrid Receptor for Electrochemical Detection of PSA                
  239 
4.1.6. Hybrid imprinting for PSA detection 
Due to various advantages offered by aptamers, and the availability of an established 
aptamer for PSA with known affinity, it was decided to investigate PSA-aptamer 
combination for the hybrid imprinting approach. In the current study, an electrochemical 
sensing platform was investigated to understand the feasibility of the hybrid imprinting 
approach for detection of PSA at clinically relevant concentrations. It was hypothesised 
that the improved bioreceptors ‘apta-MIPs’ would exhibit greater selectivity because of 
the aptamer trapped in the favourable binding conformation and the recognition ability 
of the imprinted polymer, as a result of steric and chemical selectivity. The proposed 
technique also demonstrates a targeted one step immobilisation strategy specifically for 
macromolecular surface imprinting applications, which has not been studied by other 
hybrid MIP techniques reported in the literature. It was further hypothesized that the 
particular orientation of the aptamer-bound-PSA on the sensor surface would allow for 
uniform binding site formation during the imprinting process, which is not observed in 
bulk imprinting (conventional or hybrid) technique. An electrochemical-sensing 
platform used for rapid detection of protein binding events. Studying and understanding 
such a sensing platform could help in the development of highly sensitive and selective 
MIP sensors that could be translated to other biomarkers in the future. 
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Figure 4. 3: Schematic of apta-MIP electrode preparation process: aptamer-PSA complex is 
immobilised via thiol chemistry (a) dopamine is electropolymerised to entrap the PSA (b) PSA is 
extracted by washing with detergent and acid (c) Post template extraction sensor is tested for 
rebinding of proteins (d) 
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4.2. Aims And Objectives Of Chapter 4 
The overall aim of this chapter is to construct a hybrid apta-MIP sensor for sensitive and 
selective detection of PSA. 
Key objectives of this chapter are: 
1. To study surface immobilisation strategies of PSA-aptamer complex on 
electrode surface. 
2. To understand polymerisation strategies for molecular imprinting of aptamer-
PSA. 
3. Characterisation of surface post molecular imprinting of aptamer-PSA 
complex. 
4. Evaluation of apta-MIP sensor performance by performing dose response 
studies with PSA and performing cross-reactivity studies with homologous 
proteins as well as serum proteins. 
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4.3. Materials And Methods 
4.3.1. Reagents 
Thiol terminated DNA aptamer with the sequence (5’-HS-(CH2)6-TTT TTA ATT AAA 
GCT CGC CAT CAA ATA GCT TT-3’) was obtained from Sigma Aldrich, UK. 
Prostate specific antigen (PSA) was obtained from Merck Chemicals Ltd, UK. Human 
glandular kallikrein 2 (hK2) was obtained from RnD systems, UK. Human serum 
albumin (HSA), dopamine hydrochloride, trisma base, concentrated sulphuric acid, 
potassium phosphate monobasic solution (1 M), potassium phosphate dibasic solution 
(1 M), potassium hexacyanoferrate (III), potassium hexacyanoferrate (II) trihydrate, 
hexaammineruthenium (III) chloride, TWEEN 20 , potassium chloride and magnesium 
chloride were all purchased from Sigma–Aldrich, UK. All reagents were of analytical 
grade. All aqueous solutions were prepared using ultra-pure water 18.2 MΩ cm from 
Milli-Q system with Pyrogard filter (Millipore, MA, USA). Gold working electrodes 
were obtained from CH Instruments, USA and mechanical electrode polishing kit from 
Buehler, UK. 
4.3.2. Electrochemical setup 
All electrochemical measurements were performed with the µAUTOLAB III / FRA2 
potentiostat (Metrohm Autolab, The Netherlands) with a three-electrode cell setup 
(Figure 4.4) consisting of an Ag/AgCl reference electrode (BASi, USA), connected via a 
salt bridge filled with 10mM phosphate buffer saline (PBS) pH 7.4, and a platinum (Pt) 
counter electrode (ALS, Japan). The impedance spectrum was measured in 10 mM PBS 
measurement buffer pH 7.4 containing 10 mM ferro/ferricyanide [Fe(CN)6]-3/-4 in a 
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frequency range from 100 kHz to 100 mHz, with a 10 mV a.c. voltage superimposed on 
a bias D.C. Voltage of -0.200 V vs Ag/AgCl reference electrode (corresponding to the 
formal potential of the redox couple). All measurements were performed at 20 ºC in 10 
ml glass beakers as shown in Figure 4. 4. 
 
 Figure 4. 4: Three-electrode setup with working (green), counter (white) and reference (red) 
electrodes. The set-up is connected to a potentiostat measures electrochemical changes in the 
system. 
4.3.3. Fabrication of capacitive apta-MIP sensors 
4.3.3.1. Electrode cleaning 
Gold-disk working electrodes with a radius of 1.0 mm were first mechanically polished 
for 5 min with 50 nm alumina slurry on a polishing pad. Electrodes were then sonicated 
first in ethanol for 5 min followed by 10 min sonication in ultrapure water to remove 
any residual alumina particles. The electrodes were subsequently incubated in piranha 
solution (three parts of concentrated sulphuric acid to one part of hydrogen peroxide) for 
5 minutes for chemically oxidising the surface. Electrodes were then washed thoroughly 
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with ultra-pure water to remove any residual acid. Post mechanical and chemical 
cleaning, electrodes were subjected to electrochemical cleaning in 0.5 M H2SO4 by 
scanning the potential between the oxidation and reduction potential of gold, −0.05 V 
and +1.1 V, versus Ag/AgCl reference electrode for 50 cycles until no further change in 
the voltammogram was observed. Finally, electrodes were washed with ultra-pure water 
and dried under nitrogen. 
4.3.3.2. Aptamer – PSA complex immobilisation 
Aptamers were first activated by incubating at 950 C for 10 minutes in a water bath and 
then gradually cooling them to room temperature over a period of 30 minutes. Post 
activation, 1µM DNA aptamer in TBST (Tris buffered saline with TWEEN 20) buffer 
pH 7.4 (10 mM Tris-HCl, 10 mM KCl, 10 mM MgCl2, 0.05 % TWEEN 20) was 
incubated with 1 µg/ml of PSA for 1 hour at 370 C. Clean gold electrodes were then 
immersed in the aptamer-PSA complex solution for one hour, before being rinsed with 
milliQ water. To ensure the saturation of all aptamer molecules by PSA, the electrodes 
were backfilled with 1 µg/ml PSA in TBST buffer for an additional 30 minutes. These 
bio-functionalized electrodes were then taken forward into an electropolymerisation 
strategy.  
4.3.3.3. Imprinting of the aptamer – PSA complex 
• Autopolymerisation:  
Dopamine was dissolved in Tris buffer pH 8.5 to a final concentration of 5 mM. The 
aptamer-PSA functionalised gold electrodes with were dipped into the freshly prepared 
solution of dopamine and left for an hour to allow auto-polymerisation to occur. 
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Following polymerisation, the electrodes were washed with copious amount of water 
and left in washing buffer (5 % acetic acid and 5 % SDS) overnight to extract the PSA. 
A non-imprinted polymer (NIP) was made with aptamer but in the absence of PSA. The 
electrodes were washed with water to remove residual acid and detergent and stabilised 
in PBS buffer pH 7.4 before use. 
• Electropolymerisation: 
The method for electropolymerisation of dopamine on gold electrodes was adapted from 
the procedure reported by Liu et al.22 PBS buffer (pH 7.4) containing 5mM dopamine 
was degassed with nitrogen gas for 10 minutes prior to polymerisation. The solution was 
added to the electrochemical setup such that the functionalised gold working electrode, 
reference and counter electrode were immersed in the monomer solution. Polydopamine 
was electrodeposited on gold electrodes by performing cyclic voltammetry with varying 
(7/13/25) cycles by sweeping the potential from -0.5 V to 0.5 V at a scan rate of 20 
mV/sec vs Ag/AgCl as the reference electrode. Following polymerisation, electrodes 
were thoroughly rinsed with water and left in washing buffer (5 % acetic acid and 5 % 
SDS) on a stirrer overnight to extract PSA. Electrodes were then rinsed with excess 
water to remove any residues of SDS and acetic acid in the polymer and incubated in 
PBS buffer for stabilisation.  
The non-imprinted biosensor (apta-NIP) was prepared under exactly the same 
experimental conditions in the absence of PSA but with aptamer. The DNA aptamer was 
first immobilised on the gold surface followed by electropolymerisation of dopamine. 
The apta-NIP sensor was also exposed to the same washing conditions as apta-MIP. 
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4.3.3.4. Chronocoulometry for confirming presence of aptamers 
Chronocoulometry measurements were performed using a µAUTOLAB III / FRA2 
potentiostat. To functionalise the gold electrodes, the aptamer-PSA complex was first 
immobilised on the surface. The complex was then backfilled with 1 mM 6-Mercapto-1-
hexanol (MCH) to cover any free gold surface. The aptamer-PSA functionalized gold 
electrodes were then rinsed with 5 % acetic acid and 5 % SDS solution. Gold electrodes 
functionalised with DNA aptamer washed with water were used as a control. The 
electrodes measurement were conducted by stepping the potential from −300 to 
−800 mV versus Hg/HgSO4 (K2SO4) reference electrode for 500 milli-sec (10 mM Tris–
HCl buffer pH 7.4) and subsequently recording the resulting charge flow. The same 
electrodes were then immersed in a solution of 100 µM hexamineruthenium(III) 
chloride (Ru(NH3)63+) in Tris buffer pH 7.4, and the measurements repeated.  
4.3.4. Apta-MIP characterisation 
4.3.4.1. Scanning electron microscopy (SEM) 
Scanning electron microscopy (SEM) was performed using a ZEISS SUPRA 40 
instrument (Carl Zeiss AG, Germany) in vacuum mode with an acceleration voltage of 
3kV and 1kV. 
4.3.4.2. Fourier transform infrared spectroscopy (FTIR) 
FTIR analysis was carried out on a Varian 3100 Excalibur FTIR (Agilent Technologies 
UK Limited, Cheshire, UK) using the Varian Resolutions Pro software.  
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4.3.4.3. Atomic force microscopy (AFM) characterisation 
The thickness and root mean squared (RMS) roughness of washed and unwashed apta-
MIP films on gold-coated glass slides (Au thickness 150 nm) were determined by 
(AFM) (Multimode Nanoscope V, Bruker, CA, USA). Before investigation, both 
samples were rinsed with MilliQ water and dried with a lateral flow of nitrogen. Small 
scratches were made in each film using a sharp cantilever tip, < 10 nm, on a rigid 
cantilever of spring constant 42 N/m (NuSENSE, NuNano, Bristol, UK). Keeping the 
applied force below 50 nN ensured that the scratching process did not damage the 
underlying gold film. The depth of the resulting scratches was investigated at high 
resolution utilising a compliant cantilever of spring constant 0.4 N/m with a sharper tip, 
< 2 nm, (SCANASYST-AIR-HR, Bruker, CA, USA). The greater compliance of the 
cantilever allows interaction forces normal to the sample to be maintained in the region 
of a few hundred pN, thus minimising possible film compression. Images were collected 
at a resolution of 2 nm/pixel. 
4.3.5. Apta-MIP sensor evaluation with PSA  
Capacitive changes in the apta-MIP sensor were measured by an electrochemical 
impedance spectroscopy technique. The electrodes were stabilized in 10 mM 
Fe(CN)63−/4− solution in PBS (pH 7.4) before conducting binding experiments. The apta-
MIP sensor was mounted in a three-electrode configuration as the working electrode. 
After baseline stabilization, the electrodes were dipped in 100 µl volume of different 
PSA concentrations prepared in 10 mM Fe(CN)63−/4− solution in PBS buffer (pH 7.4) 
containing 0.05 % TWEEN 20.  
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4.3.6. Preparation of conventional MIP capacitive sensors 
For the preparation of conventional capacitive MIP sensor, PSA (1 µg/ml) was mixed in 
5mM dopamine solution in PBS buffer pH 7.4. The solution was degassed for 10 
minutes with nitrogen. Dopamine solution containing PSA was then electropolymerised 
using cyclic voltammetry (13 cycles) from - 0.5 V to 0.5 V at a scan rate of 20 mV/sec 
vs Ag/AgCl as a reference electrode. The electrodes were washed with 5 % acetic acid 
and 5 % SDS solution for removal of protein, washed with water and checked for re-
binding of PSA. 
4.3.7. Apta-MIP sensor cross-reactivity evaluation  
Capacitive changes in the apta-MIP sensor were measured by an electrochemical 
impedance spectroscopy technique. The electrodes were stabilized in 10 mM 
Fe(CN)63−/4− solution in PBS (pH 7.4) before conducting binding experiments. The apta-
MIP sensor was mounted in a three-electrode configuration as the working electrode. 
After baseline stabilization, the electrodes were dipped in 100 µl volume of different 
concentration of control proteins: human kallikrein 2 (hK2) and human serum albumin 
(HSA) for sensor evaluation. 
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4.4. Results And Discussion 
4.4.1.  Fabrication of hybrid imprinted sensor for PSA 
4.4.1.1. Aptamer-PSA immobilisation 
To characterise the fabrication of different layers of the sensor, cyclic voltammetry was 
used in the presence of a redox couple, 5 mM Fe(CN)63−/4− solution in PBS (pH 7.4). 
The redox couple allowed for sensitive measurement of current and resistance on the 
electrode surface. Figure 4. 5 shows the cyclic voltammograms obtained before and after 
immobilisation of the aptamer-PSA complex. The bare gold electrode (black line) 
showed distinct oxidation (0.28 V) and reduction peaks (0.2 V) with high current levels 
of the redox couple due to its conducting nature consistent with that found in the 
literature.23 Following immobilisation of the aptamer-PSA complex on the gold surface 
(red line), a 70 % reduction in peak current along with a shift in peak voltage was 
observed indicating the formation of a SAM layer on the gold surface, which provided 
resistance to the flow of current. 
The first step in fabrication process was optimisation of immobilisation of PSA-aptamer 
complex on the electrode surface in its most preferred conformation. Conventional 
aptasensors utilise thiolated spacer molecules such as alkane thiols to avoid over-
packing of aptamers on the surface, which can impede sensor efficiency. However, these 
molecules have an inhibitory effect on the electropolymerisation of dopamine and 
therefore could not be used in the sensor fabrication process.24 It was necessary to space 
the aptamers on electrode surface to prevent possible steric hindrance for efficient 
binding of PSA to densely packed aptamers. Hence, a pre-complexing step of PSA and 
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aptamer binding was introduced before functionalisation of gold electrodes with PSA-
aptamer complex. It was hypothesised that the pre-complexed PSA-aptamer 
immobilisation would allow for a uniform SAM layer formation on the gold surface 
with auto spacing between the aptamer-PSA complex molecules due to electrostatic 
repulsion between aptamers and steric hindrance from proteins. The free gold space left 
between these aptamer-PSA complex would then be utilized to grow polydopamine.  
 
Figure 4. 5: Cyclic voltammograms showing a reduction in current and shift in peak voltage 
following immobilisation of complex performed in 10 mM PBS (pH 7.4) containing 10 mM 
ferro/ferricyanide [Fe(CN)6]3-/4.  
4.4.1.2. Molecular imprinting via autopolymerisation: 
In 2007 Phillip Messersmith’s group reported a simple method to coat virtually any 
surface with a thin layer of polydopamine by simply dipping the surface in an alkaline 
solution (pH 8.5) of dopamine.25 The group demonstrated that surface-active 
polydopamine could coat various surfaces like noble metals (Au and Ag), metals with 
-0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6
-20
-10
0
10
20
30
Voltage (V)
C
ur
re
nt
 (µ
A)
Bare Gold Electrode
Electrode immobilised w/t aptamer-PSA complex
Chapter 4                                       Development of Hybrid Receptor for Electrochemical Detection of PSA                
  251 
native oxide surfaces (Cu and stainless steel), oxides (TiO2 and SiO2), semiconductors 
(GaAs) and glass. The mechanism of autopolymerisation is believed to be similar to the 
mechanism of formation of melanin for which dopamine serves as a precursor. 
Dopamine first oxidizes to dihydroxyindole and indolequinone, which then couple in a 
stepwise fashion, to form oligomeric mats that stack on top of each other to form 
melanin.26 Due to simplicity of the process, initial imprinting studies were carried out 
with autopolymerisation process. The bio-functionalised electrodes fabricated with 
varying polydopamine thickness were measured for the reduction in peak current as a 
function of time as shown in Figure 4.6. It can be observed from Figure 4.6 that the 
current decreased with increase in polymerisation time and after 60 minutes there was 
minimal flow of current (∼ 0.1 µA) through the electrode surface. This was a result of a 
non-conducting layer of polydopamine coating the electrode leading to passivation of 
the surface. From the literature it was determined that the polymer height could range 
from 50 - 100 nm after 60 minutes of polymerisation.22,25,27 Hybrid imprinting studies 
were carried using polymerisation for 30 minutes to grow a thin polymer layer (∼ 10 
nm) close to the height of the aptamer-PSA complex. The aptamer-PSA complex height 
calculation and polymerisation optimisation has been elaborated in Section 4.4.31. 
Chapter 4                                       Development of Hybrid Receptor for Electrochemical Detection of PSA                
  252 
 
Figure 4. 6: Reduction of peak current with increase in polymerisation times 
The apta-MIPs and apta-NIPs fabricated with the autopolymerisation process were 
evaluated for their binding efficiency to PSA. Electro-impedance spectroscopy (EIS) 
was used in this study to measure capacitive changes as a result of the re-binding 
process. When the protein (PSA) is introduced at different concentrations, the di-electric 
properties of the apta-MIP polymer changes, and this change were measured using EIS. 
The binding data plotted in Figure 4.7 showed no difference between apta-MIPs and 
NIPs with very large error bars, which is suggestive of non-specific binding of PSA to 
the polymer. A possible explanation could be the porous and non-uniform nature of 
polydopamine formed via autopolymerisation,27 which, could lead to non-specific 
binding. A study by Zangmeister et al. demonstrated that after 10 minutes of 
autopolymerisation, polydopamine starts to deposit as agglomerates (formed in solution) 
of polymer onto the electrode surface.27 This could be one of the reasons for the absence 
of imprinting effect due to large chunks of polymer depositing randomly on the 
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electrode surface leading to non-uniformity of the imprinted structure and lack of 
interaction between dopamine and PSA. Additionally, as these agglomerates are not 
covalently bound it was hypothesised that some of them could be washed away during 
the protein extraction process leading to further loss of imprinting effect.27 The decrease 
in capacitance could be a result of non-specific binding of PSA to exposed gold and 
specific binding to the aptamer, which are still present on electrode surface of apta-NIP 
as well as apta-MIP. Shorter polymerisation periods also did not improve the imprinting 
process. This led us to explore electropolymerisation of polydopamine for further 
imprinting studies to get defined polymer characteristics for efficient imprinting.  
 
Figure 4. 7: Use of autopolymerisation of dopamine for imprinting. PSA binding results of apta-
MIP and NIP 
4.4.1.3. Molecular imprinting via electropolymerisation 
Electropolymerised polydopamine has been used to generate molecular imprints on 
sensor surfaces such as gold, graphene oxide, silica for protein sensing.22,28,29 For 
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surface imprinting, the oxidation/reduction potential applied for polymerisation of 
polydopamine is quite low, which prevents thiol oxidation of PSA-aptamer complex 
from the surface hence protecting the SAM layer orientation.30 Polydopamine also has 
various functional groups for hydrogen bonding, hydrophobic and hydrophilic 
interaction with PSA making it a suitable functional monomer for imprinting. Cyclic 
voltammetry was used for the oxidation and reduction of polydopamine. The potential 
of the working electrode was swept from an initial value Eo (0V) to a set potential E1 
(0.5 V) to a second set potential E2 (-0.5 V) after which the potential was reversed to its 
initial value. The potential values are set such that the oxidation and reduction potential 
of dopamine is within the range of the scanning potential of CV. Cyclic voltammogram 
of dopamine polymerisation is plotted in Figure 4.9 showing reduction in current with 
consecutive cycles. The distinct oxidation and reduction peaks represent oxidised 
species of dopamine during the polymerisation process.  The peak at 0.39 V in the 
oxidation cycle represents DAQ, while the reduction cycle shows peaks at 0.08 V which 
represents LDAC and -0.38 V represents DAC. In the second cycle, an oxidation peak 
occurs at -0.18V which represents 5,6- dihydroxyindole which further undergoes 
polymerisation.30 No new peaks were observed during polymerisation demonstrating 
that no conducting analogues were being produced during electropolymerisation. The 
polymer growth is self-limiting as the insulating polymer prevents electron transfer 
reactions for further oxidation of dopamine. 
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Figure 4. 8: Cyclic voltammograms showing electropolymerisation of dopamine on DNA 
aptamer-PSA modified gold electrodes. A reduction in peak current at 0.39V as well as at 0.07V 
and -0.35V was observed showing deposition of insulating polymer on the surface.  
Post polymerisation of polydopamine on aptamer-PSA immobilised electrodes, cyclic 
voltammetry was used to characterise the electrode surface using 5 mM 
Fe(CN)63−/4−solution in PBS pH 7.4. The peaks were significantly reduced on 
polymerisation of dopamine on the gold surface due to the non-conducting nature of the 
polymer resulting into further insulation of the electrode surface (Figure 4. 9). 
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Figure 4. 9: Cyclic voltammograms showing steps of apta-MIP fabrication-. The blue curve 
shows the reduction in peak current post polymerisation of dopamine. There is a significant 
reduction in current compared to bare gold as a result of an insulating polymer being deposited. 
The inset shows the magnified view of the peaks post polymerisation. 
4.4.1.4. Washing/Extraction step of PSA 
For extraction of protein, a number of research articles have reported a combination 
SDS and acetic acid/sulphuric acid as an effective wash solution to remove imprinted 
proteins from MIPs.31,32 Some articles have also reported the use of trypsin and 
proteinase K for digesting the protein.33,4 However, incomplete digestion can lead to 
additional washing steps and incomplete template removal from the polymer. The 
incubation time for efficient protein extraction often depends on both protein and 
polymer properties. In the current study, the most successful result was observed with an 
overnight incubation in 5 % SDS and 5 % acetic acid for extraction of protein. This was 
observed through change in resistance of the apta-MIP sensor as well as the rebinding 
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efficiency of PSA. Removal of protein was observed as an increase in current in the 
reduction curve (0.6 µA, Figure 4.10a) of the apta-MIP electrode. However, an increase 
in current was also observed in apta-NIPs (0.1 µA, Figure 4.10b). As the only 
component of NIPs is DNA aptamer, which is covalently bound, it was concluded that 
some polymer was also being removed in the washing process (Chronocoloumetry in 
Section 4.4.2 further suggests that DNA aptamers are not being removed by washing 
solution). It is well known that dopamine can auto-polymerise over time in weakly basic 
pH (pH > 7) conditions29, which could be getting removed during the washing process. 
Autopolymerisation, which can be observed by a change in colour of the polymerisation 
solution from transparent to slight brown, was observed during the last cycles of 
polymerisation in the experiments. The polymerisation solution was deoxygenated to 
retard the process but it could not be completely prevented. However, considering that 
increase in current in apta-MIP was larger than apta-NIP, it safe to conclude some 
protein was also removed from the apta-MIP surface. The electrochemical data alone 
cannot be used conclusively to understand the polymer removal, hence surface 
characterisation techniques like AFM and SEM were also explored.  
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Figure 4. 10: Cyclic voltammograms showing steps of apta- MIP fabrication performed in 
10mM PBS (pH 7.4) containing 10 mM ferro/ferricyanide [Fe(CN)6]3-/4-. The Apta-MIP shows 
an increase in current indicating removal of protein. Apta-NIPs also show an increase in 
current, although smaller, which is attributed to the loss of some polymer during the wash 
process. The increase in current 0.5V is attributed to non-faradaic current. 
4.4.2. Chronocoulometry for determination of aptamer surface coverage 
The technique of chronocoulometry has been reported in the literature for determination 
of the surface density of nucleic acids on modified electrodes.34,35 In this technique, the 
positively charged trivalent ruthenium redox molecule Ru(NH3)63+ preferentially 
exchanges its charge with the monovalent DNA counter ions which are negatively 
charged (phosphate group ion) in a low ionic strength buffer.34 At −300 mV potential 
there is less reduction of ruthenium ions however when the potential is stepped to −800 
mV potential, all surface confined Ru(NH3)63+ is reduced and a diffusion-limited current 
is produced. The charge (Q) as a function of time (t) is given as the sum of reduction of 
Ru(NH3)63+diffusing from solution, the double layer charge and the charge due to 
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reduction of surface confined Ru(NH3)63+, which is given by the integrated Cottrell 
equation36: 
𝑄 =   2𝑛𝐹𝐴𝐷!!/!𝐶!∗𝜋!/!   𝑡!/! +   𝑄!" + 𝑛𝐹𝐴Γ!                                  (4. 1)	  	  
Where n is the number of electrons per molecule for reduction, F the Faraday constant 
(C/mol), A the electrode area (cm2), D0 the diffusion coefficient (cm2/s), C0* the bulk 
concentration of Ru(NH3)63+ (mol/cm3), Qdl the capacitive charge (C) and nFAΓ0 the 
charge from the reduction of Γ0 (the amount of surface confined redox marker, in 
mol/cm2).  
Chronocoulometry was performed to calculate the number of aptamers immobilised on 
the surface as well as the effect of washing process on DNA aptamers. The technique 
was performed on DNA aptamer functionalised gold electrodes in the absence of 
polydopamine. The hypothesis was that if the washing buffer did not remove DNA 
aptamers from the gold surface in the free environment, DNA aptamers would not be 
removed from polymer layer either. Chronocoulometric data was plotted as an Anson 
plot of Q versus t1/2 (Figure 4.11). Extrapolation of a least squares fit to the linear part 
was used to determine the intercept at time zero, which corresponded to Qdl+nFAΓ0 . 
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Figure 4. 11: Anson plot of Q versus t1/2 for determination of surface charge. The measurements 
are taken before (black) and after the addition (red) of ruthenium redox molecules and the 
intercept can be extrapolated from the graphs which corresponds to Qdl+nFAΓ0 
For calculation of surface charge it was assumed that the double layer capacitance was 
approximately equal in both measurements with and without Ru(NH3)63+, therefore 
nFAΓ0 was calculated as the difference in the two intercepts. The DNA surface density 
is determined using the following equation: 
𝛤!"# =   𝛤!   𝑧 𝑚 𝑁!      (4.3)	  	  
Where ΓDNA is the DNA aptamer surface density (molecules/cm2), m the number of 
phosphate groups on the DNA aptamer, z the charge on the redox molecules Ru(NH3)63+ 
and NA is Avogadro's number.  
Two sets of electrodes one exposed to water and the second set exposed to 5 % acetic 
acid and 5 % SDS solution were measured. Γ0 (surface confined redox marker) was 
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calculated to be 5.31x10-10 molecules/cm2, which corresponds to a DNA aptamer surface 
density of approximately 2.99x1013 molecules/cm2  prior to washing. After washing (5 % 
acetic acid and 5 % SDS (aq)), Γ0 was reduced to 2.30 x 10-10 mol/cm2, which 
corresponds to 2.78 x 1013 molecules/cm2 indicating an approximate decrease of 7 %  
(Figure 4.12). Electrodes washed only with water, showed an approximate decrease of 3 
% in the number of DNA aptamer molecules. The higher percentage decrease when 
washed with acetic acid and SDS could be a result of distortion of the SAM layer 
because of drastic changes in pH and desorption of some aptamer molecules. However, 
the high number of molecules calculated on the surface (2.78 x 1013 molecules/cm2) 
indicated the presence of DNA aptamer post washing of electrodes. 
 
Figure 4. 12: Change in surface confined charged for electrodes washed with water (red) and 
electrodes washed with SDS and acetic acid (black). Change in surface confined charges 
indirectly represents the change in DNA molecules on the surface. The DNA molecules 
decreased from 2.99x1013 to 2.78x1013 post washing with SDS and acetic acid. 
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4.4.3. Apta-MIP surface characterisation 
4.4.3.1. Polydopamine thickness optimisation 
An approximate size/length determination of the DNA aptamer-PSA complex was 
calculated to design the polymer thickness on the surface for optimum imprinting 
efficiency. The DNA aptamer (single stranded DNA) consists of 32 bases, which 
corresponds to a length of 10 nm approximately. Upon undergoing conformational 
changes after binding to PSA, the secondary structure shortens to about 5-6 nm.15 PSA 
is a 30 KDa protein, which corresponds to around 4 nm in size37 making the total length 
of the complex about 9 -10 nm. The length is based on end-to-end measurement of the 
complex, which is based on the assumption that the PSA protein attaches on top of the 
aptamer. Although this gives the maximum theoretical length this may not be true in 
reality. Based on various models of aptamer-analyte binding, it is safe to assume that 
aptamers have multiple point interaction with various amino acid residues. Hence the 
actual length of the complex could be smaller than that calculated here. The electro-
synthesized polydopamine film had to be designed similar the same height of the 
aptamer-PSA complex to allow the polymer to interact with the aptamer as well as PSA, 
permitting formation of a polymeric cavity that possessed chemical and steric selectivity 
for the protein. An optimum polymer thickness would also be helpful in facilitating 
complete removal of PSA from imprinted cavities preventing any leaching of the 
template in the re-binding step. From the literature, it was observed that 30 cycles of 
polymerisation produced a polymer ~ 40 nm in thickness.22 The ideal scenario was to go 
for roughly half the polymerisation cycles however, as the surface was already pre-
modified with aptamer-PSA, which could lead to different polymer height than that 
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observed in the literature, three different cycles of polymerisation - 25, 13 and 7 were 
investigated to evaluate the apta-MIP sensor performance. As can be seen in Figure 
4.13a, the apta-MIP with 25 cycles of polymerisation showed good signal change 
however the apta-NIP also showed a high signal change leading to a low imprinting 
factor. Molecular imprinting with 7 cycles of polymerisation (Figure 4. 13b) 
demonstrated low imprinting efficiency with high initial capacitance change. It was 
proposed that this could be due to polymer layer not being thick enough to form uniform 
coverage on the entire electrode surface and some of it being removed in the washing 
step. The signal change being a result of PSA binding to aptamer and exposed gold 
surface non-specifically, indicating the absence of an imprinting effect. The results for 7 
and 25 cycles of polymerisation are from one experiment (n of 4 electrodes) only and 
were not investigated further, however in the future it would be interesting to understand 
the imprinting effect as a function of polymer height using QCM/SPR techniques. 
Thirteen cycles of polymerisation showed the best apta-MIP versus apta-NIP signal 
change and was investigated further as shown in Section 4.4. 
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Figure 4. 13: (a) Dose response of PSA for apta-MIPs with 25 cycles of polymerisation. (b) 
Dose response for apta-MIPs with 7 cycles of polymerisation. Both show a loss in sensitivity in 
terms of changes in capacitance and poor imprinting effects compared to 7 cycles of 
polymerisation as described in section 4.4.5.  
4.4.3.2. Scanning electron microscopy 
SEM was used to understand the surface coverage of the polymer as well as estimate the 
thickness of the polymer in apta-MIPs with 13 cycles of polymerisation. Figure 4.14(a) 
shows SEM of bare gold before any polymerisation. Gold is a conductive material and 
thus absorbed electrons from SEM beam to produce an image with brighter contrast. 
The contrast of the SEM image changed post polymerisation (formation apta-MIP), 
appearing darker than bare gold as seen in Figure 4.14(b).  
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Figure 4. 14: Change in contrast of the image from bare gold (a) to gold coated with apta-MIPs 
(b) is indicative of a uniform polymeric layer on the surface 
A cross section of the gold coated with apta-MIP was analysed to understand the 
thickness of the polymer layer (Figure 4.15). The bottom layer was glass followed by 
chrome and gold, which was covered by the apta-MIP layer. The slide was not kept at 
180° but was slightly tilted below 180° to see the surface more clearly and differentiate 
the polymer from the gold surface. The thickness of the apta-MIP film was dd by 
calculating the change in contrast in the image and was estimated to be around 10 nm in 
dry format (average of 9 measurements from two samples). 
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Figure 4. 15: SEM images of the cross-Section of polymer on gold. The bottom grey part is 
glass, followed by chromium (62 nm) and gold. The gold layer (90 nm) is the brightest as it 
becomes charged with electrons from the beam. The dark layer on top of the gold is the 
polydopamine layer showing thickness measurements of 8.42, 8.23 and 10.1 nm.  
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4.4.3.3. AFM 
Tapping mode atomic force microscopy (AFM) was performed to calculate the 
thickness of the polymer layer for 13 cycles of polymerisation grown on the electrodes. 
For ease of measurement AFM analysis of apta-MIP was carried out on larger areas of 
gold-coated glass slides (10 mm in diameter). Post-polymerisation a clear difference in 
wettability was observed between the apta-MIP surface (hydrophilic) and bare-gold 
which remained unchanged post-washing of the apta-MIP suggesting the presence of a 
stable polydopamine layer. The root mean square (RMS) roughness of the bare-gold 
surface was 2.0 nm and this increased to 2.6 nm following the formation of the apta-
MIP (Figure 4.16). Washing the apta-MIP with SDS and acetic acid resulted in a 
reduction in roughness to 2.2 nm. This reduction in height could be a combination of 
protein removal and some non-specifically bound polymer, which corresponds to the 
increase in current observed in Figure 4.11. The small changes in surface roughness 
suggest uniform surface coverage of the polymer on the gold electrode consistent with 
that observed in the literature.38 The thickness of the polymer layer, measured as the 
step-depth between the base of a scratch and the flat surface of the top of the film, was 
10.61 nm (n = 10; SD 1.23 nm) before washing, which decreased to 7.49 nm (n = 10; 
SD 0.42 nm) post washing. It was hypothesised that the change in thickness during the 
washing step was a result of PSA extraction and loss of some loosely associated 
polymer. It should be noted that the polymers were dried prior to their thicknesses 
measurement. It is, therefore, likely that the actual thickness would be a bit higher given 
that polydopamine has been reported to swell 1.12-1.25 times when hydrated.39 It was 
difficult to measure the polymer thickness in its hydrated form due to hydrophilic nature 
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of the polymer dragging the AFM probe on the surface, preventing it from making a 
scratch on the polymer. 
 
Figure 4. 16: The polymer depth was measured using AFM. A step edge on the polymer coated 
electrode was created by making small scratches in each film using a sharp cantilever tip, < 10 
nm, on a rigid cantilever of spring constant 42 N/m. AFM images (a,b) and graphs(c,d) 
demonstrate the height profile of the step edge created on the surface of apta-MIPs before and 
after the washing process. 
4.4.3.4. Fourier-transform Infrared Spectroscopy (FTIR)  
FTIR was performed on polymer modified gold surfaces to provide further evidence of 
polymer deposition. The spectra of bare gold and polydopamine-modified gold is 
presented in Figure 4.17 (a),(b). As the polymer layer was very thin (10 nm) it was 
difficult to obtain strong bands for the IR spectrum, which could be due to the depth of 
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IR penetration during the measurements. The depth of penetration in the sample at the 
contact position is directly dependent on wavelength of the light and can vary from 0.5-
5 µm (depending on the angle of incidence of light and the refractive index of the prism 
used).40 A thicker polymer layer (≈50 nm) was deposited to understand polymer 
properties on gold surface. An amide and hydroxyl stretch was observed from 3200-
3600 cm-1, which could be attributed to the NH and OH groups in the polydopamine 
film. An aromatic C=C and C=N stretch was also observed at 1200-1600 cm-1 from the 
aromatic ring.  
 
Figure 4. 17: FTIR spectrum of polydopamine on the gold surface (b) showing characteristic 
peaks for NH and OH groups (3200-3600 cm-1). A small C=O, C=C and C=N stretch is also 
observed from 1200-1600 cm-1. The corresponding peaks are absent in the FTIR spectrum of 
bare gold (a). 
4.4.4. Evaluation of apta-MIP sensor performance  
4.4.4.1. Apta-MIP sensor dose response with PSA 
Apta-MIP with 13 cycles of polymerisation was fabricated and tested for PSA binding 
using EIS. Apta-MIP sensor response to PSA has been plotted in Figure 4.19. A 
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decrease in impedance was observed with increasing concentrations of PSA. As PSA 
binds to the cavities of the apta-MIP, less DNA charge is exposed to the outer 
electrolyte, causing a reduction in the resistance of the system. The screening of the 
charge of the PSA-specific DNA aptamer has previously been reported in the 
literature.17,41 On the other hand apta-NIP sensor response plotted in Figure 4.18 shows 
negligible response to increasing concentrations of PSA. 
 
Figure 4. 18: Nyquist plots showing changes in impedance of the apta-MIP sensor for different 
concentration of PSA (0.1 pg/ml to 100000 pg/ml). The apta-NIP on the other hand shows 
negligible change on addition of PSA due to absence of polymeric cavities. 
The Niquist data plot can be best fitted using a modified Randall’s equivalent circuit 
(Ivium modelling software, UK) comprising two R||C (resistance in parallel with 
capacitance) circuits in series, Rs (R1||C1) (R2||C2), where Rs is the solution resistance 
C2 can be replaced by a constant phase element (CPE) with impedance 
Z(CPE) ≡ 1/Q(CPE)(jω)n. The two curves (one at low frequencies and the other at 
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higher frequencies) are likely to be associated with the electrochemical double layer and 
with the polymer itself. For the blank measurement of the sample shown in Figure 4.19 
with a 1.0 mm radius, the fitted values are R1 = 0.419 kΩcm2, R2 = 11.0 kΩcm2, 
C1 = 86.9 µFcm2, QCPE = 4.00 µFsn-1cm2 and n = 0.774, which corresponds to an 
estimated capacitance value of C2 = 0.620 µFcm-2 by using the conversion 
C2 = (R2QCPE)1/n/R2.42 The high values of charge transfer resistance (R2 = 
11.0 kΩcm2) observed for the system, are compatible with the presence of the insulating 
polymer and the electrical potential barrier created by the negative charge of the 
aptamers towards the negatively charged redox markers in solution.  
Impedance is defined as a combination of real and imaginary part of impedance: 
𝑍∗ = 𝑍! + 𝑗𝑍"                  (4.4)	  
Given the high impedance values of the system, a better evaluation of the capacitance of 
the system can be obtained by defining a complex capacitance43,44:  
𝐶∗ = 𝐶! + 𝑗𝐶" ≡    1𝑗𝜔𝑍 = − 𝑍"𝜔 𝑍 ! − 𝑗 𝑍!𝜔 𝑍 !             (4.5)               
Due to the high impedance values of the system and the relatively low exponent n of the 
CPE, estimation of the capacitance of the system through fitting of the data with an 
equivalent circuit yields large errors. The errors are then exacerbated by the calculation 
of the capacitance through the fitted values of the constant phase element. Therefore, the 
measured impedance at a fixed frequency (1 Hz) was used as the signal so that the 
evolution of the electrochemical response could be monitored without the need for 
fitting the data. The capacitance, calculated as C* = -1/jωZ” at 1 Hz, was used for 
plotting the dose response with the apta-MIP. The capacitance plots are characteristic of 
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a certain system and provide us with information on the nature of the electrochemical 
reaction occurring at the surface. Figure 4.20 shows the Cole–Cole capacitance plots at 
higher frequencies before and after PSA binding events and measurable changes in the 
capacitance can be observed upon PSA interaction with the sensor. On addition of PSA, 
it can be seen from Figure 4.19 that a greater change (≈ 60 %) is observed at higher 
frequencies indicating a fast capacitive process, followed by another curve at lower 
frequencies (inset) which could be a result of a slow capacitive process (dominated by 
diffusion of an analyte). 45 The second curve that appears at lower frequencies shows an 
increase in capacitance of the system with increasing amount of PSA, which could be 
associated with the increase in conductive pathways of the apta-MIP polymer layer due 
to screening of the aptamer charges. This is a widely reported response of an 
impedance-based (biolayer containing) sensors when using redox markers such as 
Fe(CN)63−/4−in solution.43,44 
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Figure 4. 19: Capacitance plots showing changes in capacitance of the apta-MIP and apta-NIP 
sensor for different concentration of PSA. The DNA aptamer folds into its conformation on 
binding to PSA which leads to increase conductive pathways for the redox couple leading to 
increase in capacitance the apta-MIP sensor. 
It is hypothesised the negatively charged DNA aptamer as well the polymer pose an 
electrostatic potential barrier to the negatively charged redox marker (Fe(CN)63−/4−). 
This causes resistance to the flow of redox markers to the sensor surface.  When the 
aptamer binds to PSA the aptamer folds thus screening the negative charge, and 
allowing easier flow of redox markers.17 This could explain the decrease in impedance 
of the system as PSA binds to the apta-MIP sensor (Figure 4.18).  
The apta-MIP and apta-NIP sensor PSA dose response plots are shown in Figure 4.20. 
All measurements were normalised to the baseline signal after achieving stability. The 
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apta-MIP sensor incubated with 0.1 pg/ml showed a capacitance change of 5 % while 1 
µg/ml showed a signal change of about 47 % showing high sensitivity in terms of sensor 
response. The apta-MIP sensor showed a linear response from 100 pg/ml to 100 ng/ml 
PSA, which covers the clinical range of PSA (4-10 ng/ml) for prostate cancer 
detection.46 All protein-rebinding experiments were conducted in the presence of 0.05 % 
TWEEN 20 to prevent any non-specific interactions. The DNA aptamers (in the absence 
of PSA) immobilised on gold surface embedded in electropolymerised polydopamine 
were used as the control or apta-NIP. The apta-NIPs showed a decrease in capacitance 
with a signal change of just 6 % when incubated with 1 µg/ml PSA, which could be due 
to non-specific interaction of the protein with the polydopamine. The low signal change 
for apta-NIPs could be a result of densely packed polydopamine with the DNA aptamer 
posing a significant diffusional barrier to PSA. It is proposed that during polymerisation, 
in absence of PSA, the aptamers lie flat on the electrode surface and subsequently get 
buried in the polymer preventing any interaction with PSA. 
The PSA aptamer used in this study was investigated by a collaborating group for 
development of an electrochemical aptamer only sensor.17 The aptamer alone sensor had 
limit of detection of 1 ng/ml PSA, which was 100 fold lower than the apta-MIP sensor. 
The aptamers were co-immobilised with sulfobetaine molecules (using different 
aptamer/thiol ratios), as an anti-fouling chemistry for covering any free gold surface and 
preventing non-specific binding of proteins. Although, the aptamer alone sensor does 
not have the same aptamer distribution as compared to apta-MIP due to difference in 
immobilisation strategies, it is hypothesised that the aptamer distribution would be close 
Chapter 4                                       Development of Hybrid Receptor for Electrochemical Detection of PSA                
  275 
to if not similar to apta-MIP to get maximum signal change upon binding to PSA. 
Hence, improved sensitivity suggests that there is an improvement in affinity of the new 
hybrid receptors when compared to aptamer alone receptor. 
The high sensitivity of the apta-MIP sensor could be result of a hybrid system exhibiting 
two levels of recognition towards PSA. The DNA aptamer has high affinity toward PSA 
while the polymeric cavity could be acting synergistically with the aptamer conferring 
shape and chemical selectivity. As PSA is a large macromolecule it is hypothesised, the 
aptamer has a small contact point where it docks to the protein after changing 
conformation as described in Section 5.2. This means that maximum interaction of the 
polymer could occur with the bulk protein allowing for non-covalent interaction such as 
hydrogen bond and hydrophobic interaction to be established during the polymerisation 
process. This could allow for the creation of highly selective polymeric cavity lined with 
an aptamer locked into its preferred conformation. This is in contrast to the aptamers for 
small molecules, which have multiple contact points leading to less interaction of 
template with the polymer during the imprinting process and the binding being 
dominated by the aptamer only as demonstrated in imprinting of hybrid MIP 
nanoparticles for cocaine.3 The polymer thickness also contributes to the imprinting 
effect as we see a loss in recognition with 7 cycles of polymerisation. The thickness 
determined by AFM (9 -10 nm) suggests that there is potential for significant interaction 
between PSA and polydopamine for the formation of the specific cavity. Additionally, 
growth of the polymer post binding of PSA and the aptamer leads to protection of the 
aptamer-protein interaction site preventing any hindrance during re-binding. After the 
protein is released it is hypothesised the aptamer is locked in its most favourable 
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conformation hence thermodynamically lowering its Gibb’s free energy. When the PSA 
is re-introduced it is thermodynamically favourable for it to bind to cavity with the 
aptamer resulting is higher sensitivity. Furthermore, a 100-fold increase in sensitivity 
from an aptamer alone sensor strongly suggests that the affinity of the new aptamer-MIP 
receptor is greater than the affinity of the aptamer alone system.  
 
Figure 4. 20: Dose response of apta-MIPs (blue) and apta-NIPs (green) with different 
concentrations of PSA. The apta-MIP sensor shows an increase in capacitance with different 
concentration of protein while the apta-NIP shows a negligible response to PSA. The horizontal 
pink line represents the baseline signal obtained after stabilisation of the sensor. 
To ensure that the apta-MIP sensor response was a result of an imprinting effect and not 
due to protein-protein interaction with any residual PSA trapped in the polymer, apta-
MIPs were washed only with water so as to retain the protein in the polymer. A control 
polydopamine layer without any PSA was washed with water to understand the effect 
washing on the polymer. It can be observed from Figure 4.21 that there was no change is 
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CV of the polymer pre and post washing suggesting that the polymer remains intact. It 
was known from the PSA extraction optimisation studies that PSA was difficult to 
extract without fairly harsh washing steps indicating that the protein was intact in the 
polymer layer.  
 
Figure 4. 21: Polydopamine coated electrode washed only with water shows negligible change 
in cyclic voltammetry curves before and after washing indicating no removal of polydopamine. 
PSA was introduced at the same concentrations to see if the apta-MIP sensor showed a 
response. Figure 4.22 demonstrates that apta-MIP sensors washed with water showed no 
response to PSA with a maximum signal change of 1.3 % confirming that the response 
was not a result of protein-protein interaction but due to steric and chemical selectivity 
of the apta-MIP hybrid polymer.  
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Figure 4. 22: The blue curve represents the apta-MIP sensor response to PSA while the black 
curve is the apta-MIP PSA response without extraction of PSA. It can be seen when PSA is not 
extracted from the apta-MIP there is a significantly decreased response on addition of PSA 
suggesting that protein-protein interactions do not play a role in the recognition of PSA. 
4.4.4.2. Determining the dissociation constant (Kd) of the Apta-MIP system. 
A number of different models were used for deducing the apparent Kd of the hybrid 
polymer system. One of the most basic adsorption model is the Langmuir adsorption 
model, which assumes one site specific binding and relies on saturation capacity (B) and 
equilibrium constant (K). 47,48 The model however does not take into account any 
binding site heterogeneity that commonly exists within molecularly imprinted polymer 
systems, leading to sites of different affinities and selectivity.49 The Freundlich-
Langmuir (FL) model, which is a combination of Freundlich and Langmuir adsorption 
models, takes into account this heterogeneity observed with most MIP systems.50 In the 
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FL model, saturation capacity (B) and equilibrium constant (K) are the same, however n 
(0<n<1) is the heterogeneity factor. The equation used for this model is, 
𝐵 = 𝐵𝑚𝑎𝑥 𝐾𝐹𝐿𝐶 !1+ 𝐾𝐹𝐿𝐶 !                 (4. 2) 
where; C = Concentration, B = amount of protein bound, Bmax = maximum protein 
bound, KFL = 1/Kd. Applying the FL model to the apta-MIP sensor data produced the 
isotherms shown in Figure 4.24. The R2 value obtained using this model was 0.998. The 
apparent Kd value obtained was 0.3 nM, which was much lower than the aptamer alone 
sensor 2 nM (Figure 4.23).  
 
Figure 4. 23: FL model applied to the dose response data. The data is shown on linear as well 
as logarithmic scale. The dose response curve fits well with the model (R2 value of 0.99).  
The Imprinting Factor (IF) is defined as the amount bound by MIP divided the amount 
bound by NIP, which is also known as the selectivity factor.51 As the polymer had a 
biomolecule (aptamer) incorporated in it, the selectivity is much higher than 
conventional polymer only systems as an IF of 7.8 was obtained for the apta-MIP 
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sensor. This value is similar to that reported for the hybrid mannose - polymer MIP 
system.4 
4.4.5. Conventional molecular imprinting of PSA 
A standard protocol to fabricate conventional electrochemical MIP sensors is to 
solubilize the template in the monomeric solution and subsequently apply a potential to 
deposit a polymer on the electrode surface. The template gets trapped into the polymer 
during polymerisation, which upon extraction leaves a cavity, which displays an affinity 
and selectivity for the template. This process works very well with small molecules as 
they can be mixed at known molar ratios with the monomer for maximum template 
entrapment and subsequent extracted. A similar protocol has also been applied for 
surface protein imprinting with higher concentration of protein (1-10 mg/ml) being used 
to ensure maximum entrapment of protein and creation of binding sites.52,53 This 
however may not feasible in certain cases where protein templates are expensive (PSA) 
or difficult to purify in large quantities. Studies were undertaken to understand the 
performance of the apta-MIP sensor versus conventionally prepared MIPs (without the 
aptamer and surface immobilisation of PSA) on gold surfaces. For the purpose of direct 
comparison between the conventional system and the apta-MIP sensor, the protein 
concentration was maintained at 1 µg/ml.  The conventional MIPs showed a poor 
response when compared to apta-MIP sensors with a maximum signal change of 2 % 
when incubated with 1 µg/ml PSA (Figure 4.24). One reason for this could be the 
absence of any aptamers displaying high affinity towards PSA in the MIP sensor and 
second being poor entrapment of PSA into polymer during electropolymerisation. 
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Considering only some liquid is in contact with the electrode surface where the 
electrochemical reactions are occurring the amount of protein getting trapped is going to 
be less than that present in the bulk liquid. A large degree of variation was observed in 
the rebinding experiments (see error bars in Figure 4.24 inset), which is strongly 
suggestive of binding site heterogeneity. Conventional protein imprinting does not allow 
for creation of homogenous binding sites as the template is not uniformly presented at 
the surface nor evenly distributed through the polymer layers, leading to binding cavities 
of varying depth and shapes.54 This could further lower the sensitivity of the 
conventional MIP sensor. Preparation conventional MIP sensors may require longer 
incubation times and higher protein concentrations for imprinting to show significant 
signal change as a result of the imprinting effect. Although this comparison study is not 
perfectly designed, as we are not comparing conventional monomer imprinting or an 
optimised template concentration for imprinting, it does point towards various 
shortcomings of conventional imprinting protocols that one needs overcome when 
imprinting proteins. This study also suggests that the immobilisation technique used for 
imprinting in the hybrid MIP system is more efficient than conventional imprinting for 
sensitive protein detection 
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Figure 4. 24: Comparison of conventional MIP (red) and apta-MIP (blue) sensor performance 
with different concentrations of PSA. The inset shows the magnified response data from 
conventional MIP sensors. The conventional MIP shows low signal change in comparison to 
apta-MIP and high error bars, possibly indicative of increased heterogeneity in the binding site 
population. 
4.4.6. Apta-MIP evaluation with control proteins 
4.4.6.1. Selectivity study with hk2 
To evaluate the selectivity of the apta-MIP sensor, a control protein was introduced to 
the system in a non-competitive assay. The control protein used in the study was human 
kalikrien2 (hK2), which is a kallikrein family protein sharing 80 % homology with 
PSA.55 This protein although found in 100 fold lower concentration than PSA in clinical 
samples was a stringent control to check apta-MIP sensor selectivity than a more generic 
protein like BSA. On challenging the apta-MIP sensor in a non-competitive assay, hk2 
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showed a much lower response approximately 15 % compared to 45 % signal change 
upon incubation with 1 µg/ml PSA (Figure 4.25).  
 
Figure 4. 25: Selectivity study of apta-MIP with different concentrations of hK2 (red) and 
respective PSA concentrations (blue). A lower response was observed with hK2 than PSA 
following incubation with apta-MIPs in a non-competitive binding assay. 
To understand the source of cross-reactivity the ‘aptamer only’ sensor’s response to hK2 
was studied. This demonstrated a signal change (Rct) of 1.6 %, when incubated with 
100 ng/ml of hk2 suggesting high selectivity of the aptamer for PSA.17 Due to the 
absence of a polymeric layer in the aptamer alone sensor capacitance change at lower 
frequencies could not be measured, hence a ratio of the signal change of PSA versus 
hK2 was obtained based on the assumption that both signal changes are a result of 
specific interaction only. The PSA aptamer only sensor had signal ratio of 0.18 
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(PSA/hk2) while the aptamer-MIP system signal ratio was 0.28 (Figure 4.26(a)). This 
suggested that the cross-reactivity was not a result of hK2 interacting with the DNA 
aptamer, but a combination of interaction with the MIP cavity and polydopamine.  
 
Figure 4. 26: hK2 cross-reactivity with the aptamer-MIP was compared with the aptamer 
sensor. The aptamer only sensor (b) showed a lower hK2/PSA ratio than apta-MIP sensor (a) 
indicating an increased cross-reactivity to hk2 with the apta-MIP sensor. 
The source of cross-reactivity in apta-MIP could be is could be explained by the 
mechanism of aptamer interaction with PSA as elaborated in the Section 4.2. The DNA 
aptamer relies on highly specific interactions between amino acids and nucleotides in a 
small region of the protein making the binding event highly specific to a protein. It is 
proposed that during the imprinting process the polymer first surrounds the lower 
portion of the protein where it binds the aptamer and as the polymer thickness increases 
it surrounds the protein, allowing for establishment of more non-covalent interactions 
between polymer and protein. As a result, the more specific interaction of the aptamer is 
possibly dominated by non-covalent interactions of the polymer. As most non-covalent 
bonds formed with the polymer are a result of general hydrogen bonds and given the 
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significant homology with PSA, it is not surprising that hK2 cross reacts with the MIP 
cavity. This is also observed in antibody assays where antibodies raised for PSA cross-
react with hK2 due to similar epitopic regions.56 This could be improved in the future by 
using electroactive monomers/ conventional monomers with alternative functional 
groups giving rise to higher differentiation capacity to MIP cavity. Additionally from a 
clinical point of view the concentration of hK2 is 100 fold lower in blood compared to 
PSA, which would prevent major interference from hK2 to PSA binding.57  
To further distinguish the source of cross reactivity, hK2 was incubated with 
polydopamine only (apta-NIPs) to understand non-specific binding to the polymer. Hk2 
showed a signal change of about 1.5 % (Figure 4.27) with polydopamine, which 
indicates that remaining response could be a result of cross-reactivity with the binding 
sites. The decrease in capacitance can be explained by increase in impedance 
(resistance). As the protein sticks to the polymer non-specially it provides resistance to 
the diffusion of the redox couple through an already insulated polymer layer causing an 
increase in resistance. This behaviour is observed in most EIS sensors where binding of 
proteins to surface immobilised receptor causes an increase in resistance.58,59 Protein 
cross-reactivity is not uncommon in MIP sensors due to shape of the MIP cavity. 
Moreover, a competitive binding assay will help us better understand the ability of the 
hybrid apta-MIP sensor to discriminate between PSA and hk2, however a labelled 
technique would be required to carry out such experiments for discriminating the two 
proteins which is expensive. 
 
Chapter 4                                       Development of Hybrid Receptor for Electrochemical Detection of PSA                
  286 
 
Figure 4. 27: Hk2 reactivity with apta-NIP sensor (purple) shows a signal change of 1.5 % 
showing low cross-reactivity to the polymer. The decrease in capacitance was similar to that 
observed with PSA with apta-NIPs (black) 
4.4.6.2. Selectivity study with HSA 
Another key aspect to take into account is the investigation of antifouling properties of 
the fabricated apta-MIP sensor for its application with blood samples. Human serum 
albumin (HSA) was used as a control protein to study non-specific binding, as it is one 
of the major constituents of human blood (3.5-5.0 g/dL) and helps us to understand 
whether the apta-MIP sensor could be used with clinical samples. HSA at 0.1 µg/ml and 
1 µg/ml showed signal changes of 3 % and 5 % respectively (Figure 4.28). HSA is a 
negatively charged protein at pH 7.4,60 which could lead to electrostatic repulsion 
between the polymer DNA layer and the protein leading to low signal change. When 
tested at higher concentrations of 6.7 mg/ml, HSA showed a maximum capacitive 
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change of 11 %, which could be a result of non-specific interaction with polymer as well 
as protein-protein interactions. The low signal change is beneficial as HSA is a large 
protein which is abundantly found in blood and usually lowers the sensitivity of 
biosensors.61 HSA interaction with apta-NIPs was similar to PSA interaction with apta-
NIPs showing negligible change at lower concentrations and an increase in capacitance 
with a signal change of 3.5 % at the highest concentration of 6.7 mg/ml HSA, however, 
further studies PSA spiked serum are required to help understand the potential for loss in 
sensitivity in clinical samples. Regardless, the low non-specific binding of HSA at very 
high concentrations is very encouraging for application of the apta-MIP sensor in 
measuring clinical samples.  
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Figure 4. 28: Apta-MIP response to HSA (blue) shows some non-specific binding at higher 
concentrations of HSA. A signal change of 11 % is observed for HSA concentration of 6.7 mg/ml 
with apta-MIPs. Apta-NIPs showed a lower response to HSA (purple), which is mostly due to 
absence of polymeric cavities. 
4.5. Challenges Associated With Sensor Evaluation 
Dissociation constants (Kd) could not be estimated using conventional bound vs free 
isotherms as it is difficult to estimate the actual concentration of protein bound to the 
apta-MIP sensor in these experiments. A labelled antibody or a labelled protein is 
required to estimate total amount of protein bound. Furthermore, even if a labelled 
antibody was used for detection PSA, it would difficult for it to bind to PSA entrapped 
in the polymer. A secondary technique such as SPR (surface plasmon resonance) or 
QCM (quartz crystal microbalance) could also be used to evaluate and validate apta-
MIP sensor performance in the future. The best way to find if the polymer contributed 
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towards the affinity of apta-MIP would be use the same protocol for fabricating the apta-
MIP sensors and substituting the aptamer with a molecule that has no affinity for PSA. 
This could be conducted using alkanethiols for immobilising PSA via EDC/NHS 
chemistry. However, this is challenging due to overcrowding of thiols on gold surface 
preventing polymerisation of polydopamine and subsequent removal protein would 
require enzymatic digestion due to covalent binding. Another technique that could be 
evaluated would be to use a peptide to create hybrid-MIP receptor for PSA and compare 
the two systems (This work is still on-going at University of Bath). 
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4.6. Conclusion 
The study presents the successful use of the aptamers in the application of imprinting 
PSA for building a sensitive electrochemical sensor. The apta-MIP receptor developed 
in this study was highly sensitive with LOD of 1 pg/ml, which is well below the clinical 
range. The apta-MIP receptor is also 100 times more sensitive to the aptamer alone 
sensor highlighting the advantage of imprinting. Furthermore, the low cross-reactivity 
with homologous protein suggests high selectivity of the sensor. The low non-specific 
binding to high concentration serum proteins is highly encouraging for future clinical 
use. There has been a significant amount of work published in the field of protein 
imprinting. However, some of the challenges have remained such as imprinting 
homogenous binding sites, attaching the polymers to transducer surface, controlled 
polymerisation and efficient removal of the template. Researcher has overcome some of 
these hurdles whereas some remain to be solved. Hybrid imprinting helps overcome 
majority of these challenges creating a new brand of synthetic receptors that can be aptly 
termed as ‘super-receptors’. The apta-MIP receptor developed in this project is one such 
step towards creating the next generation of receptors for clinically relevant biomarkers. 
The apta-MIP sensors can be easily adapted for various templates with existing aptamers 
to make a multiplexed biosensor or by using different affinity receptors for imprinting.  
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5.1. Introduction 
5.1.1. General overview 
The chapter extends the application of hybrid imprinting to metal-oxide-semiconductor 
field effect transistor (MOSFET) devices. MOSFET devices are more sensitive than EIS 
sensors and provide scope for miniaturisation. PSA sensing with MOSFET devices was 
carried out in order to investigate the compatibility of the hybrid-MIP system with a 
different sensing platform and to explore improvement in sensitivity of the apta-MIP 
system. Additionally, encouraging results with human serum albumin (HSA) of the apta-
MIP EIS sensor led to the testing of PSA in human plasma to explore the potential for 
clinical applications. 
5.1.2. MOSFET devices: 
Field effect transistors (FET) are semiconductor devices made up of two highly 
conducting regions separated (source and drain) by a channel, whereby the potential 
applied to an external gate controls flow of current between the two conducting 
channels.1 There are various types of FETs of which metal-oxide semiconductor FET 
devices are the most popular, finding use in practically every electronic appliance today 
(for data processing and storage). 2 MOSFET devices have also found applications in 
biosensing as a result of their stability, sensitivity and scope for miniaturization.3, 4  
There two types of semiconductor FET devices: n-channel and p-channel depending on 
the type of charge carriers present in the conducting channel. The charge carriers of the 
conducting channel constitute an inversion charge, that is, electrons in the case of a p-
type substrate (n-channel device) or holes in the case of an n-type substrate (p-channel 
device), which can be obtained by manufacturing the device with different impurities that 
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control the amount and type of charge in the device.5 MOSFETs are made with silicon as 
the semiconductor material due to various advantages such as accessibility, ease of 
manipulation of conductivity by controlled addition of impurity and the ability to change 
charge carrier (p and n channel) by doping with different impurities.5   
A common n-channel MOSFET is fabricated on a p type substrate (silicon) with heavily 
doped n+ regions, which act as source and drain (Figure 5.1). 6 A thin layer of silicon 
oxide (SiO2) or glass (typically between 2 and 50 nm) is placed on the surface of the 
substrate, between the drain and the source regions, which acts as the insulator from the 
gate electrode. Metal or polysilicon (which is a conductor) is deposited on top of the 
silicon oxide layer to form the gate electrode. Metal contacts are also made in the source 
and drain regions (Figure 5.1) to form three channels: source, drain and gate. The current 
that flows from source to drain is then controlled by application of voltage on the external 
gate terminal (Figure 5.1). To put in simple terms the flow of charge in a MOSFET 
device can be compared to tank carrying water, which is separated into two sections 
(source and drain terminal) by a barrier in the middle (gate terminal). When the barrier is 
closed there is no flow of water between the two sections of water, but when the barrier is 
opened (external voltage), water flows from higher to the lower section much like flow of 
charge in MOSFET devices. 
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Figure 5. 1: Schematic of n-MOSFET device containing the source and the drain through which 
current flows when an external voltage is applied across the gate terminal 
In a simple n-type MOSFET device the source terminal and the body of the device are 
grounded. The gate and drain voltages are applied with respect to the source. Under DC 
conditions, the source and drain are separated by the p-type substrate, which prevents 
flow of electrons between the two terminals. This is also termed as the cut-off mode. 
When a suitable external voltage is applied through the gate terminal (Vgs), the barrier to 
flow of current is lowered and electrons flows through the semiconductor channel as can 
be seen in Figure 5.2.6 The onset of current flow is defined in terms of threshold voltage 
(Vt), which is the minimum voltage (applied with respect to other terminals) required to 
induce the inversion charge.5 When Vgs is greater that Vt and a potential (Vds) is applied 
at the drain terminal (Vds > 0), current starts flowing through the channel, which is 
denoted as ‘Id’. The electrons pass from the source to drain though the channel, while no 
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current flows through the gate (gate current or Ig = 0). Gate current is zero because the 
gate is insulated from the conducting channel. Increasing the amount of Vds increases the 
channel conductivity, which leads to increase in source-drain current (Id) following 
Ohms law. This mode is also called the triode mode. Ohm’s law is followed till (Vgs-Vt) 
> Vds, inducing the electrons to flow from source to drain. However, when (Vgs-Vt) < 
Vds, there is competition between gate and drain to attract the electrons leading to a 
pinch-off condition (end of Ohm’s law) as seen in Figure 5.3.5 As drain attracts more 
electrons due to higher voltage the channel conductivity is diminished, however as a 
result of potential different between the source and the drain a constant current (Id = 
constant) flows through the channel, which is also called the saturation current. This 
mode is termed the saturation mode.5,6  
 
Figure 5. 2: Induced channel created as a result of Vgs applied at the gate terminal. 
There are three modes of operation for MOSFET devices as seen in Figure 5.3: 
1) A cut-off mode, Vgs-Vt < 0, no induced channel is created hence no flow of current;  
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2) Triode mode, Vgs-Vt > Vds > 0, current flows through the induced channel 
proportional Vds;  
3) Saturation mode, 0 < Vgs-Vt < Vds , Id current becomes constant 
 
 
Figure 5. 3: Id vs Vgs characteristic of MOSFET devices with three modes of operation: cutoff, 
triode and saturation. 
5.1.3. Application of a MOSFET device in biosensing 
MOSFET devices have been used for detection of various biomolecules such as DNA7, 
proteins8, small molecules9 and cells10 in the field of biosensing. For the purpose of 
biosensing, bio-receptors need to be immobilised on the surface of the MOSFET devices. 
The surface used for immobilisation is usually the gate terminal, which modulates the 
channel conductivity. The interaction of the bio-functionalised gates with the analyte of 
interest changes the effective surface potential of the gate terminal (open circuit potential) 
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due to changes in charge density and charge distribution of the immobilised biolayer.11 
The change in surface potential at the gate in turn modulates the channel conductivity 
causing changes in the current between source and drain terminal. This change in channel 
conductivity can be easily measured and is directly proportion to the amount of analyte 
bound to the receptor at the gate terminal. Non-covalent or covalent immobilisation of 
bio-receptors directly on the gate terminal has been widely reported in the literature for 
biosensing.11,12,13 However, this setup faces certain disadvantages like low environmental 
stability and lack of flexibility in chemical modification of the gate surface. An 
alternative strategy that is utilised is the use of an extended gate for immobilisation of 
biomolecules. The extended gate set up permits the incorporation of biocompatible 
surfaces to facilitate easy bio-functionalisation of the gate surfaces.14 The use of extended 
gate surface leads to improved stability of the MOSFET device, which permits sensitive 
detection of biomolecules. The extended gate setup also provides flexibility in bio-
functionalisation strategy by allowing the use of different materials like gold, titanium, 
carbon nano-tube, zinc in different configurations to be integrated with the device.9, 15, 16 
Extended gate FETs have been widely used for DNA hybridisation17, aptamer-protein 
interaction16, and enzymatic activity detection18 demonstrating wide application in field 
of biosensing. One significant advantage of MOSFETs is their suitability for use in 
miniaturized measurement systems, thereby allowing ease of integration with electronic 
readouts12. In this regard, a bio-FET device could be applicable to a range of point-of-
need healthcare applications. 
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5.1.4. Apta-MIP on MOSFET devices 
Chapter 4 developed and explored the use of impedance-based sensors for aptamer hybrid 
imprinting strategy for detection of PSA. Although a highly sensitive biosensor was 
developed for detection PSA, the sensor suffered from certain drawbacks such as low 
stability due to the use of redox couple solution (photosensitive), low scope for 
miniaturisation and difficulty integration with point-of-care electronic systems. MOSFET 
devices on the other hand overcome some of these drawbacks and have not been well 
studied for molecular imprinting in the literature. A recent report by Z. Iskierko et al. 
demonstrated the integration of electropolymerised bis(bithiophene) molecularly 
imprinted polymers (MIPs) within extended field effect devices for sensitive detection of 
inosine.19 The MIP-FET sensor reported an imprinting factor 4.9 with limit of detection 
(LOD) of 0.62 µM, which is suitable for inosine detection in biological samples. The 
study highlighted the advantages of using MOSFET for molecular imprinting application. 
Protein imprinting with MOSFET devices has not been explored yet, hence MOSFET 
with apta-MIPs were fabricated to test their suitability for MIP sensing. It was 
hypothesised that the MOSFET devices would be more stable and sensitive than 
impedimetric sensors, allowing for detection of PSA in diluted biological samples. Figure 
5.4 shows the development of apta-MIP on gold electrodes that were integrated into the 
extended gate MOSFET device setup. 
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Figure 5. 4: (a) In the first step the gold surface was functionalised with PSA-aptamer complex in 
a flow cell followed by electropolymerisation of polydopamine on surface to imprint the aptamer-
PSA complex (b) Post imprinting, PSA was extracted using detergent and acid to expose the 
imprinted site (c) The electrodes modified with apta-MIP were then utilized in an extended gate 
MOSFET setup to check for rebinding of PSA. 
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5.2. Aims And Objectives 
Chapter 5 extends apta-MIP hybrid impedance sensing on field effect transistor devices 
(FET). The overall aim of this chapter is to fabricate a MOSFET apta-MIP sensor and 
evaluate the sensor’s sensitivity and selectivity. 
Main objectives are chapter 5 are: 
1. Evaluation of MOSFET for apta-MIP PSA sensing. 
2. Comparison with aptamer alone MOSFET sensor. 
3. Comparison of MOSFET apta-MIP sensor’s performance to EIS apta-MIP sensor 
from Chapter 4. 
4. Detection of PSA in human plasma to understand fouling by serum proteins. 
4.4.  
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5.3. Materials And Methods  
5.3.1. Reagents: 
Thiol terminated DNA aptamer with the sequence (5’-HS-(CH2)6-TTT TTA ATT AAA 
GCT CGC CAT CAA ATA GCT TT-3’) was obtained from Sigma Aldrich, UK. Prostate 
specific antigen (PSA) was obtained from Merck Chemicals Ltd, UK. Human glandular 
kallikrein 2 (hK2) was obtained from RnD systems, UK. Human plasma albumin (HSA), 
dopamine hydrochloride, trisma base, mercaptohexano (MCH), concentrated sulphuric 
acid, potassium phosphate monobasic solution (1 M), potassium phosphate dibasic 
solution (1 M), potassium hexacyanoferrate (III), potassium hexacyanoferrate (II) 
trihydrate, hexaammineruthenium (III) chloride, tween 20, potassium chloride and 
magnesium chloride were all purchased from Sigma–Aldrich, UK. All reagents were of 
analytical grade. All aqueous solutions were prepared using ultra-pure water 18.2 MΩ cm 
from Milli Q system with Pyrogard filter (Millipore, MA, USA). Gold working 
electrodes were obtained from CH Instruments, USA and mechanical electrode polishing 
kit from Buehler, UK. 
5.3.2. Gold slide electrode preparation 
Evaporated gold electrodes (Figure 5.5) were prepared in-house on glass slides supports 
using a thermal evaporator (BOC Edwards, UK). The process was performed under fine 
vacuum (2.0×10-6 mbar) consisting of an initial deposition of 20 nm of chromium on 
glass followed by a deposition step of a thicker layer (usually between 100 and 200 nm) 
of gold. Chromium was used for easy adhesion of gold to the glass surface and thickness 
of gold was determined based on uniform coverage of gold and to prevent lift off during 
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the washing process.20 The slides were washed with ethanol and water before being used 
for apta-MIP preparation. 
 
 
Figure 5. 5: Gold evaporated electrodes used in apta-MIP electrode preparation 
5.3.3. MOSFET experimental setup 
Colleagues at the University of Bath fabricated the MOSFET devices. The extended gate 
was produced by connecting modified gold electrodes immobilized in a reaction cell to 
the gate of the n-MOSFET device via a metal wire (Figure 5.4). n-MOSFETs were made 
using 0.8 µm semiconductor switch from AMS Technologies, Germany. The threshold 
voltage (Vt) of the transistor was determined to be 0.82 V and transconductance 
calculated was 69 µA/V. The length-by-width ratio of the transistor was 10:2 µm. The 
terminals of the transistor were provided with diode protection circuitry and were 
packaged in a standard complementary-metal-oxide-semiconductor (CMOS)_ chip. A 
voltage of 50 mV was applied between the drain and source (Vd or Vds) to operate the 
transistor and the gate-source voltage (Vgs) was swept from 0.0 to 5.0 V. These settings 
prevented the current from increasing more than 75 µA, avoiding any changes in Vgs by 
heating. All electrical measurements were conducted using an Agilent B1500A 
semiconductor device analyzer. Detailed information on the specifications of the CMOS 
chip can be found in the literature.21 
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5.3.4. Apta-MIP fabrication and sensor performance 
The apta-MIPs were prepared using the protocol provided in Chapter 4, section 4.3.3. 
Briefly the apta-PSA complex was immobilised on the gold electrodes followed by 
electropolymerisation of dopamine. This was followed by extraction of PSA with acetic 
acid and SDS. The electrodes were extensively washed with water to remove residual 
acid/SDS before incubating with PBS pH 7.4 for stabilising the electrodes. Apta-NIPs 
were prepared in the same manner in the presence of aptamer but in the absence of PSA. 
The gold evaporated electrodes modified with apta-MIPs were immobilised in a flow cell 
(Figure 5.6) and then connected to the MOSFET device. Three stability measurements 
were conducted in PBS (pH 7.4) before incubating electrodes with PSA. Increasing 
concentration of PSA (0.1 fg/ml to 1 µg/mL) in PBS (pH 7.4) was incubated for half an 
hour on the electrodes. Post incubation, PSA solution was removed and electrodes were 
rinsed with PBS before measuring the response using the extended gate MOSFET setup. 
For detection of binding, a voltage of 50 mV was applied between the drain and source 
(Vd or Vds) to operate the transistor and the gate-source voltage (Vgs) was swept from 
0.0 to 5.0 V. All electrical measurements were conducted using an Agilent B1500A 
semiconductor device analyzer. Measurements for all experiments were recorded for 4 
different devices. 
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Figure 5. 6: Gold evaporated electrodes immobilised in a flow cell for electropolymerisation of 
dopamine. The electrodes were fixed in the flow cell and all binding experiments were conducted 
in situ. 
5.3.5. Control studies with hk2 protein 
For control studies 1µg/ml PSA was incubated with apta-NIP for 30 minutes before 
measuring the response. hK2 protein at a concentration of 1µg/mL was used to 
understand cross-reactivity of the apta-MIP sensor. 
5.3.6. Aptamer/MCH immobilised electrode for PSA binding 
Experiments with PSA aptamer alone were performed using the same gold evaporated 
electrodes following the protocol reported previously in Chapter 4. Briefly, electrodes 
were exposed to thiolated DNA aptamer/6- mercapto-1-hexanol (MCH, Sigma, U.K.) 
immobilization solution for 16 h in a humidity chamber. An optimized (1:100) DNA 
aptamer to total thiol was used to fabricate the biosensor. A high concentration of MCH 
was prepared in ethanol, which was diluted to working concentrations in 10 mM PBS 
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(pH 7.4). Prior to addition of MCH, DNA aptamers were heated to 95 °C for 10 min 
followed by gradual cooling over 30 min to room temperature. After immobilization, 
electrodes were rinsed with excess Milli-Q water to remove unattached thiols. In order to 
ensure complete thiol coverage of the gold surface, the electrodes were thereafter 
backfilled with 1 mM MCH for 1 h. Electrodes were then rinsed with Milli-Q water and 
placed in the 10 mM PBS (pH 7.4) for stabilization 
5.3.7. PSA binding study in human plasma  
For plasma experiments, blood obtained from a healthy female volunteer was spun down 
in a centrifuge (3200 rpm, 20 min) to remove the red blood cells. The resultant plasma 
was diluted 1000 times in a PBS buffer of pH 7.4 and then spiked with varying 
concentrations of PSA (1, 5, and 10 pg/mL PSA). For detection of binding, a voltage of 
50 mV was applied between the drain and source (Vd or Vds) to operate the transistor 
and the gate-source voltage (Vgs) was swept from 0.0 to 5.0 V. All electrical 
measurements were conducted using an Agilent B1500A semiconductor device analyzer. 
Measurements for all experiments were recorded for 4 different devices. 
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5.4. Results And Discussion 
5.4.1. Apta-MIP fabrication and PSA binding study 
The electrode fabrication process was kept consistent with the optimised apta-MIP EIS 
sensor in Chapter 4 to allow comparison between the two sensing methodologies. Dose 
response curves were generated for the apta-MIP MOSFET sensor with PSA. Fig. 5.7 (a) 
depicts the response of the device upon incubation with increasing concentrations of 
PSA. Figure 5.7 (b) shows the transfer characteristics of the device upon binding to PSA, 
demonstrating a positive shift in voltage upon introduction of PSA. Following the lag 
region of the plot, a linear response was obtained from 0.1 to 10 pg/ml of PSA after 
which no further significant change in signal was observed. A maximum voltage change 
(ΔVg) of 158 ± 42.5 mV was observed at concentration of 1 µg/mL of PSA and 
negligible changes in voltage shift was observed beyond 100 pg/ml suggesting saturation 
of binding sites. When compared to apta-NIP a change of 7.6 ± 3.21 mV (Fig. 2) was 
observed upon incubation with concentration 1 µg/mL PSA, which was 20 times lower 
apta-MIP indicating high selectivity of apta-MIPs towards the template. A high 
concentration of PSA was used with apta-NIP control to obtain maximum possible 
interaction/signal change with the sensor. The initial change of 30 mV at concentrations 
1-10 fg/mL could be an effect of PSA interacting with the apta-MIP surface. It is 
hypothesised that when PSA comes closer to the polymer surface, it causes a change in 
the distribution of charges in the bilayer leading to an initial shift in voltage. The other 
reason for initial shift in voltage could be that there are two types of binding sites present 
on the sensor surface, where high affinity binding sites fill preferentially to a population 
of lower affinity sites. The initial lower shift in voltage to analyte has been observed in 
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other FET sensors suggesting that there could be some binding (specific/non-specific) 
event occurring at lower concentration which the sensor is not able to distinguish due to 
device limitations.15 The initial change of 30 mV at concentrations between 1 and 10 
fg/mL in the MOSFET sensor could be attributed to small amounts of weak binding of 
PSA to the aptamer causing a conformational change and hence changes in the 
distribution of charges in the biolayer. Beyond 0.1 pg/ml a shift in voltage could be a 
result of PSA filling the slightly lower binding affinity sites and specifically interacting 
with the apta-MIP surface. Increase in the shift of Vgs could be a result of aptamer 
charges being screened and PSA binding to the polymeric cavity, which dominates the 
charge behaviour at the gate surface. This is consistent with other aptamer FET sensor 
where an increase voltage shift is observed upon increasing concentration of analyte.22,23 
The  current flowing through the MOSFET is based on the electric field established by 
the voltage applied to the gate electrode. Hence, the net charge of protein can modulate 
the flow of current through the device causing a shift in voltage. The FET sensors can 
detect local net-charges of PSA because of the smaller sensing depth (the Debye length) 
compared to the size of protein24. The direction of the voltage shift depends on net charge 
of PSA at pH 7.4 binding to the apta-MIP and the charge of DNA. It is hypothesised that 
upon rebinding of PSA (with a certain net charge) to the apta-MIP, there is a change in 
the electrochemical double layer and in the charge distribution of the bilayer, which 
causes a variation in the potential drop at the gate of the MOSFETs. A positive shift in 
voltage is observed upon binding of PSA to apta-MIP that corresponds to an increase in 
negative charges on the surface of the sensor; it is hypothesised that this is an effect of 
net negative charge of PSA.16 MOSFET devices also permit rapid sensing in PBS buffer 
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as there is no need to stabilize the system in redox couple solution. The lack of 
requirement of redox couple for sensing ahead of testing, which could take up to an hour 
in case of apta-MIP EIS sensors, permits rapid sensing using the apta-MIP MOSFET 
system. The apta-MIP bio-FET device was also 100 times more sensitive than apta-MIP 
impedance sensor. The increase in sensitivity could be explained by the smaller sensing 
depth (Debye length) of FET devices whereby small changes in charge behaviours can be 
easily/quickly detected upon binding of aptamer to protein.25 However, in the case of EIS 
sensor, the sensing is based on a bulk effect where the redox-couple diffuses through the 
polymer layer to detect the binding event, which could be slower, and less sensitive than 
MOSFET devices. The results from our study suggest that MOSFET devices could be a 
better platform for apta-MIP sensing that EIS, however there have not been any 
comparisons of polymeric FET and EIS sensing in the literature to support our findings.  
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Figure 5. 7:  (a) Dose response of PSA with apta-MIP FET device. (b) Transfer characteristics 
curve of apta-MIP FET device binding to PSA (Error bars represent SD, n = 4) 
In the case of the apta-NIPs, it is proposed that the aptamer lies flat on the surface in the 
absence of PSA and get buried in the polymer during the polymerisation process. In the 
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absence of a polymeric cavity PSA does not bind to the aptamer in the apta- NIP leading 
to a lower shift in voltage (Figure 5.8). This is consistent with impedance response of 
apta-NIP EIS sensor to PSA as seen in Chapter 4.   
 
Figure 5. 8: Apta-MIP response versus apta-NIP response to 1µg/mL PSA. (Error bars represent 
SD, n = 4) 
5.4.2. Control studies with hk2 protein  
To understand the selectivity of the sensor, the apta-MIP bio-FET device was subjected 
to stringent controls similar to EIS sensor by comparing the response with a homologous 
protein hK2 (80 % homologous) in a non-competitive assay. The response to 1 µg/mL 
hK2 was much lower with a change of 56 ± 13.6 mV compared to PSA (158 ± 42.5 mV) 
at the same concentration as shown in Figure 5.9. The lower hK2 response suggested that 
the apta-MIP device was more selective towards PSA. As can be observed from the 
impedance based sensors in chapter 4 the PSA aptamer reported negligible cross 
reactivity towards hK2, which therefore suggests that polymer interactions could be 
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contributing to hK2 recognition in MOSFET apta-MIP device too. The shape and 
chemical selectivity of the apta-MIP cavity, coupled with the high dependence on non-
specific hydrogen bonding likely leads to this small degree of cross-reactivity. 
 
Figure 5. 9: Apta-MIP response to 1µg/mL hK2 protein was significantly lower than apta-MIP 
response to PSA. (Error bars represent SD, n = 4) 
5.4.3. Aptamer/MCH immobilised electrode for PSA binding  
It was important to compare the apta-MIP sensor with an aptamer alone sensor to 
understand whether an improvement in affinity was achieved as a result of imprinting. 
The ratio of aptamer/thiols was chosen based on work by P. Jolly et al. to obtain even 
distribution of aptamers with maximum binding to PSA26. On comparison of apta-MIP 
with an aptamer alone FET sensor a significant increase in sensitivity was observed for 
an aptamer-MIP sensor (Figure 5.10). Aptamer only FET displayed a shift of 18 mV 
compared to 150 mV shift of apta-MIP at 1 ng/ml PSA. A negative shift in voltage was 
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observed at 0.1 pg/ml, which could be a result of non-specific binding of PSA to MCH 
SAM (self-assembled monolayer), which has been reported in literature 26,27. A positive 
shift in voltage was observed upon increasing the concentration beyond 0.1 pg/ml, 
however the response was much lower than apta-MIP sensor, suggesting an improvement 
in affinity of the hybrid receptors. Typically, low ionic strength buffers (I) are used for 
FET aptasensors that yield the solution Debye length κ−1 which allows for effective 
measurement of the intrinsic charges of the target protein by making the binding reaction 
on the surface within the electric double layer.28 The low response of aptamer only sensor 
could be a result of higher ionic strength of the buffer, which leads to screening of 
charges and a lowering of the sensor sensitivity.  
 
Figure 5. 10: Comparison of apta-MIP response to PSA with respect aptamer/MCH modified 
surface. The aptamer only device displays lower sensitivity than the apta-MIP device. (Error bars 
represent SD, n = 4) 
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5.4.4. PSA binding study in human plasma  
The sensor was further tested in human plasma to evaluate its use in clinical applications. 
Human plasma from a healthy female volunteer was used for the experiments due low 
background PSA levels. Spiking the plasma with PSA from a healthy female volunteer 
allowed for the measurement of known level of PSA in the plasma (low background 
PSA) while maintaining the ratio of PSA/plasma proteins. Plasma diluted 1000 times 
displayed very low change in signal of -2 mV as shown in (Fig. 4) which indicated good 
resistance to fouling of the apta-MIP surface by plasma proteins. The negative shift in 
voltage could be explained by the net charge of serum proteins like albumin disturbing 
the distribution of charges in the bilayer. However, the shift is negligible, which suggest 
that there is not significant interaction between the apta-MIP and serum proteins.  PSA 
concentrations between 1 and 10 pg/ml of PSA could be detected linearly in diluted 
plasma. 1 pg/ml PSA demonstrated a shift of 13 mV, which was still 2 times higher than 
the apta-NIP response at 1 µg/mL maintaining selectivity of the sensor (Figure 5.11). 
Although there was loss of recognition when compared to the response in PBS (pH 7.4), 
the results are highly encouraging due to detection of clinically relevant concentrations. 
Considering the concentration PSA in healthy men in 4 -10 ng/ml29, diluting the plasma 
by a thousand fold would enable measurement in the linear range of the sensor. The loss 
in sensitivity observed is likely explained by protein-protein interactions, which have also 
been observed in aptamer ELISA assays in serum28 and plasma30. Free PSA, which is 
derived from human plasma for the experiments, will interact with complement proteins, 
anti-chymotrypsin and albumin in plasma lowering the sensitivity of the sensor. 
However, free PSA present in the blood of patient samples is internally cleaved and 
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hence could escape interactions with anti-chymotrypsin31 potentially allowing for 
detection of PSA at a lower sensitivity. 
Nevertheless the experiment highlights the potential use of apta-MIP devices for sensitive 
detection of biomarkers in human blood at clinically relevant concentrations. The 
majority of MIP sensors have not been evaluated with human plasma due to low 
sensitivity and high non-specific binding observed with plasma proteins32,33,34. The apta-
MIP sensors demonstrated in this work are capable of detecting clinically relevant 
concentrations of protein with minimal fouling of sensor surface by plasma proteins. 
Hybrid MIP sensors may hold the key to forming the next generation of robust label free 
biosensors. The sensors were also stable at 4 0C in PBS buffer for more than 3 days 
without any observable drop in signal suggesting that these sensors could be stored for 
longer period of time. However, long-term stability measurements would be required to 
confirm these results. 
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Figure 5. 11: Apta-MIP response in 1000X diluted plasma spiked with PSA.  The sensor showed 
a lower response to PSA in diluted plasma (red) when compared to PSA in buffer (blue). The 
plasma on its own showed very little signal change (green). (Error bars represent SD, n = 4) 
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5.5. Conclusion 
In conclusion, a sensitive MOSFET apta-MIP device was developed with a higher 
sensitivity than an aptamer alone MOSFET sensor and also an apta-MIP EIS sensor. In 
addition, negligible response of the apta-MIP surface to the diluted plasma suggested 
high selectivity of the sensor towards PSA. The sensor was capable of detecting between 
1-10 pg/ml PSA in diluted plasma, which falls in the clinical range of PSA levels in men 
demonstrating potential application in clinical use. This study showcases that the 
combination of hybrid MIP receptors with MOSFET devices could help develop next 
generation of robust label free sensors that can be translated to other clinical biomarkers.
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6. Chapter: General Discussion and 
Overall Conclusions 
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6.1. General Overview Of Thesis 
Detection of prostate cancer depends primarily on early screening, which is currently based 
on detection of PSA despite various controversies surrounding the biomarker as discussed 
in Chapter 1. Looking at drawbacks of PSA, it is evident that there is an urgent need to 
look at newer biomarkers for disease stratification to help patients make informed 
decisions. The discovery of new biomarkers was outside the scope of the current project. 
However, the project could focus on building robust diagnostic platforms for currently 
available biomarkers such as t-PSA, fPSA and pro-PSA that could be then easily 
transferred to newly discovered biomarkers of PCa in the future. It was hypothesised that 
by using artificial receptors, the resulting biosensor would be more stable, robust and 
sensitive than traditional antibody biosensors. It was also proposed that integrating the 
MIPs with an electrochemical platform would allow for rapid detection of the biomarker 
and easy integration in a point-of-care device setting.  
Synthesising MIPs for protein biomarkers is a challenging task as elaborated in Chapter 1. 
Various groups have used different approaches such as bulk imprinting, epitope 
imprinting, surface imprinting, MIP nanoparticles to achieve imprinting of large 
proteins.1,2,3 However each approach has its own advantages and disadvantages, which 
need to be carefully considered before applying them for imprinting large proteins such as 
PSA. In the current work, three approaches: epitope imprinting, surface imprinting and 
hybrid imprinting were studied to imprint PSA and engineer a MIP biosensor that was 
capable of detecting PSA at clinically relevant concentrations and in clinically relevant 
media. The merits of each approach and further suggestions have been discussed in this 
section. 
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The initial work in Chapter 2 focussed on molecular imprinting of short PSA epitopes to 
screen monomers and understand imprinting efficiency using conventional bulk imprinting 
methods. This was the simplest approach to molecular imprinting of a large and complex 
biomolecule like PSA as the epitopes sequences could be readily synthesised in the 
laboratory and imprinted using fairly inexpensive monomers. A four amino acid epitope 
sequence (VANP) from C-terminus of PSA was selected for epitope imprinting. However, 
initial solubility studies demonstrated that the peptide was not soluble in non-polar 
solvents. As a result, DMSO was used a co-solvent with acetonitrile to imprinting VANP 
with MAA and AAm as the functional monomer. MAA and AAm demonstrated an 
apparent Kd of 102 µM and 154 µM with imprinting factors of 2.62 and 2.02 respectively. 
It was proposed that the low affinity could be a result of imprinted cavity relying heavily 
on hydrogen bond formation between peptide and monomers. As a result, a urea monomer 
was used to introduce ionic interaction in combination with AAM to obtain a polymer with 
better binding characteristic than MAA, AAm MIPs. However, an improvement in affinity 
(apparent Kd 194 µM) was not observed, and lower imprinting factors (1.42) were reported 
with this approach. The bulk imprinting technique allowed us to screen certain monomers 
and conduct simple binding experiments. However, the methods were too cumbersome and 
the template too scarce and expensive to undertake a larger monomer screening study. This 
would have been crucial for finding the right monomer-template combination to obtain 
high performing MIPs. One approach to overcome this hurdle in the future would be to use 
computational methods to obtain a pool of monomers that have a theoretical high affinity 
for the template and further performing an experimental screen to obtain high-affinity 
MIPs as described by Nicholls et al.4. However, it could be still quite challenging to 
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achieve MIPs with nM affinity using conventional bulk imprinting techniques and a shift 
in surface imprinting may be required with the selected monomers. 
In Chapter 3, surface imprinting of PSA epitopes was undertaken to overcome some of the 
challenges faced with bulk imprinting techniques. Surface imprinting has been 
demonstrated to be a better alternative to bulk imprinting techniques due to low solubility 
issues, faster binding kinetics and low diffusional and mass transfer barriers.3 Furthermore, 
surface imprinted MIPs can be integrated with sensing platforms to obtain efficient signal 
transduction and readouts.5 The initial experiments in Chapter 3 focused on using the pro-
PSA peptide, which in itself is a biomarker for cancer aggressiveness. It was proposed that 
results from pro-PSA epitope imprinting, if successful, could be easily transferred to the C-
terminus PSA epitopes selected in Chapter 1. Dopamine was selected as a monomer for 
imprinting due to its low oxidation potential, the presence of functional groups that could 
interact with the template to form a highly selective cavity, ease of polymerisation in PBS 
pH 7.4 and superior electrochemical properties than other electroactive monomers. The 
pro-PSA peptide was modified with MUA (thiol) linker to confine the peptide to the 
surface to build more homogenous binding to sites to improve binding kinetics and 
sensitivity of the sensor. The pro-PSA MIP sensor showed specificity towards the pro-PSA 
peptide when compared to the NIP sensor (IF of 14). The sensor also demonstrated higher 
binding affinity (apparent Kd 10 µM) and LOD (1 µM) than bulk-imprinted polymers from 
Chapter 1. The pro-PSA sensor also exhibited selectivity when challenged with a test 
peptide containing a random amino acid sequence. Surface confinement of the template 
was also seen to have a positive effect (LOD 1 µM) when compared to conventionally 
prepared (no surface immobilisation) surface imprinted sensor (LOD 10 µM). However, 
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the inability to discriminate between two closely related or homologous peptides and low 
repeatability of the sensor suggests that further optimisation maybe required for efficient 
binding. However, one major drawback of E-MIP is the lack of functionality and over 
dependence on hydrogen bonding and π-π stacking for a selective cavity formation. This 
could be addressed by the use of electropolymerisable RAFT agents6 to build a surface-
imprinted polymer with highly specific functional monomers while retaining control over 
the thickness of the polymer using electrochemical stimulus. This technique could be the 
key to building different layers of polymers with varying functionality to build next 
generations MIPs on electrically conducting transducer surfaces. 
In Chapter 4, the work on surface imprinting and electroactive monomers were continued 
for detection of fPSA. However, an alternative and more sophisticated imprinting 
technique called hybrid imprinting was explored to achieve higher sensitivity with the (E)-
MIP sensors. It was proposed that to achieve greater sensitivity (nM range) with MIPs, an 
added level of functionally would be beneficial to enhance the overall affinity of the 
imprinted polymer. The hybrid imprinting technique allowed for the incorporation of a 
receptor (aptamer) with an established affinity towards fPSA to build a polymeric cavity 
with superior recognition properties than the polymer or aptamer alone. The hybrid 
imprinted MIP demonstrated an apparent Kd of 0.3 nM could discriminate between closely 
related protein such as hK2 and also detected clinically relevant concentrations of PSA (4-
10 ng/ml). Moreover, the sensor showed very little fouling to serum protein HSA. The 
apta-MIP sensors exhibited great promise in detecting clinically relevant proteins such as 
PSA at clinically relevant concentrations with high selectivity. However, the use of redox 
solution in the system slowed the detection process and reduced the stability of the sensor. 
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Hence, in Chapter 5, the apta-MIP technique was further extended to MOSFET devices to 
increase sensitivity and provide scope for miniaturisation without the need of redox 
solution. The MOSFET devices were found to be 100 times more sensitive that EIS sensor 
and allowed the detection of PSA in PBS pH 7.4. These results encouraged some 
preliminary experiments in diluted plasma. PSA concentrations between 1 and 10 pg/ml of 
PSA could be detected linearly in diluted plasma using the MOSFET apta-MIP sensors. 
Although, a loss of sensitivity was observed when samples were measured in plasma 
(compared to PBS buffer), the experiments highlighted the potential use of apta-MIP 
devices for sensitive detection of biomarkers in human blood at clinically relevant 
concentrations.  
Despite the good sensitivity and selectivity achieved with the hybrid-MIP electrochemical 
sensing technique, further work is required to understand the mechanism of binding and 
the contribution of the polymer towards the total affinity of the MIP. Use of techniques 
such as QCM and SPR techniques could help determine binding characteristics and also 
help calculate actual affinity constants for the hybrid polymers, which could further 
support the data obtained from electrochemical sensors. Comparison studies also need to 
be carried out using different receptors such an antibodies, peptides and small molecules to 
investigate if aptamers are the most efficient receptors for hybrid imprinting technique. 
In conclusion, the current work showcases that surface imprinting has a clear advantage 
over bulk imprinting for detection of biomolecules such as peptides and proteins in terms 
of ease of fabrication, overall sensitivity and affinity. However, the combination of hybrid-
MIP receptors with electrochemical platforms gives the added advantage of detecting 
biomolecules that are found in extremely low concentrations in the human body with high 
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sensitivity and selectivity. It is proposed that hybrid imprinting could help develop the next 
generation of MIP sensors that are robust, sensitive and stable and can be translated to 
other clinical biomarkers. Furthermore, the integration of the hybrid-MIP with an 
electrochemical platform permits rapid detection of template and scope for miniaturisation, 
which allows for fabrication of a point-of-care device. It is proposed that further advances 
in the field of hybrid imprinting and sensing could allow for development of portable MIP 
sensors for clinical biomarkers in the near future. 
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